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ABSTRACT
The practice of brachytherapy and brachytherapy dosimetry was investigated with
emphasis on evaluations of dose distributions and shielding considerations for both
photon- and neutron-emitting radionuclides. Monte Carlo simulation methods were
employed to calculate dose distributions for virtual and commercial brachytherapy
sources. Radionuclides studied were 103Pd, 1251, 13 1Cs, 137Cs, 169 b, 192Ir, and 252 Cf. 252Cf
sources also emit neutrons from spontaneous fission. The brachytherapy dosimetry
protocol recommended by the American Association of Physicists in Medicine was
followed and evaluated for conditions of partial scatter (non-infinite media) and material
inhomogeneities, both commonly encountered in brachytherapy treatment. Furthermore,
energy-dependent characteristics of dosimetry parameters were evaluated and reference
calculations performed for virtual photon and neutron sources. These findings were
applied to three clinical brachytherapy cases: eye plaques using 10 3Pd, 125I, and 131Cs;
high-dose rate 252Cf treatment; and, 2 Cf plaques for superficial lesions. For eye plaques,
material heterogeneities were significant for each radionuclide with dose reduction at 5
mm of 18%, 11%, and 10% for P03pd, 125I, and 13 1Cs, respectively. For a proposed high-
dose rate 252Cf source (5mm length), relative brachytherapy dosimetry parameters were
found to be similar to those obtained for a low-dose rate Applicator Tube-type source (15
mm length). Considering 252Cf plaque brachytherapy when partial scatter conditions
were accounted for, central axis equivalent dose rate decreased by 11 ± 1% and 7 ± 2%
for depths of 4 to 50 mm, respectively. The ratio of neutron dose to total physical dose
was 70 ± 1% and 57 ± 2% for depths of 4 and 50 mm, respectively, while the fractional
dose-equivalent due to neutrons was 93 + 1% and 89 ± 2% at these depths, respectively.
Finally, shielding requirements for a clinical high-dose rate 252Cf source were explored
for common shielding materials and a linear accelerator vault. Lead, polyethylene, and
borated polyethylene were evaluated for neutron, primary photon, and secondary photon
attenuation. Half-value layers of 0.70, 0.15, and 0.13 m were obtained for lead,
polyethylene, and borated polyethylene, respectively. A linear accelerator vault was
found to adequately shield up to a 5 mg 252Cf source for regular clinical use.
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1 INTRODUCTION
1.1 Background
1.1.1 INTRODUCTION To BRA CHYTHERAPY
In the year 2007, the American Cancer Society estimated over 1.4M new cancer
diagnoses in the United States.' More than half of these patients are expected to receive
radiation therapy towards curing cancerous disease or relieving symptoms.
Approximately 0.1M patients will receive brachytherapy for the management of their
disease. Brachytherapy is the medical practice of placing material that emits ionizing
radiation directly adjacent to or within a tumor or lesion. The placement may be within a
body cavity or lumen, in tissue, or superficial. Furthermore, treatment can be delivered
over short time periods using mechanical systems to rapidly position and move a
radiation source, or over long time periods using permanently implanted radioactive
seeds.
Male patients commonly receive brachytherapy treatment for prostate cancer,
which accounted for an estimated 0.2M new cancers (29%) and 0.03M (9%) deaths in the
year 2007.1 Many anatomical sites and cancer types are treated with brachytherapy or
with a combination of brachytherapy and other treatment modalities, such as external
beam radiotherapy, surgery, or chemotherapy. For example, ocular melanoma (2,340
estimated 2007 cases) can be treated with superficial plaque brachytherapy;
gynecological cancers (78,290 estimated 2007 cancers) can be treated with specialized
applicators; and breast cancer (178,480 estimated 2007 cancers) treatments can be
augmented with a brachytherapy boost or can be treated with brachytherapy as
monotherapy.14
Brachytherapy has been applied for over a century, with the first suggestion of the
practice closely following the discovery of radioactivity in 1896. s Early encapsulated
clinical brachytherapy sources contained mg quantities of 226Ra, one of the few
radionuclides available at the turn of the 19th century. Because the modem quantity
"activity" [disintegrations s-1] was not defined at the time, early measurements of 226Ra
source strength were defined using an analytical balance.6 Through the efforts of Marie
Curie, the measurement unit "Curie" [Ci] was defined as "the quantity of emanation in
equilibrium with one gram of radium" in 1912.7 By the early 1920s, 226Ra standards
were available in Europe to calibrate and certify 226Ra sources.6'7
Brachytherapy treatments during this era comprised needles or capsules loaded
with 226Ra (ty = 1600 y) that were implanted throughout a lesion following a loading
system to obtain desired dose distributions. Examples of these loading systems are the
Quimby (1932), Manchester (1934), and Paris (1960) systems where the differences arise
from uniformity of source strength and/or the geometrical distribution of sources.8 For
example, the Paris system employs uniformly loaded sources that are regularly spaced in
one or two planes.9 By following source placement rules prescribed by each system, the
radiation oncologist (previously known as the radiation therapist) would know the
approximate shape and magnitude of dose distributions during treatment. Thus,
brachytherapists planned patient treatments while avoiding difficult hand calculations and
in the absence of computers.
Following World War II, nuclear research reactors allowed the production of
radionuclides that did not occur naturally, and new radionuclide sources were
popularized, such as 60Co, 1251, 137Cs, 1921r, and 198Au among others. In the 1950s, source
strength started being reported in equivalent mg of 226Ra (mg Ra-eq.), where the exposure
rate of the new source was compared to a 226Ra source filtered by a 0.5 mm-thick Pt
capsule.6 Thus, the decades of experience with 226Ra sources continued to guide the field
of brachytherapy with new radionuclide-based sources.
The practice of comparing radionuclide sources to 226Ra changed when
manufacturing advances allowed the miniaturization of brachytherapy sources and the
mass-production of small sources containing radionuclides with high specific activity.
These advances led to the introduction of 125I sources (ty = 59.4 d) for use in permanent
implants. With implants containing a higher number of sources, the historic dosimetry
systems were no longer adequate for determining dose distributions. The National
Cancer Institute commissioned the Interstitial Collaborative Working Group to evaluate
methods for calculating brachytherapy dose distributions. This commission was followed
in 1988 by the formation of the American Association of Physicists in Medicine (AAPM)
Task Group 43 Report (TG-43), which introduced a quantitative brachytherapy dosimetry
formalism and recommended brachytherapy dosimetry data for selected brachytherapy
sources in 1995.10 A discussion of the AAPM TG-43 brachytherapy dosimetry
formalism follows in section 1.1.2.
For much of the 2 0 th Century, brachytherapy was administered by hand, which
resulted in high radiation doses to oncologists, physicists, support personnel, and patients
in adjacent rooms. Remote afterloading was introduced in the 1960s to reduce these
concerns.1 A remote afterloader is a mechanical device that can accurately position a
small radiation source attached to a wire. By utilizing mm positioning accuracy and
varying the "dwell" time at each position, a remote afterloader can create more conformal
dose distributions than low-dose rate (LDR) brachytherapy. Due to the extreme variation
in dose rate between LDR and high-dose rate (HDR) brachytherapy, brachytherapists
must account for differences in radiobiological effect.12  Most commercial remote
afterloaders utilize a HDR 192Ir source (ty = 73.8 d) with a maximum activity of 10 Ci,
where HDR designates dose rates exceeding 12 Gy h-1 at the prescription point."
In the beginning of the 2 1st Century, novel developments in brachytherapy
technology continue to occur. For example 131Cs, a radionuclide not previously used in
brachytherapy, was developed and is in clinical use. A multi-institution phase II clinical
trial demonstrated 13 1Cs to be a viable alternative to seeds containing 125I and 103Pd,
which have been in use for 25 and 21 years, respectively.' 3 ' 5s  Other notable
advancements include the introduction of an electronic brachytherapy source, the Xoft
Inc., Axxent system.'6 The Axxent is a miniature, single-use x-ray tube allowing a peak
accelerating potential of 50 kV with a W target. Photons emitted by the Axxent exhibit
similar depth-dose characteristics to 1251; although, the Axxent exhibits increased
anisotropy near the connecting cable.'6 In contrast to radionuclide-based sources, the
Xoft Axxent does not provide a serious radiological risk to hospital personnel as a
switchable electric current is needed to generate radiation.
1.1.2 BRIEF HISTORY OF BRA CHYTHERAPY DOSIMETRY
Early brachytherapy dosimetry measurements were hindered by the lack of an
appropriate exposure calibration standard. While 226Ra standards allowed relative
classification of source strength by mass, quantitative measure of the exposure rate from
a given source was not possible. By the late 1920s, orthovoltage radiotherapy beams
were calibrated in Roentgens [R] using a free-air ionization chamber; however, a
comparable method for brachytherapy source calibration was lacking.6 Between 1920
and 1940, investigators attempted to compare treatment by orthovoltage therapy and
brachytherapy using biological dosimeters, such as the threshold erythema dose (TED)
which is the quantity required to produce erythema in 80% of irradiated subjects (-11
Gy). While biological dosimeters allowed comparison of the two modalities, the need for
a directly measurable quantity to benchmark dose distributions limited the development
of quantitative brachytherapy dosimetry.
One of the first methods to calculate dose distributions about a linear source was
demonstrated by Sievert in 1921.'7 The Sievert Integral was obtained by dividing a line
source into short sections that were treated as point sources. By summing the
contributions from each point and multiplying by an estimated exposure rate constant
(FRa), the exposure rate at a point was calculated. An example of a Sievert Integral for a
source with length L, mass of 226Ra Meq, and exposure rate constant FRa is given in
equation 1.1.1.
X(x,y) = MRaFRa e e-sec()d (1.1.1)
Ly 0
In equation 1.1.1, the encapsulation thickness, t, and average attenuation of the
encapsulation, p, contribute to the calculation of exposure at a point (x,y), where x is
along the source axis. The Sievert Integral has been shown to accurately simulate dose
distributions for 226Ra and 1921r sources in regions parallel to the source, but the technique
does not compare favorably to Monte Carlo (MC) calculations near the source long
axis." These differences are likely due to the impact of attenuation in source internal
components (e.g., Ag or Pb markers), which was not included in the Sievert Integral.
In addition to the semi-empirical Sievert Integral, individual source dosimetry in
the latter-half of the 20th Century was reported using along-and-away tables. These
tables listed the dose rate as a function of position in a two-dimensional grid along and
away from the source long axis. For multiple source implants, the brachytherapist
employed superposition to determine the total dose at any point in the implant. However,
this process became tedious as the number of sources in an implant increased.
Furthermore, it is necessary to interpolate along-and-away data, and steep dose gradients
near the source can introduce interpolation errors.
The development of Bragg-Gray cavity theory in 1957 allowed calibration of
226Ra sources in terms of exposure [R], which was the calibration standard for
orthovoltage x-rays during that era.6  Thus, brachytherapists could compare clinical
findings to outcomes from external-beam treatment. The National Institute of Standards
and Technology (NIST; formerly the National Bureau of Standards) introduced exposure
standards for 137Cs, 60 Co, 192Ir, and 1251 between 1970 and 1984 based on the Ritz Free-
Air Chamber, which is the national primary calibration standard for W x-ray sources
between 20 and 100 kVp.18 19
As described in section 1.1.1, the 1995 AAPM TG-43 Report defined a
quantitative dosimetry formalism that replaced Sievert integrals and along-and-away
tables.1 o A summary of the TG-43 brachytherapy dosimetry parameters is included in
Appendix II, section 7.2. Generally, the TG-43 formalism is designed to reproduce dose
distributions in a semi-infinite liquid water phantom. Brachytherapy dosimetry
investigators are advised to perform simulations and measurements in a phantom large
enough to minimize losses due to lack of backscattering material. 20 Because the medium
is water, no considerations are given to differences in material or tissue heterogeneities.
Both of these effects have been successfully addressed for treatment planning of external
photon beams, but still have not been incorporated into TPS for brachy. 21 23 For external
photon beam TPS, heterogeneity corrections in the mediastinum were demonstrated to
range from 5% to 16% for photon energeies between 60Co and 25 MV, with correction
factors as high as 21% for 25 MV in lung tissue.24
Since this landmark publication, brachytherapy dose distributions have largely
been reported using the AAPM TG-43 formalism. To be included in consensus treatment
data approved by the AAPM, a brachytherapy source must have MC-calculated and
experimentally-measured brachytherapy dosimetry parameters published in a peer-
reviewed journal. 25 The AAPM revised the dosimetry formalism in a 2004 update to the
TG-43 report (TG-43U1), but limited the scope to 10 3Pd and 1251 sources. 20 The AAPM
TG-43U1 formalism, which calculates the dose rate in spherical coordinates about a
source aligned along 0 = 00, is given in equation 1.1.2.
GL (r,9)6)(r, 9)= SK A gL (r)F(r,O) (1.1.2)
GL (ro, 0o)
In equation 1.1.2, SK is the air kerma strength [cGy cm2 h-], L is the dose rate constant
[cm2], GL(r,0) is the geometry function that corrects for inverse square effects, gL(r) is
the radial dose function that corrects for attenuation and scatter along 0 = 900, and F(r,0)
is the two-dimensional anisotropy function that corrects for attenuation and scatter at (r,0)
relative to (r, 900).
The radionuclide limitation was imposed by the physical dimensions of the Wide
Angle Free Air Chamber (WAFAC) air kerma strength primary calibration standard at
NIST in 1999.18 The WAFAC was developed because deficiencies were identified in the
previous standard, the Ritz Free-Air-Chamber, and the introduction of new radionuclides,
such as '03Pd, warranted a new standard.1s The WAFAC was not physically large enough
to measure air kerma strength for high-energy sources such as 192Ir due to the increased
pathlength of secondary charged particles, i.e., electrons. Nonetheless, dose distributions
in water using the TG-43 brachytherapy dosimetry formalism are published for several
high- and low-energy brachytherapy sources, such as '31Cs, 137Cs, 169yb, 192Ir, and
252Cf.26 30 To be compatible with the AAPM TG-43U1 formalism, SK and A for high-
energy radionuclides would be defined for primary calibration standards other than the
NIST WAFAC air kerma standard.
Contemporary treatment planning systems implement the TG-43 dosimetry
formalism; however, not all systems are capable of calculating the two-dimensional
dosimetry formalism. These systems employ the one-dimensional version of the formula
where the geometry function is replaced with a point source representation (r 2); and
F(r,0) is replaced with .n(r), the one-dimensional anisotropy function. When multiple
sources are employed, superposition determines the total dose distribution. Thus, the
limitations and assumptions of the AAPM TG-43 brachytherapy dosimetry formalism
discussed above are also present in contemporary brachytherapy treatment planning
systems. Even for planning systems that display three-dimensional patient data, such as
computed tomography, the material heterogeneities and volume limitations are not
included in dose calculation.
Both of the recently developed novel brachytherapy sources discussed in section
1.1.1, the 131Cs seed and electronic Xoft Axxent, can utilize the AAPM TG-43
brachytherapy dosimetry formalism and be implemented in contemporary brachytherapy
treatment planning systems. However, the formalism is not easily applied to other novel,
developing brachytherapy techniques. For example, 90Y-loaded microspheres (glass
beads with diameter 25 ± 10 gm) have been delivered to liver tumors through the hepatic
artery using interventional radiology techniques. 31 Microsphere implants result in large
numbers of small sources in a highly non-uniform manner that would not be readily
applied to the AAPM TG-43 formalism. Similarly, a technique for treating brain tumors
has been developed where a balloon is inserted into a resection cavity and filled with a
liquid 125I solution.3 2  Additional brachytherapy dosimetry research is needed to
determine if the AAPM TG-43 formalism can be modified to include these sources or if a
new formalism is needed.
1.1.3 CALIFORNIUM BRACHYTHERAPY
252Cf is a man-made trans-plutonium radionuclide that largely undergoes alpha
decay; however, 3.09% of nuclear transitions follow spontaneous fission.33 The half-life
of 252Cf is 2.645 y. Oak Ridge National Laboratory (ORNL) produced Cf isotopes from
approximately 100 g highly-enriched heavy Cm targets (244Cm, 246Cm, and 248Cm)
irradiated in the High-Flux Isotope Reactor for -7 months.34 Combinations of neutron
activation and beta decay leads to successively higher atomic numbers. For example,
neutron activation of 248Cm produces 249Cm (ty, = 64 m) that beta decays to 24 9Bk (ty, =
330 d) that beta decays to 249Cf (ty = 351 y), and subsequent neutron capture reactions are
required to produce Cf isotopes with atomic numbers 249-254.33 Due to the amount of
time required to produce 252Cf and the extensive radiochemistry needed to separate Cf
isotopes from the Cm target, 252Cf is both extremely rare and expensive.
Clinical use of the neutron-emitting radionuclide 252Cf was first proposed in 1965
by Schlea and Stoddard.35 Schlea and Stoddard noted that early radiobiological studies of
external neutron beam therapy demonstrated effectiveness in anoxic tumors that were
typically resistant to conventional photon therapies. They also described the advantage
of intracavitary and interstitial brachytherapy treatment over external neutron beam
therapy, which includes higher radiation doses to healthy tissue.3s The first medical
source containing 252Cf was described in 1967 and was modeled after a radium needle.36
Thousands of patients worldwide have been treated over the past 40 years with
252Cf-based brachytherapy.36 The mixed neutron and photon radiation has been shown to
be particularly effective for large tumors and traditionally radio-resistant tumors, such as
melanomas and late-stage cervical carcinomas. For example, Tacev et al. have reported
increased survival rates (+16%, p < 0.002) and decreased relapse rates (-17%, p <
0.0002) using 252Cf for the treatment of advanced cervical carcinoma with twelve years
post treatment follow-up in comparison to conventional treatment.37 The increased
effectiveness is attributed to a number of radiological characteristics of neutrons, such as
increased relative biological effectiveness (RBE), decreased oxygen effect, and decreased
cell-cycle dependence. In the United States, Yosh Maruyama M.D. treated many disease
sites and published nearly one hundred clinical papers on the subject before his death in
1995. Consider ref. 36 for a detailed overview of medical applications of 252Cf
brachytherapy and summary of clinical results for head and neck, gynecological, skin,
rectal, esophageal, prostate, and brain tumors, among others.
Brachytherapy dosimetry for 252Cf sources was aggressively pursued in the early
1970s once medical sources were available. 38 -4 Calculations by Krishnaswamy used MC
methods to determine a point source model for four different source types, including the
Applicator Tube (AT) source with source length L = 1.5 cm.38 Each point source was
subsequently used in a numerical integration to calculate the dose to points up to 5 cm
along and away from the source. Neutron kerma factors were not reported, and the
photon cross-sections of Storm and Israel41 were employed. Colvett et al. followed with
measurements using paired ion chambers (tissue equivalent and Al) in a large volume of
tissue equivalent liquid to simulate infinite scatter conditions. Measurements from 1 to 5
cm on the transverse plane agreed within 0.94 ± 0.02 to Krishnaswamy's calculations;
however, the measurements did not agree favorably with other reported measurements.3 9
Differences between measurements were attributed to differences in phantom size, which
resulted in varying scatter conditions, and to differences in chamber or 252Cf source
calibration. 39,40 Windham et al. calculated dose distributions for 252 Cf sources using a
one-dimensional discrete ordinates code, 21 energy groups, and neutron kerma factors
published by Ritz et al.40,42 Calculations by Windham et al. were in good agreement with
the Krishnaswamy calculations (1.01 ± 0.03) and Colvett et al. measurements (0.97 ±
0.02) for 0.5 < r < 5.0 cm on the transverse plane. Anderson reviewed these and six other
publications (3 calculations and 3 measurements) in a 1973 review paper on 252Cf
dosimetry.43 The measurements of Colvett et al. were recommended for 252Cf, although,
the Colvett et al. photon data were only recommended for AT-type sources. The
calculations of Krishnaswamy for non-AT-type sources needle sources were the
recommended alternative.43 These data were reported as along-and-away tables up to 5
cm from the source center.
The most recent determinations of 252Cf neutron dose distribution about a low-
dose rate source were published by Yanch and Zamenhof in 199244 and by Rivard et al.
in 2000.30 Yanch and Zamenhof calculated along-and-away tables using MC methods for
AT-type sources.44 Rivard adapted the TG-43 formalism for a generalized source of
variable active length and provided brachytherapy dosimetry parameters for the neutron
dose component.30
To date, 252Cf brachytherapy in the United States is applied using manually
loaded, LDR sources delivering below 2 Gy h-1 to the prescription point during patient
treatment.36 Both manual loading and LDR treatment increases radiological risk to the
brachytherapist and support personnel who must attend to patient needs during long
treatment sessions. Considering these issues, there is an interest in employing 252Cf
brachytherapy in the HDR regime. In addition, remote afterloading technology, which is
well-documented and successful for HDR 192Ir brachytherapy, is being considered for
252Cf.45 Measurement of the mixed-dose distribution about a clinical HDR 252 Cf source
has not been attempted because sources comparable in size and geometry to conventional
HDR 192Ir sources have only recently become possible due to advances in
radiochemistry.4 s Furthermore, while radiochemistry now allows an HDR source
containing > 1 mg/mm 3 of 252Cf, one has not been constructed.
1.1.4 RADIOLOGICAL PROTECTION
Brachytherapy presents unique radiological protection concerns for the
brachytherapist. Marie Curie, one of the first people to regularly handle encapsulated
radioactive sources, experienced radiation burns on her fingers after extended handling
periods.' Henri Becquerel similarly experienced skin erythema and desquamation after
carrying a few tenths of a gram of radium chloride in a glass tube in his pocket for six
hours. After noting a less intense reaction from carrying the source for one hour, he
repeated the experiment by placing the source in a 5 mm-thick lead capsule and noting
that the shielded source needed significantly more time to produce a biological effect. 46
Many of the early experimenters and clinicians died as a result of their repeated radiation
exposures.
Until the development of remote afterloading technology, brachytherapy
procedures required manual loading or placement of sources into treatment position.
These placed the brachytherapist at risk for repeated radiobiological harm. Thus, tools
were developed to increase the distance or to incorporate shielding between clinicians
and brachytherapy sources. Furthermore, LDR treatments could have durations
exceeding one week that posed a radiological risk to ancillary clinical staff, such as
nurses, who were attending to patient needs. Generally, these concerns were addressed
by using patient rooms in relatively remote locations with portable, rolling shields to
reduce radiation levels outside the room.
However, the methods that were effective for traditional photon-based
brachytherapy would not provide adequate protection for neutron-based brachytherapy
using 252Cf. While Pb shields would be effective against the photon emissions from a
252Cf source, Pb does not notably attenuate or moderate neutrons. Maruyama et al. noted
that early 252Cf treatment centers utilized a treatment vault that was originally designed
for megavoltage energy photon beams.36 At one facility in the Czech Republic, a vault
designed for a 60Co treatment unit was augmented with a 24-cm thick layer of borated
polyethylene before being used for 252Cf therapy.47 Borated polyethylene is an effective
neutron shield because the hydrogen component in polyethylene moderates the neutrons,
increasing their probability of absorption by boron, which has a high neutron-capture
cross section.
During HDR 252Cf therapy, treatment vaults will be subjected to extremely high
neutron fluence. One mg of 252Cf emits 2.314 x 109 (± 2%) neutrons s-1 and 1.3 x 1010
(± 4%) photons s-1, which correlate to approximately 0.28 Gy h-1 and 0.14 Gy h-1 at 1 m
from an unshielded source. 4s5' 4  As such, it is possible for the instantaneous dose rate
outside of the treatment vault to exceed regulatory limits. Current regulations specifiy
maximum permissible radiation doses to a member of the public at 0.02 mSv in one hour
and 0.1 mSv in one year.
Shielding calculations for 252Cf emissions were published in technical reports of
the Savannah River Laboratory by Hootman (1970) and by Hootman and Stoddard
(1971).48,49 These shielding analyses solved a one-dimensional Boltzman equation in a
slab, sphere or cylindrical geometry using discrete ordinates and anisotropic scattering.4 8
In addition, the calculations included RBE factors [sic] to convert absorbed dose (rad or
Gy) to equivalent dose (rem or Sv). Historical RBE values (1957) were employed
because radiation weighting factors were not available at the time. The International
Council for Radiation Protection (ICRP) recommended radiation weighting factors for
dose equivalent calculations in Report 60 (1990). 50
1.2 Thesis statement
1.2.1 PHOTON DOSIMETRY
As noted in section 1.1.2, the AAPM TG-43 brachytherapy dosimetry formalism
determines dose distributions in a semi-infinite volume of liquid water, i.e., dose
calculations assume negligible losses due to energy escape from the phantom.
Unfortunately, this assumption rarely simulates patient geometry. Similarly, differences
between energy absorption in water and other media have been studied with corrections
implemented for external beam treatments. However, corrections are not used for
brachytherapy.
These concepts are explored in Chapter 2, where dose distributions from virtual
and commercial photon-emitting brachytherapy sources were calculated using MC
methods and compared to the current brachytherapy dosimetry formalism in AAPM TG-
43U1 Report. While the TG-43U1 report describes commercial low-energy photon-
emitting 1251 and 103pd sources, the formalism was applied to a number of radionuclide
sources spanning a wide energy range. Furthermore, mono-energetic sources were
employed to identify generalizable characteristics in photon-based brachytherapy
dosimetry parameters.
These observations were subsequently applied to eye plaque brachytherapy using
commercial 10 3Pd, 125I, and 131Cs brachytherapy sources. Gold-alloy plaques provide
significant attenuation of emitted radiation, but existing treatment planning systems
exclude these effects. Furthermore, material inhomogeneities in plaque components have
been shown to perturb single-seed 125I dose distributions by as much as 10% at clinically
relevant distances.5 1  MC-based treatment simulations described in section 2.2
demonstrate changes in dose distributions for fully-loaded eye plaques using common
low-energy radionuclide sources. Correction factors accounting for these effects were
derived for conventional treatment plans.
1.2.2 NEUTRON DOSIMETRY
Chapter 3 extends the photon-specific effects described in Chapter 2 to neutron-
emitting sources. Thus, generalizable characteristics of neutron brachytherapy were
derived and compared to the dosimetry formalism of AAPM TG-43U1 Report in section
3.1. Distinctions between dose distributions obtained for photon and neutron
brachytherapy were established towards a better understanding of the photon contribution
in neutron-based brachytherapy. Furthermore, recommendations to future dosimetry
investigators were presented.
These analyses were broadened to a theoretical HDR 252Cf source in section 3.2.
As discussed in section 1.1.3, HDR 252Cf sources are still in development. However,
comparisons were made between LDR AT-type sources and a theoretical HDR source in
preparation for neutron-based HDR treatment.
The clinical impact of partial scatter conditions during surface plaque
brachytherapy was examined for comparison to the semi-infinite water phantom assumed
by the AAPM TG-43U1 dosimetry formalism in section 3.3. MC calculations were
performed for comparison to treatment plans calculated using conventional
brachytherapy treatment planning software in support of a 252Cf brachytherapy clinical
trial.
1.2.3 SHIELDING CONSIDERATIONS
In further support of neutron-based brachytherapy using HDR 252Cf, the shielding
requirements for mg quantities of 252 Cf were evaluated using MC methods in Chapter 4.
Shielding properties of concrete, barite concrete, lead, water, polyethelyene, and borated
polyethylene were evaluated for thicknesses up to 1 m in section 4.1. MC calculations
employed three dimensional radiation transport modeling, modem cross-section libraries,
and contemporary radiation weighting factors.
Finally, a linear accelerator vault at Tufts-New England Medical Center in
Boston, MA was assessed for shielding an HDR-equivalent 252Cf source in section 4.2.
MC calculations were performed in conjunction with ionization chamber, proportional
counter, and track-etch detector measurements of a 252Cf neutron radiography source (> 1
mg) positioned where treatment would occur within the accelerator vault. The resulting
measurements were utilized to estimate limitations on patient throughput due to radiation
exposure to personnel and to the public during HDR 2 52Cf treatment assuming
conventional permissible exposures.
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2 PHOTON DOSIMETRY
2.1 Approaches to calculating AAPM TG-43 brachytherapy dosimetry
parameters for 137Cs, 125I, 192Ir, 103Pd, and 169Yb sourcest
2.1.1 ABSTRACT
Underlying characteristics in brachytherapy dosimetry parameters for medical
radionuclides 137Cs, 125I, 192Ir, 103pd, and 169yb were examined using Monte Carlo
methods. Sources were modeled as un-encapsulated point or line sources in liquid water
to negate variations due to materials and construction. Importance of phantom size,
mode of radiation transport physics - i.e., photon transport only (MODE P) or coupled
photon:electron transport (MODE PE), phantom material, volume averaging, and Monte
Carlo tally type were studied. For non-infinite media, g(r) was found to degrade as r
approached R, the phantom radius. MCNP5 results were in agreement with those
published using GEANT4. Brachytherapy dosimetry parameters calculated using
coupled photon:electron radiation transport simulations did not differ significantly from
those using photon transport only. Radial dose from low-energy photon-emitting
radionuclides 125I and 10 3Pd were sensitive to phantom material by upto a factor of 1.4
and 2.0, respectively, between tissue-equivalent materials and water at r = 9 cm. In
comparison, high-energy photons from 137Cs, 192Ir, and 169Yb demonstrated ± 5%
differences in radial dose between water and tissue-substitutes at r = 20 cm. Similarly,
volume-averaging effects were found to be more significant for low-energy
t Reproduced from: C. S. Melhus and M. J. Rivard, "Approaches to calculating AAPM TG-43
brachytherapy dosimetry parameters for 13 7Cs, 1251, 192Ir, 10 3Pd, and 169yb sources," Med. Phys. 33, 1729-
1737 (2006).
radionuclides. When modeling line sources with L 5 0.5 cm, the 2-D anisotropy function
was largely within ± 0.5% of unity for 137Cs, 1251, and 192Ir. However, an energy and
geometry effect was noted for 10 3Pd and 69Yb, with Pd-103F(0.5,00 ) = 1.05 and Yb-
169F(0.5,00) = 0.98 for L = 0.5 cm. Simulations of monoenergetic photons for L = 0.5 cm
produced energy-dependent variations in F(r,0) having a maximum value at 10 keV,
minimum at 50 keV, and - 1.0 for higher-energy photons up to 750 keV. Both the F6
cell heating and *F4 track-length estimators were employed to determine brachytherapy
dosimetry parameters. F6 was found to be necessary for g(r), while both tallies provided
equivalent results for F(r,0).
2.1.2 INTRODUCTION
For brachytherapy dosimetry calculations using radiation transport codes, TG-
43U1 makes a number of "good practice" recommendations. 20  These nine
recommendations include allowing for adequate backscatter material, utilizing modem
photon cross-sections, and maintaining volume-averaging effects below 1%, among
others. Regardless of the TG-43U1 guidance, the dosimetry investigator is allowed
considerable flexibility in designing and conducting both simulations and measurements,
resulting in notable methodology variations between authors. These variations are clearly
evidenced in Appendix A of TG-43U1, which includes a discussion of the number of
authors and publications dedicated to an individual seed design (manufacturer and
model), and each publication contains investigator-specific methodologies and
approaches. Additional complexity is added as the scope extends to multiple seed
models, each with a unique subset of contributing dosimetry investigators and related
methodologies that change over time in response to new discoveries, other publications,
and AAPM recommendations.
Furthermore, specific dosimetry parameters have garnered considerable interest in
the brachytherapy dosimetry community during recent years.58ss 63 For example, dosimetry
investigators have suggested both adding complexity" and simplifying the geometry
function, G(r,0), 60 towards improving brachytherapy dosimetry. The AAPM TG-43UI
currently recommends either a line- or point-source approach to approximate all
commercially available brachytherapy seeds. As much of the recent interest relates to
derivation of G(r,0), the AAPM published a clarification stressing the need for consistent
application of a geometry function, rather than accurate representation of particle
streaming behavior.63
Unlike G(r,0), which is not a function of radionuclide energy spectrum and is
purely mathematical, other AAPM TG-43UI brachytherapy dosimetry parameters are
determined by comparing absorbed dose measurements or calculations within a phantom.
The brachytherapy dosimetry investigator must carefully model and sample the phantom
to avoid introducing bias related to the radiation transport model or technique. Errors
incurred through inappropriate technique usage can be magnified when dose distribution
results are processed using the dosimetry formalism because of the relative nature of the
calculations.
Assuming further advances in computer processing capabilities, the current
dosimetry formalism standard may eventually be abandoned in favor of direct MC-based
brachytherapy dosimetry simulations,64,'6 though careful measurements will be needed to
commission such a system. At present, the brachytherapy dosimetry formalism presented
in the AAPM TG-43U1 report represents the current standard. Therefore, this
publication provides reference brachytherapy dosimetry parameters for a variety of un-
encapsulated medical radionuclides using MCNP5. This goal will not only elucidate
inherent characteristics of each individual source photon spectrum, but also provide
reference data towards comparing with other MC-based brachytherapy dosimetry
calculations. At the same time, the impact of phantom geometry, including backscatter
and sampling volume effects, and phantom material will be explored for MCNP5.
2.1.3 MATERIALS AND METHODS
Dose distributions from five radionuclides (137Cs, 1251, 192Ir, 10 3Pd, and 169Yb) used
for brachytherapy were modeled. The 2004 update to the AAPM TG-43 report included
only low-energy photon emitting brachytherapy sources containing 1251 or 103Pd.20 This
study employed the same formalism and extended it to high-energy photon sources (EAVG
> 50 keV) with a more energetic population of secondary particles. All photon energies
were included in spectral characterization with the exception of those below 9 keV,
because the average pathlength is < 0.2 cm in water. Photon and electron spectra for each
radionuclide were taken from the National Nuclear Data Center (NNDC).33 Furthermore,
AAPM TG-43U1 recommended photon energy and emission frequencies for 1251 and
103Pd and the 192Ir spectrum of Glasgow and Dillman66 were used in radiation transport
simulations for comparison to results obtained using NNDC-published values.
Simulations were performed using version 5 of the MCNP Monte Carlo code
(MCNP5) developed by Los Alamos National Laboratory.6 7 The default MCNP5 photon
cross-section library, p04, was applied, which is based upon Release 8 of ENDF/B-VI.68
Computed results of cell particle fluence, energy fluence, and heating were obtained
using the MCNP F4, *F4, and F6 tallies, respectively. These three tallies correspond to
track length estimates in a cell of photon flux, product of photon flux with photon energy,
and energy deposition, respectively. Source encapsulation was not included in any of the
simulations in order to ascertain underlying characteristics of each radiation spectrum in
materials of dosimetric interest and to eliminate manufacturer-specific effects due to
source construction. Water was modeled using an atomic ratio of 2:1 for H:O and a mass
density of 0.998 g cm 3 at standard temperature and pressure, 22 0 C and 101.325 kPa,
respectively. Due to their low-energy photon emissions and subsequent rapid dose
falloff, 103Pd and 125I results were excluded beyond 9 cm and 15 cm, respectively.69
2.1.3.1 Radial dose function
The radial dose function, g(r), was assessed for each radionuclide photon
spectrum using an un-encapsulated point source in a spherical water phantom with R = 50
cm in radius, i.e., X-Ag(r)R. where the prefix subscript denotes the radionuclide and the
suffix subscript denotes the phantom radius. Concentric spheres were designed to create
spherical shells in which MCNP5 tallies were computed, allowing calculation of g(r) at
radial distances between 0.1 and 20 cm. Values of R were 5, 10, 15, 20, 25, 30, 35, 40,
and 45 cm were used to assess full scatter conditions. While a smaller radius is generally
representative of human anatomy, e.g., the R = 15 cm used by Daskalov et. al. for HDR
192Ir calculations 29, g(r)50 data is presented here. Varying the radial width of the sampling
volume, i.e., the thickness of the spherical shell, assessed the impact of volumetric
averaging. Data were collected for 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.5, 1, and 2 cm thick
shells, as well as for a variable thickness of 5% or 10% of the radial distance. The inner
and outer radii defining the sampling volume were equally displaced from the reported
point of calculation. Volume averaging errors caused by non-zero voxel width were
evaluated for ± 0.5% variation in g(r) by comparing results to the 0.01 cm-thick voxel.
Simulations were also performed in breast tissue, muscle, soft tissue, and four-component
soft tissue, as defined in ICRU 44,70 and presented by NIST,71 to compare with the in-
water calculations required by TG-43U1.
Source emissions were modeled as photon and electron spectra for all five
radionuclides. To determine the impact of simplifying radiation transport calculations for
the five photon source spectra, photon-only (MODE P) and coupled photon:electron
(MODE PE) calculations were performed. Furthermore, simulations of electrons emitted
following P-decay or electron capture, including auger electrons, were performed using
the default MCNP5 electron transport mode (par = 3) to evaluate whether electron-only
transport (MODE E) or secondary photons generated by electrons (MODE PE)
contributed to total radial dose deposition. The algorithm used for default electron
transport calculation is subject to non-physical energy effects, see for example Ref. 72,
and may not accurately reproduce electron dose distributions. As such, comparisons of
electron and photon transport are made on a relative basis to show order-of-magnitude
results.
The F6 energy deposition tally was evaluated by transporting 0.001 to 10 MeV
photons from a point source through a sphere of liquid water(R = 15 cm) and sampling
within a thin sampling volume (spherical shell) 0.01 cm from the source. Using the tally
energy card (En), energy bins were established with an average energy bin width of 7% ±
6% (± 1 s.d.) of the bin energy. A ratio of F6 and *F4 results for each energy bin was
taken to evaluate energy absorption coefficients (!len p-1) employed when using MCNP5.
The dose rate per mCi was calculated from F6 results at (ro,0 0) to allow comparison of
radial dose data in a non-normalized manner. The normalized and balkanized nature of
TG-43U1 dosimetry parameters, such as g(r), precludes clear understanding of absolute
dose rates. Thus, the dosimetry investigator may use dose rate values for additional
comparison and benchmarking. It is important to note, however, that the AAPM
discourages use of apparent activity or exposure rate constants that describe dose rate as a
function of source radioactivity.20
The statistical uncertainties for 107 starting particles were < 0.05% at r = 1 cm for
all radionuclides for a spherical shell with radial thickness of 0.01 cm. At r = 10 cm,
statistical uncertainties were 5 0.06% for high-energy sources and 0.2% for 125I. For
103 Pd, statistical uncertainties were 0.7% and 0.1% for 107 and 5x108 starting particles,
respectively. At r = 20 cm, statistical uncertainties were 5 0.1% for 13 7Cs, 192Ir, and
169yb"
2.1.3.2 MC F(r, 9) analysis
The 2-D anisotropy function F(r,0) was calculated for six active lengths (0, 0.1,
0.2, 0.3, 0.4, and 0.5 cm) in a liquid water phantom of R = 25 cm for low-energy and R =
40 cm for high-energy radionuclides. Monoenergetic photons were generated for active
lengths of 0.1, 0.3, and 0.5 cm at 10, 20, 30, 50, 75, 100, 200, 300, 500, and 750 keV for
comparison to the radionuclide energy spectra. Line sources were approximated using a
cylinder with radius 10-6 cm. A series of intersecting concentric spheres and cones were
designed to provide 10 angular resolution about the long axis of the source. Data were
calculated at 11 radial distances between 0.5 and 12 cm, and two voxel thickness models
were examined - a fixed radial width of 0.02 cm and variable width determined using
10% of the radial distance at the point of calculation.
Monte Carlo simulations were performed using MODE P transport. A total of 5 x
107 starting particles were utilized for all radionuclides, with the exception of l03Pd that
required 2.5 x 108 starting particle histories for improved statistics. The concentric cones
result in sampling volumes that are cylindrically located about the long axis of the source.
As a result the minimum statistical uncertainty occurs on the transverse plane (0 = 900)
and the maximum uncertainty is located on the long axis of the source (0 = 00 and 1800),
where the sampling volume is approximately 450 times smaller. At a radial distance of 1
cm from a point source and a bin-width of 10% of the radial distance, the statistical
uncertainties at 50 and 85' were 0.5% and 0.2% for 137Cs; 0.5% and 0.1% for 125I; 0.5%
and 0.2% for 192Ir; 0.3% and 0.1% for 10 3Pd; and, 0.5% and 0.2% for 169Yb, respectively.
At a radial distance of 10 cm from a point source and a bin-width of 10% of the radial
distance, the statistical uncertainties at 50 and 850 were 0.5% and 0.1% for 137Cs; 1.4%
and 0.4% for 125I; 0.4% and 0.1% for 192Ir; 3.3% and 1.0% for 103Pd; and, 0.4% and 0.1%
for 169Yb, respectively.
In addition, data from the transverse plane were taken to determine gL(r) for each
active length and radionuclide, and a comparison of the point source (L = 0 cm) result
was made to the values calculated using concentric spheres. In this way, results obtained
using 4t geometry were compared to those employing the relatively small sampling
volumes introduced using concentric cones as described above.
2.1.4 RESULTS AND DISCUSSION
2.1.4.1 Phantom size
The effect of phantom size is shown in Figure 2.1.1 as the ratio of gp(r) calculated
for a given phantom thickness and gp(r) for a 50 cm radius phantom. For all
radionuclides at any distance, g(r) for R < 50 cm was less than or equal to g(r)50.
Furthermore, as r approached R, the ratio of g(r)/g(r)50o rapidly diminished from unity.
This decrease became more pronounced as r increased due to the increased proportion of
scatter dose compared to primary dose. Similarly, this increase was more pronounced
and gradual for sources having higher average photon energy (137Cs, 192Ir, 169Yb) in
comparison to lower average energy sources (125I and 103Pd).
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Figure 2.1.1: Comparison of g(r) values calculated for a given phantom size, R,
compared to R = 50 cm, which is assumed to provide full scatter conditions. Data
for 7Cs, 125I, 192Ir, 103Pd, and 169yb include curves for R = 5, 10, 15, 20, 25, 30,
35, 40, and 45 cm shown from left to right. Curves for large phantom sizes within
statistical uncertainty of unity, e.g., R = 45 and 40 cm, are not discernable. Note
the variation in the x-ordinate for the low-energy radionuclides 125I and '03Pd.
Similarly, P6rez-Calatayud et al. determined phantom sizes needed to provide full
scatter conditions for 137Cs, 125I, 192Ir, and 103Pd using the GEANT4 Monte Carlo code.73
Although they did not report the photon cross-sections utilized in their study, reasonable
comparisons may be made between results using the GEANT4 and MCNP5 Monte Carlo
codes. P6rez-Calatayud et al. observed full scatter conditions within 0.5% for I-125g(10)15
and Pd-103g(10)15. Using MCNP5 in this study, 1-125g(10)1s/I.125g(10)so = 0.997 ± 0.001 and
Pd-103g(l0)15/Pd-103g(10)5o = 0.989 ± 0.002. This study obtained Cs-137g(20)40/Cs-137g(20)50o =
0.996 ± 0.001 and Ir-192g(20)40/lr-192g(20)50 = 0.997 ± 0.001 which is in agreement with
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Perez-Calatayud et al. who noted full scatter conditions within 0.5% for g(20)40 for both
radionuclides. Excellent agreement was also obtained for 137Cs and 192Ir at all r and R,
with differences < 0.3% between our results and those obtained by Perez-Calatayud et al.
We recommended R > 40 cm for 169yb to provide full scatter conditions (within 0.2%)
for r < 20 cm.
2.1.4.2 MCNP5 F6 tally
The dosimetry investigator using MCNP5 has several cell or surface-based tally
options to choose from. Volume-based tallies are preferred as they reduce the statistical
uncertainties and improve the accuracy of MCNP5 simulations, though, the sampling
volume must be sufficiently small to minimize differences in particle fluence and average
photon path length within the cell. The *F4 tally, providing energy flux results in MeV
cm -2, can be converted to absorbed dose through application of appropriate Pen P-1
coefficeints. However, the investigator is required to segment results into energy bins
compatible with published pen p-I coefficeints, or include a tally multiplier (FMn) card to
convert results from MeV cm -2 to MeV g-1 in a direct fashion. Using F6 tally results and
a radial voxel thickness of 0.01 cm, un-encapsulated g(r) in water for a point source is
shown in Table 2.1.1. These reference data may be used to benchmark other radiation
transport codes and ensure accurate derivation of brachytherapy dosimetry parameters
between other sampling geometries and radiation transport codes.
Table 2.1.1: Radial dose functions for un-encapsulated point sources in a 50 cm-
radius liquid water phantom using the MCNP5 F6 cell-heating tally. Based upon
the number of histories simulated and the MCNP5 coefficient of variation in the
tally result, all results have a maximum statistical uncertainty of 0.1%. The tally
volume at each distance was a spherical shell of radial thickness 0.01 cm centered
on the specified r. Italicized data for
attributed to substantive attenuation.
1251r [cm]
0.1
0.2
0.3
0.5
0.8
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
6.0
7.0
8.0
9.0
10.0
11.0
12.0
13.0
14.0
15.0
16.0
17.0
18.0
19.0
20.0
1.006
1.006
1.005
1.004
1.002
1.000
0.995
0.990
0.985
0.979
0.972
0.966
0.958
0.951
0.936
0.920
0.903
0.885
0.866
0.847
0.826
0.805
0.784
0.763
0.740
0.717
0.695
0.672
0.649
1.004
1.018
1.025
1.030
1.017
1.000
0.939
0.862
0.780
0.699
0.622
0.549
0.482
0.422
0.319
0.239
0.179
0.132
0.0972
0.0719
0.0527
0.0386
0.0283
0.0207
0.0152
0.0112
0.0082
0.0061
0.0044
'ZI and '0 3Pd indicate larger uncertainties
gp(r)192Ir
0.988
0.990
0.992
0.994
0.998
1.000
1.005
1.009
1.012
1.014
1.015
1.015
1.014
1.013
1.006
0.997
0.984
0.968
0.949
0.927
0.903
0.876
0.848
0.817
0.785
0.751
0.715
0.677
0.638
1.469
1.429
1.381
1.274
1.107
1.000
0.761
0.571
0.424
0.313
0.229
0.168
0.123
0.0902
0.0483
0.0261
0.0142
0.0080
0.0046
0.0029
0.0019
0.0013
0.0010
0.0008
0.000 7
0.0006
0.0006
0.0005
0.0005
0.874
0.890
0.905
0.934
0.974
1.000
1.056
1.103
1.142
1.172
1.197
1.213
1.224
1.229
1.226
1.206
1.175
1.135
1.088
1.035
0.983
0.927
0.871
0.816
0.763
0.712
0.6616
0.6152
0.5705
Towards determining these parameters, the F6 tally with appropriate units of MeV
g-1 is recommended for simulating radiation transport using MCNP because it directly
correlates with absorbed dose rate without using potentially inconsistent g p-1
_ __
137CS 103pd 169yb
coefficeints. The F6 tally, generating cell-heating data, incorporates MCNP5 lten P-1
values that were evaluated by taking the ratio of F6 and *F4 tally results. Comparison of
MCNP5-derived values and ,,en p-' values published by NIST71 gives an average of 0.999
± 0.002 (± 1 s.d.) for photon energies between 15 keV and 1.5 MeV. Thus, the F6 tally
now adequately estimates absorbed dose rates for conventional photon-emitting
brachytherapy sources and obviates the need to use and modify alternate tallies.
2.1.4.3 Radial dose function
Williamson calculated g(r) with the MCPT radiation transport code for an un-
encapsulated 125I point source in water,74 using a modified version of the DLC-146
photon cross-sections released in 1989. Comparison of the 125I results in this study to
Williamson show agreement within 0.5% up to 7 cm, followed by a rapid divergence to
1.8% at 11 cm and 8.2% at 14 cm. The primary difference between this study and
Williamson is due to disparity in phantom size. Repeating the simulation described
above using an R = 15 cm liquid water phantom resulted in a maximum disagreement of
1.3% at 14 cm.
When assessed using *F4 tallies, differences between MODE PE and MODE P
transport to account for the dosimetric impact of electrons for 0.1 < r < 20 cm was <
0.2% for 137Cs, < 0.1% for 192Ir, and < 0.03% for 169Yb. Thus, the proportion of dose
contributed by electrons was less than 1:500 for these high-energy radionuclides. For
low-energy sources such as 10 3Pd and 125I, electron contributions were < 1:3,000.
Similarly, MODE PE and MODE E simulations of source electrons for the five
radionuclides yielded inconsequential contributions to the total dose past 0.3 cm. For
example, MODE PE simulations of source electrons from 169Yb yielded *F4 results <
0.01% of the source photons from 169Yb. Therefore, brachytherapy dosimetry
calculations using MODE P simulation of the source photon spectrum is adequate
towards determining dose distributions in water as recommended in TG-43U1.
Justification for this simplification is required for other radiation sources having
considerably different energies, or beyond the radial ranges studied.
For the three high-energy radionuclides, there was no variation in g(r) > ± 0.5%
for voxel thickness of 0.2 cm and below and variable voxel thickness of 5% and 10% of
the radial distance similarly provided comparable (± 0.5%) g(r) data. For the low-energy
radionuclides, there were few noticeable volume-averaging effects at large radial
distances below a voxel thickness of 0.2 cm. 1251 exhibited < ± 0.5% variation for voxel
thickness < 0.05 cm, and 10 3Pd demonstrated few minor deviations within ± 0.6% for
voxel thickness of < 0.1 cm. Variable voxel widths of 5% and 10% did not reproduce
g(r) within + 0.5% of that for 0.01 cm-thick shells for 125I and 10 3Pd due to the rapid
radial dose falloff of these radionuclides. The maximum errors incurred using variable
voxel width for low-energy radionuclides was 1.5% and the average difference was 0.2%
+ 0.01% in comparison to the 0.01 cm-thick shells.
Comparisons of dose rates and gp(r) calculated using the spherical sampling space
or the space divided into conics produced identical results within the statistical
uncertainties for all radionuclides and r values examined. Thus, there were no artifacts
from the MCNP software when dividing the space using different methods.
The calculated radial dose functions for L = 0.2, 0.3, and 0.4 cm were compared
to the average of the value calculated for neighboring lengths (0.1 cm increments). For
example, gL(r) calculated from L = 0.2 cm F(r,0) values was compared to the average of
gL(r) calculated from L = 0.1 cm and L = 0.3 cm. For 137Cs, 192Ir, and 169Yb, the average
of the neighboring values produced gL(r) data that were within 0.5% of the calculated one
for all radial distances evaluated. The low-energy radionuclides provided interpolated
gL(r) values within 0.8% for 1251 and within 1.2% for '0 3 Pd of the calculated values.
Thus, radial dose function data for non-integer active lengths can be closely interpolated
from calculated values. Additional work is required, however, to determine if gL(r) can
be appropriately extrapolated to smaller or larger active lengths than those calculated.
Table 2.1.2 shows the absolute dose rates in water per contained mCi of
radionuclide at ro and 0o for the five radionuclides. In addition, the ratio of the dose rate
in each tissue-model to liquid water is also provided. The (F1)x values in the original TG-
43 report'o can be compared to dose rates calculated in this study; however, significant
differences in the photon spectra and calculation methodologies are present. Ratios of
0.702, 1.105, and 1.001 were obtained for 103Pd, 192Ir, and 1251, respectively, by
comparing Table 2.1.2 data to TG-43 values.
Table 2.1.2: Dose rate per contained mCi of activity in water at ro for each
radionuclide for the point source approximation. Also shown is the ratio of the
dose rate in materials of dosimetric interest (from Refs. 70 and 71) to that in
liquid water.
(ro,Oo) x d(ro, Oo) / walerb(ro,Oo)
[cGy h-1 mCi -1]  Breast muscle soft tissue 4-component
tissue
Cs-137 3.153 0.992 0.991 0.991 0.989
1-125 1.321 0.852 1.016 1.018 0.942
Ir-192 4.541 0.993 0.992 0.992 0.990
Pd-103 0.910 0.898 0.981 0.977 0.966
Yb-169 1.996 0.936 1.014 1.017 0.967
Comparison of g(r) calculated in four materials of dosimetric interest to g(r) in
liquid water is shown in Figure 2.1.2 for 137Cs, 1251, 19 2Ir, 103Pd, and 169yb. There were
notable variations in g(r) at large radial distances for the low-energy photon
brachytherapy sources, 125I and l03pd. Factor of 2 differences in g(r) between water and
ICRU 44 breast tissue were present for 10 3Pd at a depth of 9 cm, and g(r) for ICRU
muscle and soft tissue were approximately 30% below that in water at a depth of 9 cm for
both 125I and 10 3Pd. Conversely, high-energy 137Cs and 192Ir exhibited only a 4%
reduction of g(r) in ICRU muscle and soft tissue in comparison to liquid water at a
penetration of 20 cm. Generally, 169Yb was more sensitive to phantom material in
comparison to 137Cs or 192Ir. At 10 cm, g(r) in the four tissue compositions studied was
approximately within ± 1% of g(r) in water for 137Cs and 192Ir, but differences increased
to ± 5% for 169Yb.
2.0
31.1
4 .5
!.3
o 1
1.0
0.3
0.6
0.1 1.0 Distance[cm] 10.0 01ista. ce [c ] 1.0 Distance[cm] 10.0
I
at
m
a
0.1 1.0
D.94
0.92
0.90
0 ..22f Tu -'
Distance [cm] Distance [am]
4CacpTmae - Yb-169
0.1 1.0 10.0
Distance [cm]
Figure 2.1.2: Comparison of g(r) calculated in four tissue substitutes to g(r)
calculated in liquid water for 13 CS, 125I, 192r, 103Pd, and 169Yb. Because low-
energy photons are strongly attenuated through transport in neutral density
material, the 125I and o03Pd photons exhibit the greatest difference between g(r) in
tissue and in liquid water. Of the three high-energy sources, 169yb is the most
strongly affected by transport in non-water media.
Reniers used MCNP4C and the EPDL97 cross-section library to study the impact
of tissue composition on brachytherapy dosimetry parameters for low-energy photon
emitting radionuclides using the IBt seed design.75 Differences of 10% and 15% at a
depth of 5 cm in muscle for 125I and 0o3Pd were reported by Reniers, while this study
yielded differences of 9.7 ± 0.2% and 17.7 ± 0.3%, respectively. Similarly, Reniers
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noted that g(5) for '03Pd in water was underestimated by up to 50% in comparison to
breast tissue, an effect also observed in this study with waterg(5)/breastg(5) = 67% using a
differently expressed ratio. Thus, our observations of bare point sources were supported
by Reniers' findings for low-energy radionuclides in a specific seed design, and we agree
that advances in brachytherapy source dosimetry should incorporate tissue composition to
better reflect non-trivial differences that may occur, especially for low-energy photon-
emitting brachytherapy sources.
Incorporating TG-43U1 recommended photon spectra for 125I and l03Pd resulted
in MCNP5 F6 tally results within 0.1% and 0.8%, respectively, of those using the NNDC
photon data for all radii. The difference in dose rates for 125I are within the statistical
uncertainties (0.5% max), and differences for 10 3Pd are likely due to the more detailed
NNDC photon spectra (14 vs 8 lines above 10 keV) with slightly different intensities.
Furthermore, normalized dose rate values such as using g(r) computed with the TG-43U1
photon data were on average < 0.03% different for 125I and <0.3% different for '03pd in
comparison to the results in Table 2.1.1. Radiation transport calculations using the
NNDC photon spectrum and that of Glasgow and Dillman provided similarly comparable
g(r) data for 192Ir. Differences in F6-based dose rates using NNDC data or Glasgow and
Dillman photon spectra were -1.6% at 0.1 cm, increased to +1.7% at 1 cm, and were
approximately +1.9% to r = 20 cm. These tally ratios correspond to Ir-192g(r) ratios of -
3.2% at 0.1 cm, -0.7% at 0.5 cm, and < 0.3% from 0.8 cm to 20 cm. As such, the NNDC
192Ir photon spectrum with 25 P-decay photons and 16 electron capture photons (each
including 6 characteristic x-rays) provides similar radiation transport results to the classic
Glasgow and Dillman spectra having 36 3-decay photons (including 21 characteristic x-
rays), 34 electron capture photons (including 21 characteristic x-rays), and 49
bremsstrahlung photons between 0.006 and 1.3 MeV.
While a coarse 192Ir spectra is presented in the 1995 AAPM TG-43 report,10 the
AAPM has not yet recommended photon energy spectra for 137Cs, 1921r, or 169Yb to be
used for Monte Carlo simulations of brachytherapy dose deposition. The widely used
192Ir photon spectrum of Glasgow and Dillman could be evaluated and adapted by the
AAPM for this purpose.29' 76'77 Other radionuclides, such as 137Cs, have had a number of
disparate sources cited for energy spectra used in radiation transport calculations and
would benefit from a standardized spectrum, as well as a review of the impact of each
variation.7
s-so
2.1.4.1 F(r, 9) analysis
F(r,0) data calculated using six effective lengths between 0.0 and 0.5 cm were
largely within 0.5% of unity for 0.5 < r < 12 cm for 137Cs and 1251. For L = 0.5 cm, Ir-
192F(0.5,00 ) approached 1.01 for decreasing 0. A similar increase in F(r,0) with
decreasing 0 was more strongly exhibited by 103Pd for L = 0.5 cm, with Pd-103F(0.5,00 ) =
1.048, Pd-103F(1,0 0) = 1.031, and Pd-103F(1.5,00 ) = 1.023. The increase in F(r,0) for small r
and 0 was similarly exhibited for active lengths of 0.4 and 0.3 cm with Pd-103F(0.5,00 ) =
1.031 and 1.017, respectively. 169Yb exhibited the opposite effect, where F(r,0) was
reduced below unity for increased active length, decreased radius, and decreased polar
angle with Yb-169F(0.5,00 ) = 0.984 and Yb- 169F(1,0 0) = 0.992. As observed for Pd-103F(r,0),
the magnitude of the deviation from unity for Yb-169F(r,0) was reduced along with
reduction in L. All these results were statistically significant, and perturbations of the
dose distribution beyond those accounted for by g(r) were not expected since the
radionuclide distributions were un-encapsulated. Reported deviations in source
anisotropy commonly occur along the source long-axes where end welds and other
mechanical features are present. Thus, the Yb-169F(r,0) < 1.0 result at 0 = 00 was notable
because it occurred in the absence of a capsule, and the Pd-lo03F(r,0) > 1.0 result was
notable because commercial sources have not exhibited a dose rate on the long axis larger
than that on the transverse plane for the same r value. Observed anisotropy effects,
attributed to source photon absorption in the liquid water medium, suggest a relationship
between L and photon energy.
Therefore, Monte Carlo simulations were performed using monoenergetic
photons to further examine these observations. Figure 2.1.3 shows F(0.5,0) for ten
energies between 10 and 750 keV for L = 0.5 cm. Considering the observed behavior of
169yb, with an average energy of 93.3 keV, the F(r,0) data is consistent with the values
depicted in Figure 2.1.3 between 100 and 75 keV. A 5% difference in F(0.5,00) between
20 and 30 keV photons was detected. 1251 with an average photon energy of 28.4 keV did
not exhibit the F(r,0) effect observed for o0 3Pd, because of the average photon energy of
10 3Pd is 20.7 keV. In practice, the 103Pd photon spectrum is hardened following
transmission through the brachytherapy encapsulation, and F(r,0) > 1.0 is not observed.
For example, the two 103Pd sources included in AAPM TG-43U1 have F(0.5,0°) - 0.68
for Leff- 0.4 cm. Thus, the 103Pd sources in TG-43U1 would have lower F(r, 0) values if
not for the geometry effect on F(r,0) noted in this study for a bare source. Additional
work is needed to differentiate encapsulation effects from energy-related geometrical
effects exhibited in Figure 2.1.3.
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Figure 2.1.3: Mono-energetic photon F(r,0) for an active length of 0.5 cm and a
radial distance of 0.5 cm. F(r,0) data were calculated using 10, 15, 20, 30, 40, 50,
60, 75, 100, 200, 300, 500, and 750 keV photons and plotted as a function of
energy in 100 increments. The insert displays the low-energy behavior of the
curves where F(0.5,0) increases to a maximum of 2.08 at F(0.5,00 ).
Table 2.1.3: 2D anisotropy function data for multiple active lengths at 10, 50,
and 100 keV. L = 0.1, 0.3, and 0.5 cm were employed to show variations in
F(r,0) as a function of both active length and energy for an un-encapsulated line
source.
F(0.5,0)
10 keV 50 keV 100 keV
L (cm)= 0.1 0.3 0.5 0.1 0.3 0.5 0.1 0.3 0.5
00 1.044 1.332 2.083 0.995 0.989 0.976 0.997 0.993 0.987
100 1.033 1.314 2.035 0.998 0.993 0.977 0.998 0.996 0.988
200 1.031 1.272 1.856 0.998 0.991 0.979 0.999 0.994 0.990
300 1.032 1.226 1.654 1.000 0.993 0.983 0.999 0.995 0.991
400 1.019 1.171 1.456 0.998 0.996 0.989 0.999 0.997 0.994
500 1.018 1.111 1.289 1.000 0.997 0.992 1.000 0.998 0.995
600 1.010 1.069 1.158 0.999 0.998 0.995 0.999 0.998 0.997
700 1.010 1.027 1.066 1.000 0.998 0.999 0.999 0.998 0.999
800 0.997 1.002 1.012 1.000 1.000 1.001 1.000 1.000 1.001
Table 2.1.3 shows F(0.5,0) for L = 0.1, 0.3, and 0.5 cm at 10, 50, and 100 keV
towards demonstrating trends in energy-related geometrical effects. For low energy
sources, F(r,0) can increase dramatically at short radial distances and low 0. In contrast,
photon energies above 50 keV yield F(r,0) values near unity near the transverse plane.
Volume averaging effects were not observed when comparing two different voxel
thickness models. Comparable F(r,0) data were obtained with a radial thickness of 0.02
cm and 10% of the radial distance at the point of calculation for all radionuclides. For
each L, data were averaged at 11 radial distances and 9 angles between 00 and 800.
Average differences were less than 0.1% with a maximum standard deviation of 0.3% for
137Cs, 192Ir, and 169Yb. 1251 and 10 3Pd exhibited maximum average differences of 0.2% ±
0.7% and 0.2% + 0.4%, respectively. However, the increased differences were due to
increased statistical uncertainties at large r and small 0 for the weakly penetrating, low
energy radionuclides.
Unlike g(r) where MCNP tally choice significantly impacted the result, the *F4
tally and F6 tally provided comparable F(r,0) values for each radionuclide. Performing
the same comparison described above for all r and 0 at each active length (99 data points
for 6 L values), the standard deviation of the differences between F6 and *F4-derived
F(r,0) was 0.3% for all radionuclides, with decreasing differences for increasing photon
energy. Within the statistical uncertainties, F(r,O) results obtained using either *F4 or F6
were identical. Though the *F4 tally does not use the energy-dependent pen p-1, it is
dependent on spectral changes. Unlike g(r), however, F(r,O) is determined at a fixed r
and is not as subject to variations in photon spectra.
2.1.5 CONCLUSIONS
Radiation transport calculations are essential towards establishing brachytherapy
dosimetry parameters via methods delineated in the AAPM TG-43U1 report. Numerous
publications have presented various radiation transport codes and methodologies specific
to a commercial seed, while few investigations have addressed generalizable issues
pertinent to all sources. Simulations similar to those described here can be used to
benchmark various radiation transport codes and assure a common standard for all
investigators. Furthermore, tissue inhomogeneities and non-infinite media are inherent
aspects of actual brachytherapy administration, and both were shown to cause significant
variations in calculated brachytherapy dosimetry parameters. Thus, it is important for
future investigators to model these effects, and/or work to advance the field of
brachytherapy towards Monte Carlo-based treatment planning systems when appropriate
to account for tissue heterogeneities and scatter conditions.
2.2 COMS eye plaque brachytherapy dosimetry for '03Pd, 125I, and 131CSt
2.2.1 ABSTRACT
MC simulations were performed to estimate brachytherapy dose distributions for
Collaborative Ocular Melanoma Study (COMS) eye plaques. Brachytherapy seed
models 200, 6711, and CS-1 Rev2 carrying '03Pd, 125I, and 131Cs radionuclides,
respectively, were modeled and benchmarked against previously published values.
Calculated dose rate constants, McA, were 0.684, 0.924, and 1.052 cGy h-' U-' (±2.6%,
k= 1 uncertainty) for the models 200, 6711, and CS-1 Rev2, respectively. The seeds were
t Submitted to Medical Physics on 12/14/2007: C. S. Melhus and M. J. Rivard, "COMS eye plaque
brachytherapy dosimetry for o03Pd, 125I, and '3 tCs," (07-853).
distributed into 12, 14, 16, 18, and 20 mm-diameter COMS eye plaques. Simulations
were performed in both heterogeneous and homogeneous environments, where the latter
were in-water and the former included the silastic seed carrier insert and gold-alloy
plaque. MC-based homogenous central axis dose distributions agreed within 2% ± 1% (±
1 s.d.) to hand-calculated values. For heterogeneous simulations, notable photon
attenuation was observed in the silastic insert, with dose reduction at 5 mm of 18%, 11%,
and 10% for 103Pd, 125I, and 13 1Cs, respectively. A depth-dependent correction factor was
derived to correct homogenous central-axis dose distributions for plaque component
heterogeneities, which were found to be significant at short radial distances.
2.2.2 INTRODUCTION
COMS was initiated during the 1980s to compare episcleral plaque brachytherapy
using 125I to enucleation, or removal of the involved eye.2 Although many plaque designs
have been utilized, the COMS protocol required use of a standardized plaque.
Brachytherapy seeds were placed in channels within a polymer carrier that was adhered
to a gold-alloy plaque. Brachytherapy dosimetry calculations for the protocol
incorporated a number of assumptions that have been examined in the recent literature.
These include: collimation by the plaque, photon absorption in the seed carrier, and
characteristic gold x-rays from the plaque, among others. 51' 81'8 2 While these studies have
helped further understanding of eye plaque brachytherapy dosimetry, the AAPM recently
created Radiation Therapy Committee Task Group 129 to formally review these studies
and make recommendations to improve the standard of care. This work employs Monte
Carlo techniques to simulate dose distributions from COMS eye plaques for
commercially available brachytherapy seeds carrying either 10 3Pd, 1251, or 131Cs. While
other studies have employed Monte Carlo techniques to evaluate dose distributions from
a single-seed in a plaque, this study is the first to our knowledge to fully model all of the
brachytherapy seeds in COMS eye plaques.
2.2.3 MATERIALS AND METHODS
Brachytherapy dose distributions were simulated with the MCNP5 Monte Carlo
radiation transport code published by Los Alamos National Laboratory.67  The
MCPLIB04 photon cross-section library was applied using data from ENDF/B-VI.68
Particle energy fluence and cell-heating tallies (*F4 and F6, respectively) were employed
to calculate kerma per starting particle, which is equivalent to absorbed dose for the
photon energies studied. Energy fluence tallies in MeV cm "2 were modified by Hubbell
and Seltzer's7 1 tabulated tCn p-1 [cm 2 g-] values to provide MC results in dose per
starting particle. Photon emissions from 103Pd, 1251, and 131Cs were simulated using
emission frequencies from the National Nuclear Data Center (NNDC).3 3 Photon energies
below 10 keV that do not substantially penetrate Ti seed encapsulation were not included
in these simulations.
2.2.3.1 Seed dosimetry benchmarking
Three brachytherapy seed models were studied: model 200, model 6711, and
model CS-1 Rev2 containing 103Pd, 1251, and 131Cs, respectively. The model 200
(Theragenics Corp.; Buford, GA) has an effective active length of 4.23 mm with source
photons emitting from a thin Pd-metal coating on two right-cylindrical graphite markers
separated by a lead marker.20 Although variation in Pd thickness is possible, a nominal
thickness of 2 gm was chosen for comparison to Williamson' 4 and to the AAPM TG-
43U1 report.2o Source component dimensions and composition were replicated from
Williamson.' 4 The model 6711 brachytherapy seed, known as the OncoSeed TM (Oncura;
Arlington Heights, IL) has consensus brachytherapy dosimetry data available for an
active length, L, of 3.0 mm.20 However, a more recent publication by Dolan et al. notes
that current manufacturing practices produce L = 2.8 mm with beveled edges on a right-
cylindrical silver marker. Is The 125I radionuclide is adsorbed onto the surface of the Ag
marker in a 2 jim-thick halide coating. Other aspects of the model 6711 seed followed
those presented by Dolan et al.15 The model CS-1 Rev2 (IsoRay Inc.; Richland, WA) has
a 4.0 mm long gold marker with a Pyrex/ceramic coating, which carries the 131Cs
radionuclide.2 6 Source dimensions and composition were modeled per Rivard (L = 4.0
mm).26
To determine brachytherapy dosimetry parameters each seed was simulated in a
15 cm radius sphere of liquid water (p = 0.998 g cm-3), with a hydrogen-to-oxygen
atomic ratio of 2:1. 2D dose distributions were evaluated using a series of concentric
spheres and cones as described by Rivard.83 Results of these calculations were compared
to AAPM consensus data and/or to specific publications if AAPM consensus values were
not available, e.g., for the CS-1 Rev2. Specifically, gL(r) was determined for 1 < r < 70
mm, and F(r,0) was evaluated in 100 angular increments for 5 < r < 75 mm.
In addition to the relative brachytherapy dosimetry parameters, calculations of the
air kerma strength, sK, and dose rate constant, McA, were performed. Due to different
techniques used by individual investigators, several parameters were examined in the
determination of SK. The primary difference was the technique employed to enforce the
6=5 keV photon cutoff. Dosimetry investigators either eliminated tally contributions
from photons with E, < 5 keV or incorporated a thin Al filter between the source and the
MC tally volumes. The latter approach mimics measurement of SK with the National
Institute of Standards and Technology Wide Angle Free-Air Chamber (NIST WAFAC)
as described in Appendix B of the AAPM TG-43UI report.20 A correction for photon
attenuation in the Al filter (kfoil) was made by comparing calculations in vacuo with and
without the filter present. In addition, correction for air attenuation was evaluated using
two methods: (a) performing simulations in vacuum with modified *F4 tallies; and (b)
calculating F6 tally results directly in air and correcting them with air attenuation
coefficients determined from *F4 results in vacuum and in air. Finally, the internal seed
structure was removed by replacing all components with a vacuum and also by replacing
the seed with a point source for determination of apparent activity (Aapp), where Aapp is
the activity of an unfiltered source providing the same air kerma strength as the filtered
source.84 As discussed below, Aapp is required to calculate dose from a brachytherapy
seed with a given contained activity.
MC geometry for air kerma calculations utilized a 200 cm-radius phantom with 1
mm-thick spherical shells spaced every 5 cm between 5 and 150 cm. The sampling
volume within the spherical shells was delineated by the intersection of the spherical
shells with a +8' cone in the transverse plane of the seed. For simulations with the Al
filter to block Ti K-edge x-rays, a 0.08 mm-thick spherical Al shell (p= 2.7 g cm -3) was
placed at r = 2 cm. This thickness of Al was similarly applied by Williamson; 14 although,
other investigations have used different thickness, e.g., 0.08636 mm for comparison to
the NIST WAFAC.ss When air was included in the model, the 40% relative humidity air
recommended by TG-43U1 was incorporated.20
Calculations used 2 x 108 starting particles. This limited statistical uncertainties
below 0.1% for air kerma calculations. For in-water calculations with 1251 and 131Cs,
statistical uncertainties were < 0.4% upto a distance of 7 cm along the transverse plane,
and at an angle of 50 from the long axis were 0.8% and 2% at 2 and 7 cm, respectively.
For comparison, 103Pd photon statistical uncertainties on the transverse plane were 1% at
7 cm. At 50 from the long axis, statistical uncertainties were 1% and 5% at 2 and 7 cm,
respectively, for the model 200 seed.
2.2.3.2 COMS plaque simulations
Standard COMS eye plaques with diameters of 12, 14, 16, 18, and 20 mm were
simulated. These plaques assume a standard eye diameter of 24.6 mm and place the seed
centers a distance of 1.4 mm from the outer sclera on the surface of a sphere of radius
13.7 mm.8 6 For reproducible seed placement, troughs are molded into a medical grade
silastic insert. The troughs are arranged in regular geometric shapes that provide
cylindrical symmetry about the plaque central axis. The silastic insert is bonded to a 0.5
mm-thick plaque cast from Modulay, a gold alloy material used in dental medicine. Six
eyelets spaced 300 apart are welded to the outer edge of the plaque for suturing the
assembly to the eye during treatment. Descriptions of COMS plaques and related
dosimetry are available in the literature and their references.2'5 •'8 2'8 7'88
Models 200, 6711, and CS-1 Rev2 seeds modeled as described above were
inserted in silastic medium using the MCNP universe card [U] and copied and translated
into the various plaque geometries with the cell translation card [TRCL]. Seed center
coordinates followed the schema determined by R.W. Kline and reproduced in Rivard et
al.8 9  Silastic composition followed Chiu-Tsao et aLs.5  Elemental composition of
Modulay was gold, silver, copper, and palladium with mass percents of 77%, 14%, 8%,
and 1% respectively.8 2 Plaques were centered in a 15-cm radius sphere of liquid water to
provide adequate photon backscatter, although, full-scatter geometry does not simulate
patient treatment when the plaque is implanted near the patient surface. Comparison to
homogenous brachytherapy dose distributions using the TG-43U1 formalism were made
by replacing silastic and Modulay with liquid water. Inclusion of the silastic and
Modulay elements is described as 'HETERO' for heterogeneous media, while homogenous
liquid water simulations is called 'HOMo.' For comparison to the single seed MC
calculations of Chiu-Tsao et al. in a 20 mm diameter plaque, additional simulations were
performed with a single seed in the silastic carrier.
Central axis depth doses to water were calculated in a 0.05 mm-radius cylinder,
divided into 0.01 mm-thick sampling regions from the outer sclera to a depth of 13.4 mm
in 0.5 mm steps. Additionally, the MCNP FMESH tally was employed to obtain a
rectilinear volume of modified *F4 tally results encompassing the entire plaque. The
rectilinear mesh had a grid spacing of 0.5 mm with the following dimensions: 25 mm x
25 mm parallel to the plaque face and 24 mm to -7.5 mm along the central axis where the
origin is at the outer sclera on the plaque central axis.
MC-calculated dose per starting particle was converted to absorbed dose using
Eq. 2.2.1.
d(xyz)=sd(x,Y,Z) seed SK . . SK SK -1-K n (2.2.1)
sK SP SK
Where: d(x, y, z) dose rate at position x,y,z
,d(x, y, z) dose rate per starting particle at position x,y,z
seed SK per seed needed to deliver d (x, y, z)
cont
SP, os sK per starting particle for the encapsulated source
spK p p  sK per starting particle for the apparent, un-encapsulated
point source
I number of photons per decay
K constant representing starting particles per mCi-h
n number of seeds
Generally, terms in Eq. 2.2.1 convert the contained activity per seed in mCi to apparent
air kerma strength of the encapsulated source. The total dose delivered was calculated by
integrating d (x, y, z) over the prescribed treatment time. Following the American
Brachytherapy Society (ABS) recommendations for uveal melanoma brachytherapy, 2 a
treatment time of 168 h was utilized and source strength per seed (seed SK) was chosen to
deliver a total dose of 85 Gy at 5 mm on the central axis. While a 168 h treatment time
may not deliver the recommended dose rate during treatment, the results are directly
comparable to the conventional brachytherapy dose calculations of Rivard et al.89
For mesh tallies, statistical uncertainties of 4%, 3%, and 2% were obtained at 25
mm on the plaque central axis for 103Pd, 1251, and 131Cs, respectively, for 2 x 10S starting
particles. At the prescription depth (r = 5 mm), central axis statistical uncertainties were
< 1% for all radionuclides and increased to 3%, 2%, and 1% at 12.5 mm off-axis for
103Pd, 125I, and 131Cs, respectively. For tally regions shielded by the plaque in HETERO
calculations, statistical uncertainties increased notably due to significant photon
attenuation. Statistical uncertainties exceeding 40% were prevalent in this region.
Plaque simulations generally required between 8 and 24 h of computing time on a 2.4
GHz Pentium D computer, though no variance reduction techniques were utilized.
2.2.4 RESULTS AND DISCUSSION
2.2.4.1 Seed dosimetry benchmarking
Radial dose function results for the models 200, 6711, and CS-1 Rev2
brachytherapy seeds are presented in Table 2.2.1. Table 2.2.1 also includes the percent
difference between the results of this study and consensus or reference gL(r) data. AAPM
TG-43U1,20 Dolan et al.,'s and Rivard2 6 were used for reference gL(r) values. gL(r)
comparison for the CS-1 Rev2 were excellent (< 0.5%) because the seed model utilized
in each study was identical. For the models 200 and 6711, gL(r) results were generally <
2%, although, larger variation occurred due to the difference in MC code, tally type, and
volume-averaging. Similar gL(r) agreement was observed for comparison of the model
200 to Williamson' 4 and for the model 6711 to TG-43U 1.20 Given the compound
uncertainties, agreement between these datasets was acceptable.
Table 2.2.1: Radial dose function using the line source approximation for the
three seed models and comparison to reference data.
gL(r) Percent-difference from reference
(%
r [mm] 200 6711 CS-1 Rev2 200 A  6711 CS-1 Rev2c
1 0.925 1.072 0.959 2 -3 < 0.5
3 1.324 1.086 0.993 -4 -2
4 1.297 1.081 1.001 -5 -1 -
5 1.258 1.070 1.008 -3 -1 < 0.5
10 1.000 1.000 1.000 - -
15 0.753 0.908 0.963 1 1 < 0.5
20 0.556 0.814 0.908 1 1 < 0.5
30 0.299 0.633 0.777 -1 1 < 0.5
40 0.162 0.482 0.641 -1 1 < 0.5
50 0.086 0.361 0.520 -3 2 < 0.5
70 0.026 0.199 0.323 -2 3 < 0.5
A Ref. 14
B Ref. 15
c Ref. 26
2D anisotropy results were compared to TG-43U1 for '03Pd and 125I and to Rivard
for 131Cs. 20 ,26 Model 200 10 3Pd results were compared from r=2.5 to 75 mm at nine radial
distances with an average agreement of 2.5 ± 5.7% (± 1 s.d.). TG-43U1 offers 125I F(r,0)
data between r-5 and 50 mm at six distances20 and results agreed within an average of
3.3 ± 5.5% (± 1 s.d.). For the model CS-i Rev2 131Cs seed, F(r,0) agreed within 0.4 ±
1.2% (± 1 s.d.) to Rivard over thirteen radial distances between 0.5 and 70 mm.26 As
observed for gL(r), very good agreement was observed for the 131Cs seed due to a shared
seed model. For the 10 3Pd and 125I seeds, differences between our MC result and
reference data were as high as ±20% directly on the source long axis for r < 2 cm. These
variations were expected due to geometrical differences in tally sampling volumes given
the short radial distance and high dose gradient. However, design of the COMS eye
plaque mitigates concerns for source-end anisotropy because seeds are oriented parallel
to the eye scleral surface where photons emitted along the source long axes are unlikely
to escape the eye plaque Modulay walls.
For the models 200, 6711, and CS-i Rev2, McA values of 0.684, 0.924, and 1.052
cGy h-W U-1, respectively, exhibited good agreement to published values. AAPM
consensus McA from TG-43U1 for the models 200 and 6711 are 0.686 (-0.3%) and 0.950
(-0.5%) cGy h- ' U-', respectively.20 For additional comparison, Dolan et al. obtained
MCA = 0.942 cGy h-1 U-1 (-1.9%) for the model 6711.1 s For the model CS-1 Rev2,
Rivard calculated 1.046 cGy h-' U-' (+0.6%), 6 and Wittman and Fisher simulated 1.040
cGy h-' U-' (+1.2%).85 Calculation of McA differed by less than 0.2% when cell-heating
[F6] tallies were used in place of track-length estimators [modified *F4].
Determination of SK using a thin-Al filter did not impact McA in comparison to
employing the DE/DF card to enforce the 8 > 5 keV photon energy cutoff. Aluminum
filter correction factors (kfoil) of 1.066, 1.033, and 1.021 were determined for 10 3Pd, 1251,
and 131Cs, respectively, for 0.08 mm thickness. For comparison, kfoit factors measured for
the NIST WAFAC with a 0.08636 mm-thick Al filter were 1.078 and 1.039 for the
models 200 and 6711, respectively.'8 Wittman and Fisher calculated the NIST WAFAC
correction factor for 131Cs using an average photon energy and ýt p'-1 values to obtain kfoil
=1.026.85 Our MC-derived kfoil values for a 0.08 mm Al filter are in good agreement with
the slightly larger factors required for a thicker filter. Calculated SK per mCi values were:
0.721, 0.717, and 0.404 U mCi-1 for the models 200, 6711, and CS-1 Rev2, respectively.
These sK results are compared to 0.700 U mCi-1 (-2.9%) for Williamson's WAFAC
simulation of the model 200,14 0.763 U mCi -1' (+6.4%) for the Dolan et al. WAFAC
simulation of the model 6711,15 and 0.410 U mCi l- (+1.6%) for Wittman and Fisher's
model CS-1 Rev2 calculation. ss85
Although no longer recommended by the AAPM TG-43U1 report,2 A,,pp was
determined to be 0.539 mCi for the model 200, 0.549 mCi for the model 6711, and 0.719
mCi for the model CS-1 Rev2. Calculations of Aapp using the source distribution in
vacuum without the seed components were statistically equivalent to the un-encapsulated
point-source result. Incorporating the corresponding sK, SK / App for each seed was
determined to be 1.336, 1.296, and 0.562 cm 2 cGy h-1 mCi-' for the models 200, 6711,
and CS-1 Rev2, respectively. Previous calculations of Aapp divided the measured SK by
an assumed exposure factor (F)x9, and resulted in values of 1.293 (-3%) and 1.270 (-2%)
for the models 200 and 6711, respectively.8 4 Our MC-derived sK / App for the models
200 and 6711 are in good agreement with accepted values; however, a confirming
measurement of sK / Aap is needed for the model CS-1 Rev2.
2.2.4.2 COMS plaque simulations
Table 2.2.2 tabulates central axis depth dose distributions for HETERO
calculations that deliver a prescription dose (Dx) of 85 Gy at 5 mm depth for a 168 h
implant. The sK per seed required to administer the stated dose is also listed. In addition,
the HETERO/HOMo ratio per starting particle is shown to demonstrate the impact of
silastic attenuation as a function of depth. These ratios demonstrate that HETERO
calculations require approximately +22.6 + 0.3% (± 1 s.d.), +12.8 + 0.2% (± 1 s.d.), and
+10.6 ± 0.2% (± 1 s.d.) more sK in each 103Pd, 125I, and 1 31Cs seed, respectively, to deliver
the same DR. to 5 mm depth.
Table 2.2.2: Central axis dose distributions for 12-20 mm diameter COMS eye plaques loaded
with 'O' Pd, 1251, or 131Cs brachytherapy seeds. The listed sK was chosen to deliver 85 Gy to 5 mm
depth for each plaque size. In addition, the ratio of HETERO/HOMO per starting particle is
included, indicating the impact of attenuation in the silastic seed carrier as a function of treatment
depth. Finally, sK to deliver 85 Gy in HOMO media is presented.
COMS eye plaque diameter [mm] COMS eye plaque diameter [mm]
Central 12 14 16 18 20 12 14 16 18 20
axis
[mm] o03Pd model 200 in HETERO medium [Gy] lo3Pd model 200 HETERO/HOMO Ratio
0.0 365.7 322.6 258.5 249.8 226.2 0.77 0.76 0.74 0.75 0.74
0.5 312.7 279.2 233.0 220.5 203.5 0.78 0.78 0.76 0.76 0.76
1.0 268.2 241.8 210.9 197.2 182.6 0.80 0.79 0.78 0.77 0.77
1.5 229.6 212.4 189.0 177.2 163.6 0.81 0.80 0.79 0.79 0.78
2.0 199.4 185.5 168.9 160.6 150.7 0.81 0.81 0.80 0.80 0.79
2.5 170.9 162.5 151.2 143.2 136.4 0.82 0.81 0.80 0.80 0.80
3.0 146.9 142.7 134.2 129.4 124.6 0.82 0.81 0.81 0.80 0.80
3.5 127.9 124.3 120.6 116.9 112.6 0.82 0.82 0.81 0.81 0.80
4.0 110.9 109.5 107.3 105.3 102.6 0.82 0.82 0.81 0.81 0.81
4.5 96.8 96.7 95.1 94.6 92.1 0.82 0.82 0.82 0.81 0.81
5.0 85.0 85.0 85.0 85.0 85.0 0.82 0.82 0.81 0.82 0.81
6.0 65.8 67.4 68.4 69.9 69.7 0.82 0.82 0.82 0.82 0.82
7.0 51.9 53.2 54.6 56.2 57.4 0.82 0.82 0.82 0.81 0.82
8.0 41.1 42.6 44.2 46.6 47.7 0.82 0.82 0.82 0.82 0.82
9.0 32.7 34.6 36.3 38.3 39.5 0.81 0.82 0.81 0.82 0.82
10.0 26.1 28.3 29.7 31.9 33.1 0.81 0.82 0.82 0.83 0.82
sJ[U1 7.290 4.811 5.060 3.393 3.120 5.966 3.932 4.113 2.770 2.542
1251 model 6711 in HETERO medium [Gy] 125I model 6711 HETERO/HOMO Ratio
0.0 357.3 313.8 252.4 246.1 221.6 0.88 0.87 0.86 0.86 0.86
0.5 301.4 267.1 224.7 217.0 197.3 0.89 0.88 0.87 0.87 0.87
1.0 256.7 230.5 202.1 190.7 176.9 0.89 0.88 0.88 0.87 0.87
1.5 218.7 200.6 179.0 170.2 158.4 0.89 0.89 0.88 0.87 0.87
2.0 188.2 175.2 160.8 153.4 144.2 0.89 0.89 0.88 0.88 0.88
2.5 162.9 153.5 143.9 140.1 130.6 0.90 0.89 0.88 0.88 0.88
3.0 141.2 135.4 128.8 125.7 119.4 0.90 0.89 0.89 0.89 0.88
3.5 123.8 120.2 115.9 113.7 110.6 0.89 0.89 0.89 0.88 0.88
4.0 108.3 106.6 104.3 103.8 99.7 0.89 0.89 0.89 0.89 0.88
4.5 95.6 95.0 93.9 94.1 91.8 0.89 0.89 0.89 0.89 0.89
5.0 85.0 85.0 85.0 85.0 85.0 0.89 0.89 0.89 0.88 0.89
6.0 67.2 68.3 69.1 71.2 70.3 0.88 0.88 0.88 0.88 0.88
7.0 53.7 55.4 56.6 60.0 59.8 0.88 0.87 0.87 0.88 0.88
8.0 44.0 45.8 47.2 50.9 50.9 0.87 0.87 0.88 0.88 0.88
9.0 36.4 37.8 39.3 42.3 43.9 0.86 0.87 0.87 0.88 0.88
10.0 30.3 31.7 33.3 35.9 36.8 0.86 0.87 0.87 0.87 0.87
sJAU1 4.738 3.088 3.225 2.174 1.969 4.204 2.742 2.856 1.922 1.749
131Cs model Rev2 in HETERO medium [Gy] 131Cs model Rev2 HETERO/HOMO Ratio
0.0 335.3 292.8 242.3 228.8 212.0 0.91 0.91 0.90 0.90 0.89
0.5 284.7 253.4 217.8 202.5 188.5 0.92 0.91 0.90 0.90 0.90
1.0 243.8 220.6 195.0 181.3 172.0 0.92 0.92 0.91 0.90 0.90
1.5 211.2 193.4 175.2 163.8 156.1 0.92 0.92 0.91 0.91 0.91
2.0 183.1 170.0 158.1 147.7 141.0 0.92 0.92 0.91 0.90 0.90
2.5 159.3 151.0 141.3 135.3 129.6 0.92 0.92 0.91 0.91 0.91
3.0 139.2 133.7 128.2 122.7 119.1 0.92 0.91 0.91 0.91 0.91
3.5 122.8 119.5 115.6 112.2 110.2 0.91 0.91 0.91 0.91 0.91
4.0 107.9 106.5 104.4 101.5 100.4 0.91 0.91 0.90 0.91 0.91
4.5 95.6 94.4 94.4 92.9 93.0 0.91 0.91 0.91 0.91 0.91
5.0 85.0 85.0 85.0 85.0 85.0 0.90 0.91 0.90 0.91 0.90
6.0 68.0 69.2 70.2 71.1 72.2 0.90 0.90 0.90 0.90 0.90
7.0 55.3 56.8 58.7 59.5 61.4 0.89 0.89 0.89 0.89 0.90
8.0 45.4 47.6 48.9 50.8 52.8 0.88 0.89 0.89 0.89 0.89
9.0 38.0 39.7 41.1 43.3 45.2 0.87 0.89 0.88 0.89 0.89
10.0 32.0 33.5 35.1 37.0 39.1 0.87 0.87 0.88 0.88 0.88
s,[U] 5.257 3.403 3.568 2.348 2.166 4.749 3.081 3.218 2.128 1.956
Comparison of our HOMO plaque simulations were made to hand calculations89
following the eye plaque dosimetry recommendations of the AAPM TG-43U1 report in
Appendix C.20 As for this study, hand calculations determined sK per seed necessary to
deliver 85 Gy to 5 mm. The ratio of MC-calculated to hand-calculated sK per seed to
deliver DRx, was 1.02 + 0.01 (+ 1 s.d.), 1.03 ± 0.01 (+ 1 s.d.), and 1.00 ± < 0.005 (± 1 s.d.)
for the models 200, 6711, and CS-1 Rev2, respectively. In addition to sK per seed
comparison, the central axis dose HoMo/hand-calculation ratio was evaluated in 1 mm
steps between the inner sclera (0 mm) and 10 mm. For the model 200, the ratio was 0.98
+ 0.01 (± 1 s.d.) for 0 < r < 3 mm and 1.00 + 0.01 (+ 1 s.d.) for 3 < r < 10 mm. For the
model 6711, the HoMo/hand-calculation ratio was 1.00 ± 0.01 (± 1 s.d.) for r < 9 mm and
0.98 ± 0.01 (± 1 s.d.) for r = 10 mm. The ratio was 1.00 ± 0.01 (± 1 s.d.) for all r for the
model CS-1 Rev2. The agreement between MC and hand calculations not only validates
our dose calculation methodology (Eq. 2.2.1), but also supports recommendations in
Appendix C of the AAPM TG-43U1 for determining COMS doses at short radial
distances in homogenous liquid water media.20
While the original COMS protocol assumed negligible impact on implant
dosimetry due to the silastic insert and Modulay plaque, it is now well recognized that
these materials perturb dose distributions.8 14-s288 Chiu-Tsao et al. evaluated the impact of
heterogeneities using MC methods for a single model 6711 seed at the center of a 20 mm
diameter COMS plaque.5 1 They observed an approximate reduction of 10% at a depth of
10 mm on the central axis due to photon attenuation in silastic, a factor that has
subsequently been employed to reanalyze results of the COMS study.90 The Plaque
Simulator software [version 4; BEBIG GmbH, Berlin Germany] - which uses the AAPM
TG-43U1 brachytherapy dosimetry formalism, patient-specific imaging, and factors to
account for plaque collimation, among other features - similarly applies the 10%
correction of Chiu-Tsao et al. for silastic attenuation. 82 Our single seed simulations for
the model 6711 in a 20 mm plaque obtained a difference of -11% for HETERO/HOMo,
which is in good agreement with Chiu-Tsao et al. For the models 200 and CS-1 Rev2
HETERO/HOMO differences of -18% and -12%, respectively, were observed at 10 mm
depth. Figure 2.2.1 presents the ratio of HETERO/HOMO ratios for the single seed to the
fully-loaded plaque using a 20 mm diameter plaque. Figure 2.2.1 demonstrates that a
10% correction factor for the model 6711 is adequate for r > 5 mm central axis dose
calculations; however, the scleral dose is over-estimated when using a single-seed
correction factor. For COMS implants using 03oPd, some investigators have introduced
applicators that employ a thin gold insert to guide seed placement to obviate the need for
silastic." The insert was designed to alleviate the expected large attenuation of 103Pd in
silastic,82'8 7 which we determined to be in excess of 18% at 5 mm depth in this study.
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Figure 2.2.1: Ratio of HETERO/HOMO for a single seed and fully-loaded (n=24)
20 mm eye plaque. Note differences below 5 mm where the single seed model
over-estimates the heterogeneity correction factor; however, the ratio for r > 5
mm, which is the ABS-recommended depth for lesion height below 5 mm, is
within +2%.
Figure 2.2.2 presents the average ratio of HETERO/HOMO central axis dose when
sK is chosen to deliver DRx = 85 Gy at 5 mm depth for five plaque diameters. The ABS
recommendations and COMS protocol dictates a minimum prescription depth of 5 mm.
Our study shows that the impact of silastic attenuation on dose distributions can vary
significantly for r < 5 mm. Furthermore, dose to organs at risk, namely inner and outer
sclera, could be over-estimated.
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Figure 2.2.2: HETERO/HOMO ratio for DRx = 85 Gy at 5 mm depth and averaged
over five plaque sizes. For all three radionuclides, dose to inner and outer sclera
is reduced in comparison to dose calculated in HOMo water medium. Error bars
represent ± 1 s.d.
Figure 2.2.2 demonstrates that a constant factor may not be adequate to account for
silastic attenuation when r < 5 mm; however, a 1D function can modify central axis dose
to account for silastic attenuation. Coefficients of a fourth order polynomial equation
(Eq. 2.2.2) that calculates the HETERO/HOMO ratio per starting particle as a function of
central axis distance, r, in mm are given in Table 2.2.3.
DHeler (r)
Cs (r) = DH (r) = ar 4 + air 3 +a 2r2 +a 3r +a 4  (2.2.2)DHomo (r)
In Table 2.2.3, ai coefficients were derived by fitting the average HETERO/HOMO ratio
from five plaque sizes.
Table 2.2.3: Fourth-order polynomial coefficients to calculate the
HETERO/HOMO ratio per starting particle as a function of distance along the
central axis for -1 < r < 10 mm. Note that distance should be reported in mm.
Seed model a4  a3  a2  a a0  R
200 ('0 3Pd) 7.478E-1 4.375E-2 -1.029E-2 1.056E-3 -3.931E-5 0.99
6711 (1251) 8.629E-1 2.062E-2 -5.433E-3 5.336E-4 -1.904E-5 0.98
CS-1 Rev2 (131Cs) 8.993E-1 1.505E-2 -5.167E-3 5.872E-4 -2.434E-5 0.99
-- 200
- -- 6711 
-
- CS-1 Rev2
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Absolute dose distributions for the 16 mm COMS plaques are presented in Figure
2.2.3 for both HOMO and HETERO MC simulations after a 168 h treatment. Note the
increase in penumbra and depth dose with increasing photon energy.
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Figure 2.2.3: Dose [Gy] for a 16 mm COMS eye plaque with SK per seed to
deliver DR, (5 mm) = 85 Gy. Seed model and heterogeneity correction were as
follows: A) HOMO model 200, B) HETERO model 200, C) HOMO model 6711, D)
HETERO model 6711, E) HOMO model CS-1 Rev2, and F) HETERO model CS-1
Rev2. Note increased penetration due to increased average photon energy.
2.2.4.3 Uncertainty analysis
Uncertainty analyses followed recommendations introduced by the AAPM TG-
43U1 Report2o and expanded upon by Rivard.26 In addition to the Type A stochastic
uncertainties described above, Type B systematic uncertainties were calculated assuming
r = 0.5 cm. Because seed component geometry and internal dynamic motion were not
explicitly examined and because radial distances were small, the AAPM TG-43U1
recommended value of 2% was utilized for seed geometry-related uncertainty.20
Uncertainty in source photon spectrum, phantom composition, MC physics modeling,
and Pen p-1 values were taken to be 0.1%, 0.01%, 0.3%, and 1.2%, respectively, per
Rivard.26  These uncertainties combine in quadrature to account for a total (k=l)
uncertainty of 2.6% at r = 5 mm on the central axis for all three radionuclides.
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Considering calculations at 12.5 mm off the plaque central axis at 5 mm, the k=
uncertainty rises to 3.8%, 3.1%, and 2.6% for 103Pd, 1251, and 131Cs, respectively.
2.2.5 CONCLUSIONS
Three brachytherapy seeds - the model 200 103Pd seed, the model CS-1 Rev2
131Cs seed, and the model 6711 1251 seed - were simulated using MCNP5. Calculations
of gL(r), F(r,0), sK, SKI App, and McA were in good agreement to previously published
values. Seeds were subsequently modeled in standard COMS eye plaques, and dose
calculations performed to evaluate the impact of absorption in plaque components.
Previous observations of 10% dose reduction for a single 125I seeds at 10 mm due to the
silastic seed carrier were validated, and MC calculations performed to assess attenuation
as a function of depth for fully-loaded plaques. These calculations confirmed that silastic
attenuation must be taken into account in treatment planning and that a depth-dependent
scaling factor could be used for central axis dose calculations, including organs at risk -
inner and outer sclera. Most importantly, clinical practices not accounting for attenuation
in plaque components may be delivering 10% - 20% below the desired therapeutic dose,
depending on the combination of radionuclide and plaque composition. Towards
improving the clinical utility of these simulations, the plaque model should be integrated
with a human eye model, allowing determination of dose to other organs at risk,
including the lens and optic nerve.
3 NEUTRON DOSIMETRY
3.1 Approaches to calculating AAPM TG-43 brachytherapy dosimetry
parameters for neutron sources
3.1.1 ABSTRACT
Purpose: Generally, the 2004 AAPM TG-43U1 brachytherapy dosimetry formalism has
been applied only to photon emitting radionuclides. Recent MC studies of un-
encapsulated virtual photon sources yielded distinct energy and geometry-specific dose
deposition characteristics not readily apparent with encapsulated sources. Towards
improving understanding of neutron-based brachytherapy, MC techniques were similarly
applied to virtual, un-encapsulated neutron sources.
Materials and methods: The MCNP5 code was utilized for all calculations. Dose to
water was determined using the F6 (cell-heating) tally for monoenergetic neutron sources
between 0.001 and 10 MeV. These energies bound those emitted by encapsulated
neutron sources such as Am:Be or 252Cf. The DLC-220 cross-section library was used,
and the impact of thermal scattering factors, S(a,p), were evaluated. gL(r) and F(r,0)
were determined for L < 0.5 cm using varying tally-sampling geometries for neutron and
secondary photon dose, which was generated using MODE NP transport in phanta
between 5 and 50 cm radius. In addition, comparisons of F6 and modified-F4 tallies
were made.
Results: Inclusion of S(a,p) provided notably higher F6 values at thermal energies due
to the increased kerma contributions from thermalized neutrons. Considering radial dose
deposition, comparison of phantom size showed high energy neutrons were less sensitive
to a decrease in phantom radius. At 3 cm from the surface of a 15 cm phantom, g(r)
changed by 1%, 4%, and 8% for 2, 0.2, and 0.002 MeV neutrons, respectively, in
comparison to a 30 cm phantom. Considering the same phantom ratio at 0.1 cm from the
surface, 0.88 and 0.26 are obtained for 2 and 0.1 MeV neutrons. Radial dose values
plotted as a function of energy showed a nadir at 0.1 MeV for distances > 10 cm, a
maximum at 0.01 MeV for distances < 0.5 cm, and a trend towards unity for energies > 1
MeV. Volume averaging for neutron dose deposition was shown to be similar to that of
photon deposition, with spherical shell widths below 1 mm providing statistically
equivalent tally results.
Conclusions: Characteristics of neutron physical dose distributions in brachytherapy
were evaluated for virtual sources using the TG-43U1 dosimetry formalism. These
insights allow for improvement in the design of novel neutron brachytherapy sources.
3.1.2 INTRODUCTION
As discussed in sections 1.1.1 and 2.1, the 2004 AAPM TG-43U1 brachytherapy
dosimetry formalism applied only to encapsulated 103Pd and 1251 sources. However,
brachytherapy dosimetry investigators have applied the formalism to various photon-
emitting radionuclide sources. The formalism was applied to 252Cf by Rivard in 200030
which was the first application of the TG-43 formalism to neutron-emitting sources.
Section 2.1 demonstrated energy and geometry-specific dose distribution characteristics
for AAPM TG-43 brachytherapy dosimetry parameters of un-encapsulated virtual photon
sources. Towards improving understanding of neutron-based brachytherapy, similar MC
techniques were applied to virtual neutron sources.
3.1.3 MATERIALS AND METHODS
3.1.3.1 MC simulations
Dose distributions for monoenergetic neutrons were modeled and evaluated using
the AAPM TG-43U1 brachytherapy dosimetry formalism. The formalism was also
applied to secondary photons generated during neutron transport.
Simulations in liquid water were performed using the MCNP5 radiation transport
code.67 Cell heating tallies were obtained using the MCNP F6 tallies. MODE N P
transport physics was utilized to calculate secondary photons generated through neutron
transport. For comparison to F6-derived results, neutron particle fluence (F4) tallies were
modified using International Commission on Radiation Units and Measurement (ICRU)
neutron kerma coefficients published in Report 63 for comparison to unmodified cell
heating tallies (F6). 91 ICRU-63 kerma coefficients include neutron energies between
2.53 x 10-8 and 150 MeV; however, MCNP5 tracks neutrons with energies as low as 10-11
MeV. Radiation dose deposited by secondary photons was calculated by multiplying
energy fluence tallies (*F4) by the mass-energy absorption coefficients for water
published by Hubbell and Seltzer. 71
As for photon simulations in section 2.1, source encapsulation was not included.
Water was modeled using a 2:1 atomic ratio for 'H: 160 and a mass density of 0.998 g cm
3. For neutron transport, the MCNP5 neutron cross-section library 66c from ENDF/B-VI
was employed,68 and the default MCNP5 photon cross-section library, p04, was applied.
The thermal neutron scattering library LWTR.60t was selected to include S(a,3) factors,
which incorporate additional molecular scattering considerations for neutrons below 4
eV.6 7 Additional simulations were performed without S(a,p) factors to determine the
impact on tally results.
3.1.3.2 Phantom size
The impact of limited phantom size was evaluated using gp(r) for monoenergetic
neutrons (0.001, 0.01, 0.1, and 1 MeV) in a spherical water phantom. For comparison,
the 252Cf neutron energy spectrum published by Mannhart was similarly modeled.9 2
Concentric spheres were simulated to define spherical shells allowing calculation of gp(r)
at radial distances between 0.5 and 25 cm. For comparison to gp(r)so, gP(r)R was
calculated with R = 5, 10, 15, 20, 25, 30, 35, 40, and 45 cm. In addition to neutron gp(r),
the secondary photon gp(r) was determined.
Volumetric averaging for 252Cf neutrons was assed by varying the thickness of the
tally volume (i.e., spherical shell). Shells with thickness of 0.002, 0.005, 0.01, 0.02, 0.05,
0.1, 0.2, 0.5, and 1 cm were used in simulations and results normalized to the 0.01 cm-
thick voxel. The sampling volume was defined by equally displacing the inner and outer
radii from the point of calculation. Volume averaging errors were evaluated at 23
distances between 0.5 and 20 cm for + 0.5% variation in gp(r) in comparison to the 0.01
cm-thick voxel.
3.1.3.3 Radial dose function
Radial dose functions were calculated for monoenergetic neutron sources
following the brachytherapy dosimetry formalism in AAPM TG-43U1.20 Neutron
energies of 0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 0.7, 1, 2, and 5 MeV were
simulated. The gp(r) values were calculated between 0.1 < r < 14.9 cm at 41 radial
distances. Calculations were performed in liquid water spheres with R = 15 and 30 cm.
Statistical uncertainties for neutron tally results were below 0.5% for all neutron
energies and distances using 107 starting particles. Secondary photons yielded statistical
uncertainties between 2% and 5% at short radial distances (< 1 cm) where insufficient
neutron interactions have occurred to engender secondary photons. For 1.5 < r < 15 cm,
the statistical uncertainties for secondary photons were below 0.5%.
3.1.3.4 F(r, 0)
F(r,0) for monoenergetic primary neutrons was calculated for 0.5 < r < 5.0 cm
using three active lengths (0.1, 0.3, and 0.5 cm) in a liquid water phantom of R = 10 cm.
Neutron energies of 0.001, 0.002, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, and 5 MeV were
included. The simulation geometry was similar to that used for photon analyses,
described in section 2.1.3.2. The line source was a cylinder of radius
10-6 cm; 10 angular resolution was included; and, voxel thickness of 5% of the radial
distance was employed. Radial distances were 0.5, 0.75, 0.9, 1, 1.5, 2, 2.5, 3, and 5 cm.
ICRU 63-modified F4 tally results were used to determine F(r,0) following the AAPM
TG-43UI brachytherapy dosimetry formalism (see section 7.2).20
MCNP5 simulations used MODE N P transport with at least 7 x 106 starting
particles. As observed for photons, the minimum statistical uncertainty was along the
transverse plane, while the maximum statistical uncertainty was along the long axis. At r
= 1 cm for L = 0.1 cm, the statistical uncertainties at 5' and 850 were 1.4% and 0.4% for
0.001 MeV; 1.5% and 0.4% for 0.01 MeV; 1.4% and 0.4% for 0.1 MeV; and, 1.2% and
0.3% for 1 MeV, respectively. At r = 5 cm for L = 0.5 cm, the corresponding statistical
uncertainties at 50 and 850 were 0.3% and 0.1% for 0.001 MeV (n = 2 x 107); 2.3% and
0.7% for 0.01 MeV; 2.9% and 0.8% for 0.1 MeV; and, 1.4% and 0.4% for 1 MeV,
respectively.
3.1.4 RESULTS AND DISCUSSION
3.1.4.1 Phantom size
The ratio of gp(r)R to gp(r)50 is shown in Figure 3.1.1 for 0.001, 0.01, 0.1, and 1
MeV neutrons. For a R > 10 cm, gp(r)R:gP(r)50 for 0.001, 0.01, and 0.1 MeV neutrons are
equivalent. The gp(r) ratios for 1 MeV neutrons differ from the other three energies for
all phantom radii. For comparison, Figure 3.1.2 demonstrates gp(r)R:gp(r)50 for 252Cf
neutrons.
Unlike the case for photon radiation, the gp(r) ratios are nearly independent of
phantom size. The magnitude of the neutron dose fall-off near the phantom surface is
similar for all phantom sizes, with slight variations for R = 5 cm where the calculated
dose at 1 cm may vary due to limited backscatter compared to larger phantom sizes.
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Figure 3.1.2: Ratio of neutron gp(r) to gp(r)so for 252Cf neutrons.
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Table 3.1.1 shows the gp(r)5so for the four neutron energies and 2 52 Cf spectrum
simulated. Note that a radial dose function value of 0.5 occurs at approximately 8, 2, 2,
and 5 cm for 0.001, 0.01, 0.1, and 1 MeV and at 8 cm for 252 Cf neutrons. In contrast, a
gp(r)5so value of 0.5 for l' 3pd and 125I photon sources occurs at approximately r = 2.0 and
4.5 cm, respectively.
Table 3.1.1: gp(r)50 calculated for 0.001,
F6 tally modified by S(aj3) for water.
shown.
R [cm]
0.5
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
11.0
12.0
13.0
14.0
15.0
16.0
17.0
18.0
19.0
20.0
0.001
MeV
1.28
1.00
0.75
0.73
0.76
0.76
0.70
0.61
0.51
0.41
0.32
0.25
0.19
0.14
0.10
0.08
0.06
0.04
0.03
0.02
0.02
0.01
MeV
1.36
1.00
0.52
0.28
0.17
0.12
0.09
0.08
0.06
0.05
0.04
0.03
0.02
0.02
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.01, 0.1, and 1 MeV neutrons using the
In addition, gp(r) for 2 52Cf neutrons is
gp(r)5o
0.1
MeV
1.20
1.00
0.64
0.38
0.21
0.12
0.06
0.04
0.02
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1
MeV
1.02
1.00
0.88
0.73
0.59
0.46
0.36
0.28
0.21
0.16
0.12
0.09
0.06
0.05
0.03
0.02
0.02
0.01
0.01
0.01
0.00
252Cf
1.01
1.00
0.96
0.90
0.82
0.75
0.67
0.60
0.53
0.47
0.42
0.37
0.33
0.29
0.26
0.23
0.20
0.18
0.15
0.14
0.12
The impact of phantom size on secondary photons is shown in Figure 3.1.3 for
monoenergetic neutrons and in Figure 3.1.4 for 252Cf neutrons. Unlike the neutrons gp(r)
ratios in Figure 3.1.1 and 3.1.2, the ratio of gp(r) to gp(r)50 for secondary photons varies
as a function of phantom radius. As the phantom radius increases, however, the ratio
approaches unity.
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Figure 3.1.3: Ratio of secondary photon gp(r) to gP(r)50 generated for starting
neutron energies of 0.001, 0.01, 0.1, and 1 MeV for R < 25 cm.
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Figure 3.1.4: Ratio of secondary photon gp(r)R to gp(r)50 for 252Cf neutrons.
Variation of voxel width for 252Cf neutrons showed no variation in g(r) > ± 0.5%
for voxel thickness of 0.1 cm and below. A voxel width of 0.2 cm differed from 0.01 cm
at only 13% (3 of 23) radial distances. As shown for photon radiation, voxel widths > 0.5
cm resulted in notable volume-averaging effects.
3.1.4.2 Radial dose function
The gp(r) 15 for monoenergetic neutrons is shown in Figure 3.1.5 as a function of
energy with each line indicating isodistances. A strong correlation between gp(r) and
energy is observed. There is a nadir for neutrons with approximately 0.1 MeV in energy
for distances > 5 cm. For example, gp(12) is 50 times smaller for 0.1 MeV neutrons than
for 0.001 MeV neutrons. Maximum gp(r) occurred at low energies (< 0.01 MeV) for
short radial distances (< 0.5 cm). There is a trend towards unity for neutron energies > 1
MeV due to decreased probability of interaction for neutrons at higher energies.
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Figure 3.1.5: MC-calculated gp(r)15 plotted as a function of energy for 0.1 < r <
12 cm. Note that the curves represent different radial distances. The most
significant attenuation along the transverse plane occurs at 0.1 MeV.
Similarly, gp(r)15 for secondary photons is shown in Figure 3.1.6 as a function of
incident neutron energy. In contrast to neutrons and primary photon radiation (see
section 2.1), gp(r) for secondary photons is lowest at short radial distances and highest at
greater radial distances. This change is due to the rate of secondary photon generation as
a function of distance in water. Neutrons emitted from the point source need to undergo
sufficient incoherent scattering and capture interactions to create secondary photons,
resulting in a gp(r) shape for secondary photons that is significantly different from those
of conventional brachytherapy sources. Furthermore, there is not a strong correlation
between gp(r) and neutron energy for secondary photons. For r < 5 cm, gp(r) is nearly
constant due to the rate of secondary photon generation; however, gp(r) increases as
neutron energy increases for r> 5 cm.
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Figure 3.1.6: MC-calculated gp(r)5i for secondary photons plotted as a function
of neutron energy for 0.1 < r < 12 cm. For r < 5 cm, gp(r) is approximately
constant as a function of energy.
Comparison of the ICRU 63-modified F4 tally and F6 tally for neutron gp(r)15 is
shown in Figure 3.1.7 in the absence of S(a,p).
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Figure 3.1.7: Ratio of gp(r)15 calculated using the ICRU 63-modified F4 tally to
the F6 tally.
As shown in Figure 3.1.7, F6-calculated physical dose is approximately 10% lager at r >
7 cm for neutron energies below 0.01 MeV. The ratio converges above 1 MeV; although,
slight variations (< 2%) are evident at higher neutron energies. The difference between
the two methods results from the contributions of neutrons below the lowest energy
reported in ICRU 63 (2.5 x 10-8 MeV). MCNP5 tracks neutrons with energies as low as
10-11 MeV; thus, ICRU 63-modified F4 tallies employ a constant kerma coefficient for
neutrons below 2.5 x 10-8 MeV. Inclusion of thermal neutron scattering factors, S(a,p),
increased the difference between ICRU 63-adjusted F4 and F6 results due to the increase
in the population of thermal neutrons (En < 10-8 MeV).
3.1.4.3 F(r, )
Figure 3.1.8 shows F(0.5,8) for an active length of 5 mm as a function of neutron
energy. In contrast to Figure 2.1.3 that demonstrates a significant increase in F(0.5,0)
near the long axis for low-energy photons, F(0.5,0) for neutrons increased by
approximately 7% for 0.001 MeV neutrons along the source long-axis. As neutron
energy increased beyond 1 Mev, F(0.5,0) approached unity.
1.
1.
1.
01.
,rf
1.
1.
1.
O.
1 E-03 1E-02 1E-01 1 E-00
Energy [MeVI
1 E-01
Figure 3.1.8: F(0.5,0) as a function of energy for L = 0.5 cm.
As r is increased, the shapes of the curves in Figure 3.1.8 remain, but the magnitude of
the values was reduced. For example, F(r,300 ) is 1.05 and 1.03 at r = 0.5 and 2.0 cm,
respectively.
As the active length is reduced, F(r,0) approaches unity.
F(0.5,00 ) is 1.01 and is unity at F(2.0,00 ).
increasing neutron energy and active length.
Table 3.1.2:
For L = 0.1 cm,
Table 3.1.2 shows F(0.5,0) values for
2D anisotropy function data for two active lengths at 0.001, 0.01,
0.1, and 1 MeV neutrons. L = 0.1 and 0.5 cm were employed to show variations
in F(r,0) as a function of both active length and energy for an un-encapsulated
neutron-emitting line source.
included.
Note that only contributions due to neutrons are
F(0.5,O)
0.001 MeV 0.01 MeV 0.1 MeV 1 MeV
L (cm)= 0.1 0.5 0.1 0.5 0.1 0.5 0.1 0.5
00 1.015 1.08 1.012 1.07 1.008 1.04 1.008 1.00
100 1.00 1.07 1.00 1.07 1.00 1.04 1.00 1.00
200 1.00 1.06 1.00 1.06 1.00 1.03 1.00 1.00
300 1.00 1.05 1.00 1.05 1.00 1.03 1.00 1.00
400 1.00 1.04 1.00 1.04 1.00 1.02 1.00 1.00
500 1.00 1.02 1.00 1.02 1.00 1.01 1.00 1.00
600 1.00 1.01 1.00 1.01 1.00 1.01 1.00 1.00
700 1.00 1.01 1.00 1.01 1.00 1.01 1.00 1.00
800 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
3.1.5 CONCLUSIONS
Monoenergetic virtual neutron point sources were utilized to examine
characteristics of neutron brachytherapy. As for photon sources, gp(r) for neutron sources
was found to be sensitive to phantom size; however, partial scatter effects for neutron
radiation did not vary strongly as a function of phantom size. For a given neutron energy
spectrum, a correction factor could be obtained when calculating dose in a partial scatter
environment.
Furthermore, Monte Carlo methods were varied to evaluate methodologies for
calculating AAPM TG-43 brachytherapy dosimetry parameters. Inclusion of the neutron
S(a,13) thermal scattering factor was found to impact calculations of brachytherapy
dosimetry parameters for neutrons below 1 MeV in energy. Comparisons of ICRU 63-
modified F4 results were notably different from cell-heating tallies (F6) due to MCNP5
tracking neutrons with energy below 2.5 x 10-8 MeV. Dosimetry investigators using
ICRU63-modified F4 tallies should evaluate the neutron spectrum to determine whether
thermal neutrons will contribute significantly to kerma at the point of calculation.
Furthermore, the differences between calculation methodologies were strongly dependent
on radial distance which engenders moderation to thermal neutron energies.
3.2 Clinical brachytherapy dosimetry parameters and mixed-field
dosimetry for a high dose rate Cf-252 brachytherapy source.t
3.2.1 ABSTRACT
Since the early 1970's, thousands of patients have been treated worldwide using low dose
rate (LDR) californium-252 brachytherapy sources. With recent advances in
radiochemistry for concentrating the radionuclide and increasing the effective specific
activity, there is now potential for fabrication of high dose rate (HDR) 252Cf
t Reproduced from: C. S. Melhus, M. J. Rivard, B. L. Kirk, and L. C. Leal, "Clinical brachytherapy
dosimetry parameters and mixed-field dosimetry for a high dose rate Cf-252 brachytherapy source," The
Monte Carlo method: Versatility unbounded in a dynamic computing world, Amer Nuc Soc, p. 269
(2005).
brachytherapy sources. Consequently, the mixed-field radiation dose distributions from
this novel source type must be characterized preceding delivery of patient treatments.
Towards clinical implementation of HDR 252Cf brachytherapy at Tufts-New England
Medical Center, the mixed-field dosimetry for this source type has been examined using
Monte Carlo methods (MCNP5) and compared to dose distributions produced by
traditional HDR 192Ir brachytherapy sources and other medically acceptable sources. The
mixed-field dose distribution in the vicinity of a proposed HDR 252Cf brachytherapy
source was calculated in a spherical phantom composed of water. The 252Cf neutron
energy spectrum was modeled using the ENDF7205 energy spectrum as currently
recommended by NIST. The 252Cf photon energy spectrum was modeled using the bare
252Cf source spectrum as measured by Skarsvig et al. (Phys Rev C, 1980). The source
capsule was composed of a Pt/Ir-10% alloy, with the radioactive source modeled as a
cylindrical Pd wire. A 252Cf source active length of 5.0 mm was used. The MCNP F4
and F6 (track length estimate of energy flux and deposition, respectively) calculation
tallies were utilized for determining various dosimetric components. These include the
source photon, neutron capture photon, and fast neutron dose components. Calculations
were performed in a polar coordinate system to readily permit conversion of dose
distribution results into the AAPM TG-43U1 dosimetry formalism for extracting clinical
dosimetry parameters. Using this dosimetry formalism, results indicated that dosimetry
parameters for HDR 25 2Cf sources did not significantly differ from those determined for
LDR 252Cf sources. These data may now be integrated into brachytherapy treatment
planning software to permit clinical implementation of HDR 252Cf brachytherapy.
3.2.2 INTRODUCTION
In the first proposed medical application of 252Cfbrachytherapy, a preliminary 1D
dose distribution was shown comparing the estimated localized dose deposition from an
implanted source to that expected from an external collimated beam.3 s Although the
figure clearly demonstrated sparing of healthy tissue through administering interstitial or
intracavity radiation therapy, the figure could not be utilized towards implementing
treatment planning of 252Cf brachytherapy. Many authors subsequently improved upon
the 1D characterization using experimental and calculative techniques to either determine
the transverse plane dose or compute an along-and-away dose rate table. Anderson
collected and compared the results of nine publications in 1973, and recommended the
data of Colvett et al. (1972) for describing the applicator tube type source, an LDR
source design.4 3
Although Anderson noted that additional dosimetry measurements were
warranted, few studies of 252Cf brachytherapy dosimetry parameters were published until
the 1992 Yanch and Zamenhof Monte Carlo study in support of boron neutron capture
therapy, which presented along-and-away dose rate tables. 4" The AAPM Task Group
No. 43 report, published in 1995, established a factorized, polar coordinate system for
representing the dose distribution about a brachytherapy source. 1' The TG-43 dosimetry
formalism improved the accuracy of reproducing dose distributions towards clinical
implementation, compared to 2D interpolations between data points on an along-and-
away table. The TG-43 formalism also provided a means for evaluating similar
brachytherapy source designs through direct comparison of the different parameters, e.g.,
radial dose function g(r) or anisotropy function Oan (r). Rivard et al. (1999) first applied
the TG-43 methodology to the neutron absorbed dose from an LDR 252Cf applicator tube
type source. 93
TG-43 was recently evaluated and updated.20 The updated report was limited to
03Pd and 1251 sources due to uncertainties involved in applying the methodology to high-
energy and/or mixed-field radiations. In this study, the TG-43U1 methodology was
applied to the neutron and photon radiations from a theoretical HDR 252Cf source.
3.2.3 MATERIALS AND METHODS
3.2.3.1 Monte Carlo source model geometry
The HDR 252Cf source is shown in Figure 3.2.1. A right cylinder with an active
length L = 5.00 mm and a radius of 0.39 mm was used as the source volume. Although
sources manufactured at ORNL are in the from of a Pd:Cf20 3 cermet rod, the source
material was modeled solely as Pd.4s For a 2 mg source strength, i.e., 2 mg of 252Cf, the
cermet wire is approximately 7% 252Cf by mass. The source was contained in a
cylindrical Pt/Ir-10% capsule with an outer length of 8.80 mm and outer radius of 0.648
mm. An air gap between the source element and capsule was not included, and the
theoretical capsule was in contact with the source in all directions.
L=88m I IPnnQ~nll
r = 0.39 mm
r = 0.65 mm
L = 8.8 mm D Pd/Cf2 03 source
Figure 3.2.1: Schematic of theoretical HDR 252Cf source modeled in this study.
The theoretical source was positioned in the center of a 50 cm diameter water
phantom. Assuming standard temperature and pressure, a mass density of 0.998 g cm-3
for water was applied, and the S(ca,L) thermal neutron scattering library LWTR.60t was
selected. Table 3.2.1 shows the elemental composition and density of the materials used
in this study, in addition to the photon and neutron cross-section libraries called.
Table 3.2.1: The MCNP5 cross-section library called for neutrons and photons (n
/ p) and the nuclide mass composition of the three materials included in the
simulations.
cross-section Mass perclibraries
Nuclide n/p H20 P
1H 66c / 04p 11.19
160 66c / 04p 88.81
106Pd 66c / 04p 1
191Ir 66c / 04p
193Ir 66c / 04p
Pt 42c / 04p
p [g cm -3] 0.998
3.2.3.2 Monte Carlo tally types and simulation defaults
ent of material
d-Cf20 3  Pt/Ir-10%
00.00
3.73
6.27
90.00
12.0 21.505
Version 5 of the Monte Carlo N-Particle Transport Code System (MCNP5) was
used to perform radiation transport calculations.67  Two separate simulations were
performed to assess the dose distribution from neutrons and photons emitted by 2 52Cf.
The first used MODE N P to determine the dose from neutrons and from photons induced
through neutron transport as a result of capture or inelastic scattering, hereafter called
"secondary" photons. The second set of simulations used MODE P to predict the dose
distribution from photons emitted directly from 252Cf, referred to as "primary" photons.
For both MODE N P and MODE P calculations, the track length estimate of cell-
heating tally (F6) was employed to determine the energy deposited in the cell in units of
MeV g-1 per source particle. In addition, at 11 radial distances between 0.75 and 17.5
cm, F6 and F4 (track-length estimator [cm-2]), tallies were calculated at 38 energies
between 0 and 20 MeV for neutrons, and F6, F4, and *F4 (track-length estimator of
energy flux [MeV cm-2]) tallies were determined at 0.05 MeV increments between 0 and
8.35 MeV for primary and secondary photons.
For neutron transport, comparison of F6 and F4 results were evaluated to ensure
that energy deposition closely matched neutron kerma coefficients published by the
International Commission on Radiation Units and Measurement (ICRU) in Report 63. 9~
Photon transport results were similarly appraised by comparing the ratio of F6 and *F4
results to the appropriate mass-energy attenuation coefficient published by NIST. 71
Photo-nuclear physics (PHYS:P) was not incorporated because (y,n) cross-
sections for the materials in Table 3.2.1 are negligible below 10 MeV. 71 Preliminary
analyses were performed using 108 histories for MODE N P neutron transport equations
and 109 histories for MODE P primary photon transport. Variance reduction techniques
were not employed.
3.2.3.3 252Cf radiation spectrum
Spontaneous fission of 252Cf occurs in 3.092% of disintegrations, and results in
the emission of 2.314 x 109 neutrons s-1 mg-1 and 1.320 x 1010 photons s-1 mg-'. The
neutron energy spectrum was modeled using data measured by Mannhart and published
in the Evaluated Nuclear Data Files (ENDF/B-VI) by the Cross-Section Evaluation
Working Group at Brookhaven National Laboratory in 1991.92,94
Photon energy spectra were modeled using data published by Skarsvig (1980) for
energies between 0.114 and 2.54 MeV and Verbinski et al. (1973) for energies between
2.54 and 8.5 MeV.95' 96 The Skarsvig-Verbinski data comprises 23 energy bins between 0
and 8.5 MeV, but does not include delayed emissions from the relaxation of fission
products. Additional Monte Carlo simulations were performed using values
recommended by Knauer et al. (1991).97 The Knauer et al. spectrum includes thirteen 0.5
MeV energy bins between 0 and 6.5 MeV, and nearly 50% of the photons are emitted by
fission products below 2.0 MeV. The average energy is 0.72 and 0.77 MeV for the
Skarsvig-Verbinski and Knauer et al. spectra, respectively.
The ENDF do not include data for photon radiation from 252Cf. Additional
measurements of 252Cf photon radiation are needed to improve accuracy and consistency
of future computational studies.
3.2.3.4 Dosimetry methodology
The TG-43U1 protocol for the calculation of brachytherapy dosimetry parameters
was followed, including the nine specifications for reporting Monte Carlo methodology.
Both ID and 2D parameters were determined for a theoretical encapsulated HDR 252Cf
source. While the protocol includes only low-energy photon-emitting radionuclides, the
methodology was applied towards describing the mixed-field dose distribution about a
252Cf source. Similar utilization of the original Task Group No. 43 methodology has been
made by Rivard et al. and by Rivard for low-dose rate 252Cf neutron dosimetry.93' 30
The dosimetry parameters g(r), F(r,0), and 4an(r) were determined using a polar
coordinate sampling space similar to that described by Rivard et al.6 9 Radial sampling at
twelve points from 0.5 to 20 cm was taken on the transverse plane with step sizes varying
between 0.5 and 5 cm. Radial sampling did not occur in the outermost 5 cm of the
phantom due to the inadequate amount of backscatter material at the phantom edge.
Sampling off the transverse plane was taken in 10 polar angle increments. The source
and resultant dose distribution were assumed to be symmetric about the transverse plane,
cylindrically symmetric about the source long axis, and azimuthal angle data were
averaged. The gp(r) for total photon radiation was calculated from a weighted sum of
primary and secondary 252Cf photon radiation data. A multiplicative factor of 1.320 x
1010 s-1 mg-1 was applied to the primary radiation data and 2.314 x 109 s-1 mg- to the
secondary radiation data to account for the differential emission rate of 252Cf primary
photons with respect to secondary photons induced by spontaneous fission neutrons.
In this study, TG-43U1 brachytherapy dosimetry parameters computed for the
hypothetical HDR 252Cf source described above are determined and compared to similar
data published for LDR 252Cf applicator tube (AT) type sources. In addition, dosimetry
parameters for common medical radionuclide sources are presented in contrast to the
mixed-field behavior exhibited by HDR 252Cf.
3.2.4 RESULTS AND DISCUSSION
Statistical uncertainties in F6 tallies of neutron dose on the transverse plane
ranged from 0.1% to 0.4% from 0.5 to 20 cm, and 0.4% to 0.6% at the same distances for
primary photon dose. Due to smaller solid angles, the statistical uncertainties increased
for positions towards the source long axes. At 50, the statistical uncertainties of neutron
dose ranged from 0.3% to 1.2% from 0.5 to 20 cm, with values of 1.7% to 2.1% for
photon dose at these same distances. Statistical uncertainties for photon transport were
higher due to the lower density of energy deposition in the phantom, because the mean
free path for photons - 1 MeV is longer than the average distance per neutron collision at
the same energy.
3.2.4.1 Dosimetric coefficients
For neutron transport simulations, comparison of F6 and F4 tallies provide an
estimate of fluence-to-dose kerma coefficients, which are compared to values published
in ICRU 63 in Figure 3.2.2. Similarly, the ratio of F6 and *F4 tallies for photon
transport were taken to estimate mass-energy absorption coefficients, and are compared
to coefficients published by NIST in Figure 3.2.3 for 12 positions along the transverse
axis.
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Figure 3.2.2: Comparison of liquid water neutron kerma coefficients published
in ICRU 6391 and those determined using MCNP5. The MC-calculated data are
presented for simulations including and excluding the thermal neutron scattering
factor S(a,13), which impacts energy deposition below 1 eV (see insert).
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Figure 3.2.3: Comparison of liquid water photon energy-absorption coefficients
calculated using MCNP5 and those of Hubbell and Seltzer.71
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Neutron kerma coefficients calculated using MCNP5 are in good agreement with
those published in ICRU Report 63 over seven decades of energy between 1 eV and 20
MeV. For thermal to low-energy neutrons (below 1 eV), there is a factor of 1.5
difference between this study and ICRU 63 for simulations employing the thermal
neutron scattering factor S(a,3) for light water. Removal of S(a,3) results in better
agreement to ICRU 63, with an average ratio of 0.98 ± 0.04 (± 1 s.d.) at 27 data points
over nine orders of magnitude.
For photon energy deposition, a ratio of energy absorption coefficients calculated
with MCNP5 and values published by NIST had an average of 1.01 ± 0.04 (± 1 s.d.) at 19
points over four decades. For photon energies below 0.1 MeV, MCNP5 calculated values
were found to be sensitive to energy bin width as a result of rapid adsorption of low-
energy photons.
3.2.4.2 Radial dose function g(r)
The HDR 2 52 Cf radial dose functions are shown in Figure 3.2.4 for neutron
radiation and in Figure 3.2.5 for primary photon radiation. In Figure 3.2.4, gp(r) for
252Cf neutrons is compared to similar data published by Rivard (2000) and by Yanch and
Zamenhof (1992) for an AT type source (L = 1.5 cm). Radial dose function for primary
photons displayed in Figure 3.2.5 is compared to photon data calculated from Yanch and
Zamenhof, to 192 Ir data published in TG-43, and to 125I data for the Best Medical model
2301 seed published in AAPM report TG-43U1.
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Figure 3.2.4: Radial dose functions for HDR 2 52Cf neutrons compared to similar
results for an LDR 252Cf AT-type source published by Rivard (2000) and by
Yanch and Zamenhof (1992).
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Figure 3.2.5: Radial dose function for 252Cf photons in comparison to data
published by Yanch and Zamenhof. In addition, gp(r) for two photon-emitting
brachytherapy sources, the Best Medical model 2301 125I seed and a 192Ir source,
is shown.
Rivard determined the radial dose function using MCNP4B for a 252Cf point
source in a 30 cm water phantom assuming a Maxwellian neutron energy spectrum.
Yanch and Zamenhof used MCNP3B to estimate gp(r) in water from an applicator tube
-- ~---~~ -- ~ -~~-~--- -- -- ------ ~~r
(AT) type source in a cylinder of height 60 cm and radius 30 cm with a Watt fission
spectrum representing the 252Cf neutron emissions. Ratios of gp(r) to Rivard (2000) have
an average value of 0.98 ± 0.03 (± 1 s.d.) between radial distances of 1 and 10 cm. Aside
from utilizing a different neutron spectral model, differences in the neutron gp(r) data of
Yanch and Zamenhof and this work are largely due to the neutron cross-sections and
kerma coefficients called by MCNP3B compared to the modem, up-to-date values in
MCNP5. Further, Yanch and Zamenhof did not employ S(a,3) in their simulation to
account for neutron moderation in liquid water. The discontinuity at gp(9) in the Yanch
and Zamenhof data likely resulted from the precision of the data presented, and is not
supported by the results of Rivard or this study.
Because secondary photons are induced outside of the source capsule, the total
photon gp(r) builds to a maximum value at a depth of approximately 10 cm. The total
photon radial dose function of Yanch and Zamenhof, calculated by subtracting the
neutron dose from the total (neutron and photon) dose, exhibits similar behavior and
supports the results of this study.
The low-energy radiations emitted by 1251 provide a steep radial dose function in
contrast to 252Cf neutrons and photons, due to the rapid attenuation of photons below 0.05
MeV in water. High energy photons from 192Ir have an average energy of 0.37 MeV, and
a gp(r) similar to that of 252Cf primary photons. At r = 9 cm, gp(r) decreases only 10% for
252Cf and 192Ir photons, but there is a reduction of over 50% reduction for 252Cf neutrons
over the same distance. Thus, the radial dose function behavior of radiation emitted by
HDR 252Cf is within the range of data presented for commonly applied medical
radionuclides.
Over all radial distances, the ratio of gp(r) results for the Skarsvig-Verbinski and
Knauer et al. primary 252Cf photon spectra had an average value of 0.98 ± 0.01 (± 1 s.d.).
The ratios showed a slight increase with radial distance, such that the values were 0.99
and 0.97 at 2 and 20 cm, respectively. Thus, calculation of gp(r) using the 252Cf photon
spectrum recommended by Knauer et al., which includes decay photons from fission
products, was comparable to that determined using the primary photon emissions of
Skarsvhg-Verbinski.
3.2.4.3 Anisotropy function F(r, 0)
Table 3.2.2 and Table 3.2.3 displays the 2D anisotropy function data for neutron
and photon radiation, respectively, for the HDR source shown in Figure 3.2.1. In Table
3.2.3, the F6 tally results for primary and secondary photons were summed prior to
calculating F(r,0), as described above. Data are presented in 100 increments, representing
the average of three degrees about each value, e.g., the data for 50' is the average of 490,
50° , and 510. Because of source symmetry, data equally spaced above and below the
transverse plane was averaged to determine F90(r,0), e.g., the data for 200 is the average
of 200 and 1600.
Table 3.2.2: 2D anisotropy functions for neutrons emitted from the HDR 252Cf
source.
F90(r,0)
r [cm] 00 100 200 300 400 500 600 700 800 900
0.5 0.97 0.98 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00
1.0 0.97 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.5 0.98 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2.0 0.98 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2.5 0.98 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
3.0 0.97 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
4.0 0.98 0.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
5.0 0.98 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
7.0 0.97 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
10.0 0.98 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
15.0 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00
20.0 1.00 0.98 0.99 1.00 1.00 1.00 1.00 1.01 1.00 1.00
Table 3.2.3: 2D anisotro~p functions for total photon (primary and secondary)
radiation emitted from the 52Cf source.
F9o(r,8)
r [cm] 00 100 200 300 400 500 600 700 800 900
0.5 0.70 0.72 0.87 0.93 0.97 0.98 0.99 1.00 1.00 1.00
1.0 0.67 0.72 0.86 0.92 0.96 0.98 0.99 0.99 1.00 1.00
1.5 0.70 0.73 0.86 0.92 0.96 0.98 0.99 0.99 1.00 1.00
2.0 0.70 0.74 0.87 0.92 0.96 0.98 0.99 1.00 1.00 1.00
2.5 0.69 0.75 0.87 0.92 0.95 0.98 0.99 0.99 1.00 1.00
3.0 0.71 0.76 0.87 0.93 0.96 0.98 0.99 1.00 1.00 1.00
4.0 0.73 0.79 0.88 0.93 0.96 0.98 0.99 1.00 1.00 1.00
5.0 0.76 0.81 0.89 0.94 0.96 0.98 0.99 1.00 1.00 1.00
7.0 0.71 0.76 0.87 0.93 0.96 0.98 0.99 1.00 1.00 1.00
10.0 0.73 0.79 0.89 0.93 0.96 0.98 0.99 1.00 1.00 1.00
15.0 0.88 0.89 0.94 0.96 0.98 0.98 0.99 1.00 1.00 1.00
20.0 0.88 0.90 0.94 0.97 0.98 0.99 0.99 1.00 1.00 1.00
For both neutrons and photons, 99.9% of F90(r,0) data points were within 1% of
the F(r,0) for all radial distances and angles. For neutrons, 99% of the data were within ±
1% of the average value. For the photon data, adherence within ± 1% of the average
values was 77% and increased to 98% for ± 5% agreement between F90(r,0) and F(r,0).
Table 3.2.3 shows that anisotropy of the total photon emissions from a HDR 252Cf
source increases with decreasing 0 and with decreasing radial distance, an effect that is
exhibited by most photon-emitting brachytherapy sources described in TG-43U1. In
contrast, 2D neutron dose deposition demonstrates only a 3% deviation along the source
long-axis at a distance of 0.5 cm. This effect, attributed to the low rate of interaction
between 252Cf neutrons and the source encapsulation, was also noted in Rivard et al. and
Rivard.93 ,30
Impact of the choice of 252Cf primary photon spectrum on F9o(r,0) is shown in
Table 3.2.4 for selected radial distances. Over all distances, there was an average ratio of
1.04 ± 0.02 (± 1 s.d.) along the long axis (0 = 00) and approaches unity towards the
transverse plane with a standard deviation below 0.01 for 500, 600, 700, and 800.
Table 3.2.4: Ratio of the 2D anisotropy functions for 252Cf primary photon
emissions between the Knauer et al. and the Skarsvig-Verbinski spectra. Data
recommended by Knauer et al. includes estimates of the delayed photon intensity
from the decay of 252Cf fission products.
F 90(r, )Knauer et al. / F90 (r,)SkarsvAg-Verbinski
r [cm] 00 100 200 300 400 500 600 700 800 900
0.5 1.06 1.06 1.04 1.02 1.01 1.00 1.00 1.00 1.00 1.00
1.0 1.07 1.05 1.03 1.02 1.01 1.01 1.00 1.00 1.00 1.00
1.5 1.03 1.05 1.03 1.02 1.01 1.00 1.00 1.00 1.00 1.00
2.0 1.02 1.05 1.02 1.02 1.01 1.00 1.00 1.00 1.00 1.00
3.0 1.05 1.04 1.02 1.02 1.02 1.00 1.00 1.00 1.00 1.00
5.0 1.04 1.03 1.03 1.02 1.01 1.01 1.00 1.00 1.00 1.00
10.0 1.05 1.04 1.03 1.02 1.02 1.00 1.00 1.00 1.00 1.00
20.0 1.03 1.02 1.01 1.01 1.01 1.00 1.00 1.01 1.00 1.00
As such, utilization of the photon data of Knauer et al. will not significantly
perturb the 2D anisotropy about the HDR 252Cf source. The largest effects will occur
towards the ends of the source at small radial distances. As expected, the 2D anisotropy
function values using the photon energy spectrum from Knauer et al. were higher than
the 2D anisotropy function values using the photon energy spectrum from Skarsvig-
Verbinski. This was due to the slightly higher average photon energy of Knauer et al.
and increased path length through the capsule at oblique angles (0 - O) along the source
long-axis.
3.2.4.4 1D anisotropyfunction 5an(r)
ID anisotropy functions 'an(r), calculated from the 2D anisotropy data in Tables
3.2.2 and 3.2.3, are displayed in Table 3.2.5 for neutron and total photon radiations. For
comparison, .an(r) for two photon emitting brachytherapy sources are included: the Best
Medical model 2301 125I seed characterized in TG-43U1 and a high-energy 192Ir source
described in TG-43.
Table 3.2.5: Comparison of ID anisotropy functions between the neutron and
photon emissions from a HDR 252Cf source and two commonplace photon
emitting medical sources. 192Ir data was taken from TG-43, and 1251 data was the
Best Medical model 2301 described in TG-43U1. Radial dose function gp(r) data
are included for reference.
an(r) gp(r)
Radius 252Cf 252Cf 1921r 1251 252 Cf 252Cf
[cm] neutrons photons photons photons Neutrons photons
0.5 1.21 1.18 0.953 0.947
1.0 1.12 1.09 0.991 0.945 1.000 1.000
1.5 1.11 1.07 0.992 1.029
2.0 1.10 1.07 0.947 0.987 0.973 1.047
2.5 1.10 1.07 0.944 1.073
3.0 1.10 1.07 0.897 0.968 0.912 1.096
4.0 1.10 1.06 0.942 0.971 0.838 1.159
5.0 1.10 1.07 0.998 0.969 0.758 1.209
7.0 1.09 1.06 0.965 0.969 0.609 1.312
10.0 1.10 1.06 0.425 1.386
15.0 1.09 1.08 0.228 1.319
20.0 1.10 1.08 0.120 1.120
Compared to conventional photon-emitting brachytherapy sources, e.g., 192Ir and
125I, neutrons and photons from 252Cf exhibit little change in their ID anisotropy as a
function of distance. Within 2 cm, both 252Cf datasets show a steep increase in
anisotropy approaching the source capsule.
3.2.5 CONCLUSIONS
Radiation transport simulations were performed to evaluate the dosimetric
characteristics of a simplified HDR 252Cf brachytherapy source. Calculations performed
to validate the MCNP5 F6 tally in comparison to the *F4 and F4 tallies typically
indicated agreement of results with 2%. Subsequent simulations utilized models of 252Cf
neutron and photon emission to determine the 2D and ID brachytherapy dosimetry
parameters defined in the AAPM TG-43U1 report. The radial dose function for both
neutrons and photons was consistent with previously published values, and within the
range of variation exhibited by common medical radionuclide sources. 252Cf neutron
radiation exhibited little anisotropy about the plane-symmetric HDR capsule, and
concomitant primary and secondary photons showed a general decrease in anisotropy
with increasing radial distance, as expected due to scattered radiation. Further,
evaluation of two separate 252Cf primary photon spectra yielded comparable dosimetry
parameters.
In conjunction, with an appropriate dose rate constant for this HDR 2 52Cf source,
data presented here may be incorporated into contemporary radiation therapy treatment
planning systems towards clinical implementation and patient treatment.
3.3 Monte Carlo validation of clinical brachytherapy dosimetry under
partial scatter conditions for neutron-emitting sources
3.3.1 ABSTRACT
Purpose: Monte Carlo models were generated in support of a clinical trial on the
effectiveness of neutron-based brachytherapy for a patient treated with a plaque
containing LDR Cf-252 AT-Type sources. Because the AAPM brachytherapy dosimetry
formalism does not replicate partial scatter conditions of superficial brachytherapy, MC
simulations were performed to evaluate treatment time and dose distributions generated
using conventional methods.
Method and Materials: Clinical calculations employed the AAPM dosimetry formalism
with modified parameters for the neutron dose component. MC simulations utilized
MCNP5 and track length estimator tallies. Computations applied a rectilinear mesh to
tabulate neutron transport, including induced photons, and primary photon transport in a
14x14x5 cm 3 volume with 9 mm3 voxels. Patient surface was simulated using a 20 cm
radius hemisphere of water, with a corresponding hemisphere of air. For comparison to
the AAPM formalism,the air was replaced with water. An RBE of 6 converted results to
cGy-eq for the neutron component. Results were normalized to 0.1 mg Cf-252 source
strength.
Results: At the 4 mm prescription depth, calculated dose rates were 198 ± 3 and 236 + 3
cGy-eq h-1 at plaque center and 24 mm offset, respectively. The central 4x4 cm 2 area
received 281 + 71 cGy-eq h-W. For comparison, full-scatter simulations yielded 222 + 2
cGy-eq h-1 at plaque center and 299 + 72 cGy-eq h-1 over a 4x4 cm 2 area; although,
computation time increased by a factor of 6.6. Dose ratios of full- (4n) to partial-scatter
(2nr) environments changed from 1.12 to 1.08 as depth increased from 0.4 to 5 cm.
Approximately 90 ± 1% of the dose-equivalent was due to neutrons, while neutron
physical dose was 70 ± 1% and 57 ± 2% of the total at 0.4 and 5.0 cm depths,
respectively.
Conclusion: Dose can be overestimated upto 10% by assuming full-scatter conditions for
Cf-252 plaque brachytherapy. MC simulations are recommended to validate treatment
plans generated using conventional methods.
3.3.2 INTRODUCTION
MC simulations were performed in support of a clinical trial on the safety and
effectiveness of neutron-based brachytherapy for locally advanced, recurrent, or radio-
resistant malignancies. A patient with recurrent disease was treated superficially using a
plaque containing eight LDR AT-type 252Cf sources. Because the AAPM brachytherapy
dosimetry formalism does not replicate partial scatter conditions of superficial
brachytherapy, MC simulations were performed to evaluate treatment time and dose
distributions generated using conventional methods.
3.3.3 MATERIALS AND METHODS
Clinical treatment time was calculated with the Philips Pinnacle3 planning system
(v7.6c) using the AAPM brachytherapy dosimetry formalism. In lieu of normalizing
source emission rate with the dose rate constant (A), calculations were relative to
contained 252Cf mass. Source emission rates were 2.31 x 109 neutrons s' and 1.32 x 1010
primary photons s- per mg of 252Cf, with the sources containing a total of 0.1 mg.
MC calculations utilized MCNP5 and the DLC-220 cross-section libraries. Two
simulations were performed for each calculation: MODE NP for neutron transport, which
also tallied secondary photons, and MODE P for primary photon transport. MC-based
single-source brachytherapy dosimetry parameters were developed following the
recommendations in the AAPM TG-43UI report.20 A RBE of 6 was employed to convert
neutron physical dose to cGy-eq for low dose rate 252Cfbrachytherapy.
Patient skin surface was simulated using a 20 cm radius hemisphere of liquid
water (p = 0.998 g cm-3), with a corresponding hemisphere of air (p = 1.2 mg cm-3). A
rectilinear mesh tabulated energy deposited using the F4 tally modified by ICRU 63
kerma factors for neutrons" and the *F4 tally modified by NIST energy absorption
coefficients for photons.71 The AT-Type source was modeled following Ref. 93, and the
MCNP UNIVERSE and transformation (TRN) cards were used to distribute sources into the
plaque geometry (Figure 3.3.1). In horizontal planes parallel to the plaque, dose was
tabulated in 0.2 cm increments over a 14x14 cm 2 grid, repeated in 0.22 cm vertical
increments to a depth of 5.6 cm. For comparison to full-scatter conditions employed in
the AAPM brachytherapy dosimetry formalism, additional simulations were performed
with the air replaced by water.
Adequate starting particle histories were computed to ensure statistical
uncertainties below approximately 2% in all voxels in the mesh. Variance reductions
techniques were not employed.
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Figure 3.3.1: 252Cf sources arrayed in the plaque geometry.
3.3.4 RESULTS
Isodose contours for the plaque simulation are shown in Figure 3.3.2 at a depth of
0.4 cm from the surface. Each source can be delineated from the eight regions with dose
rates > 250 cGy-eq h'. Central regions of 2x2, 3x3, 4x4, and 5x5 cm 2 have dose-
equivalent rates of 237 ± 23, 267 ± 57, 281 ± 71, and 293 ± 76 cGy-eq h-l, respectively,
and physical dose rates of 54 ± 6, 61 ± 13, 64 ± 16, and 67 + 17 cGy h-1, respectively. In
these regions, reported uncertainties are standard deviations representing dose rate
variation within the mesh.. Depending on the lesion size, daily 2 Gy-eq low dose rate
treatments can be delivered in less than a one-hour treatment session.
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Figure 3.3.2: Isodose distribution in 50 cGy-eq h' increments at a depth of 0.4
cm, including both neutron and photon dose components.
For full-scatter calculations in the liquid water sphere, central doses were 257 ±
22, 286 ± 58, 299 ± 72, and 311 ± 78 cGy-eq h' for 2x2, 3x3, 4x4, and 5x5 cm2 areas at
the center of the plaque, respectively. As such, replacing the hemisphere of air with
water increases total dose-equivalent rate by approximately 7%. On the plaque central
axis, this effect increases with depth from +12% at 0.4 cm to +7% at 5 cm from the
surface and is more pronounced for the photon component. Photon dose rates increased
from +20% to +29% over the 0.4 to 5 cm range, while the corresponding neutron
increases were +11% to +5%. Thus, overall scatter effects are dominated by the neutron
component for dose-equivalent rate calculations, and special consideration is necessary
when prescribing physical dose. In addition to the increased dose rate in the full-scatter
case, computational time required for radiation transport is increased by a factor of 1.2
and 6.6 for MODE P and MODE NP transport, respectively. This increase in computer
time is expected due to the 47n scattering medium in comparison to the 2Rt plaque model,
where the neutrons are unlikely to interact with air.
Dose profiles of the total dose-equivalent are shown in Figures 3.3.3 and 3.3.4 for
the center of the plaque and for a 2.4 cm offset, respectively. As a function of depth,
dose rates at the plaque center did not follow r-2 or r-1 behavior; instead, dose rates fell
exponentially by a factor of -0.458 for neutrons and by -0.345 for photons.
Depth dose values along the central axis in Figure 3.3.4 (distance = 0 cm) are
comparable to those in Figure 3.3.3, though narrower due to the offset from plaque
center. While the profiles in Figure 3.3.3 are oriented along the longest dimension of the
plaque, the area receiving > 150 cGy-eq h-1 at 0.6 cm depth is approximately 6x6 cm 2.
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Figure 3.3.4: Dose profiles at a distance of 2.4 cm from the plaque center. Due
to the orientation of the plaque (see Figure 3.3.2), the dose plateaus are narrower.
3.3.5 CONCLUSIONS
Monte Carlo methods were used to simulate treatment of superficial lesions using
252Cf brachytherapy. These demonstrated that dose-equivalent could be overestimated by
upto 10% when using full-scatter conditions in comparison to MC simulation of a plaque.

4 Shielding considerations
4.1 Storage safe shielding assessment for a HDR californium-252
brachytherapy sourcet
4.1.1 ABSTRACT
In pursuit of implementing HDR 252Cf brachytherapy, a suitable external storage
safe must be designed and constructed to store the medical source when not in use. The
shielding capabilities of polyethylene, RICORADTM, and Pb were examined for both
neutron and photon radiations using Monte Carlo methods. RICORADTM is a heat-
resistant plastic, with 2.00%-mass boron in a polyethylene-based matrix having a mass
density of 0.945 g cm "3. Due to the high-hydrogen content, the fission-energy 252Cf
neutrons are readily attenuated by RICORADTM and polyethylene, and the boron loading
in RICORADTM further helps prevent creation of 511 keV gamma-rays from neutron
capture by hydrogen. Pb readily attenuates 252Cf photons. Results of shielding
calculations using MCNP were incorporated into the design of a spherical
RICORADTM/Pb safe for storage of 1 mg of 252Cf that would reduce the external
radiation fields to levels below regulatory concerns. Practical considerations governing
safe design included exposure levels, material availability, and total safe weight and size.
Results are presented per milligram of 252Cf and can be scaled as needed for other source
strengths.
t Reproduced from: C. S. Melhus, M. J. Rivard, B. L. Kirk, and L. C. Leal, "Clinical brachytherapy
dosimetry parameters and mixed-field dosimetry for a high dose rate Cf-252 brachytherapy source," The
Monte Carlo method: Versatility unbounded in a dynamic computing world, Amer Nuc Soc, p. 269
(2005).
4.1.2 INTRODUCTION
Californium brachytherapy was first proposed nearly forty years ago as the
promise of radiotherapy with neutrons first became apparent.35 Since that time, a handful
of clinical centers around the world have employed low dose rate (LDR) intra-cavity or
interstitial californium therapy to treat tumors from head-to-toe. Thorough reviews of the
clinical results and radiobiological advantages have been published by Maruyama. 98 '36
Miniaturized high dose rate (HDR) 252 Cf sources (-1 mg) recently became
available through advances in radiochemistry. 45 As such, HDR 252Cf brachytherapy
sources compatible with modem remote afterloader technology are feasible. For
standard-of-care brachytherapy employing a HDR 192Ir source, a tungsten-alloy storage
safe has been integrated into the remote afterloading unit. However, it is not feasible to
construct a compact storage safe to attenuate the mixed-field radiation emissions from
252Cf due to the increased path length of neutrons and photons in suitably hydrogenous
materials in comparison to the shorter path length of 192Ir photons in the W-alloy.
Therefore, an external storage safe must be employed. Additionally, to minimize the size
of the storage safe, a multiple component shield is needed to address the different
requirements of the mixed neutron/photon radiation fields.
In this study, the shielding properties of polyethylene, Pb, and RICORADTM - a
borated polyethylene product manufactured by Reactor Experiments, Inc. (San Carlos,
CA)t - were investigated using Monte Carlo methods. In addition, preliminary models of
a multi-component safe, employing Pb and RICORAD TM to maximize photon and
neutron attenuation, respectively, were investigated.
4.1.3 MATERIALS AND METHODS
4.1.3.1 252Cf radiation spectrum
Californium-252 is one of the few radionuclides that decay via spontaneous
fission. One milligram of 252Cf emits 2.314 x 109 neutrons per second through this decay
mode, although spontaneous fission accounts for only 3.092% of disintegrations. 4s
Historically, 252Cf neutron emission was modeled using either a Maxwellian or Watt
The company has been acquired by Thermo Electron Corporation, Yokohama City, Japan.
fission model43 and the appropriate built-in MCNP source probability function, e.g., f= -
2 or -3 on the SP card, respectively. In this work, neutron emission data published by
Mannhart and integrated into the Evaluated Nuclear Data File (ENDF) were used.92
Figure 4.1.1 compares the three neutron spectra normalized to unity at the most probable
energy: 0.7, 0.9, and 1.2 MeV for the Mannhart, Watt, and Maxwellian models,
respectively.
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Figure 4.1.1: Comparison of normalized Mannhart 252Cf neutron emission
spectrum, Watt fission spectrum, and Maxwellian fission spectrum. In this study,
the Mannhart neutron spectrum was utilized.
Prompt 252Cf gamma rays are emitted stochastically through spontaneous fission,
but a representative spectrum was not available in the ENDF. Verbinski et al. measured
the prompt gamma ray emission from 252Cf using 13 energy bins between 0.14 and 10
MeV.96 Skarsvag similarly measured the prompt gamma ray spectrum for photons above
0.114 MeV using 18 energy bins, but binned photons above 2.54 MeV.95 Above 2.54
MeV, the number of gammas per fission was 0.43 and 0.426 and the percent of total
emission was 4.42% and 5.46% for Skarsvag and Verbinski et al., respectively. Thus, the
data of Verbinski et al., which had finer energy resolution, was used for prompt gamma
ray energies above 2.54 MeV.
The photon emission rate from 1 mg of 252Cf was taken to be 1.3 x 1010 s-1, which
was employed in shielding calculations performed by Hootman and Stoddard (1971) and
by da Silva and Crispim (2001).49 99 Dividing the neutron emission rate by the average
number of neutrons per fission (3.7676) and multiplying by the average number of
prompt photons per fission (9.7), as measured by Skarsvig, yielded a prompt gamma
emission rate of 5.96 x 109 s-1. There is a factor of 2.2 between the two values because
delayed gamma rays from the decay of fission product progeny were not included by
Skarsvig. Hootman and Stoddard published photon spectral data for fission product
gamma rays, but did not cite the source of their spectral data. Additionally, only four
energy bins between 0 and 2 MeV were used. Figure 4.1.2 displays the relative
intensities of prompt and delayed gamma rays published by Skarsvig and by Hootman
and Stoddard.
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Figure 4.1.2: Prompt and delayed photon emission spectrum from spontaneous
fission of 252Cf and decay of fission daughter products, respectively. The prompt
gamma ray spectrum measured by Skarsvig and modified using data by Verbinski
et al. was used in this study.
Although the prompt photon spectrum of Skarsvig underestimates the total
number of low-energy photons (e.g., 0.25 and 0.75 MeV) presented by Hootman and
Stoddard, similar trends are exhibited between the two datasets. Since modem
measurements or calculations of the delayed photon spectrum are lacking, the prompt
photon emission data of Skarsvag was employed with the total photon emission rate of
1.3 x 10' 0 s' mg-1
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4.1.3.2 Radiation transport simulations
4.1.3.2.1 Monte Carlo tally types and simulation defaults
Radiation transport calculations were conducted using version 5 of the Monte
Carlo N-Particle Transport Code System (MCNP5), which employs the DLC-220 cross-
section library published in 2004.67 Initial calculations were performed on a 1.4 GHz
computer running the Windows 2000 (Microsoft Inc.; Redmond, WA) system, and final
calculations were undertaken at Oak Ridge National Laboratory's C-Pile.'0 0t 0 ' For each
shield thickness, two separate calculations were performed. One simulated the
penetration of 252Cf neutrons through the shield using MODE N P to include the
generation and transport of secondary photons. The second simulated the attenuation of
252Cf photons through the shield in MODE P.
For neutron transport, the F4 tally estimator was used in conjunction with a tally
modifier (i.e., DE and DF) to determine the equivalent dose to ICRU four-component
tissue in a vacuum.7° The neutron tally modifier included two components: (1) kerma
coefficients to convert neutron fluence (cm-2 ) to absorbed dose [Gy] and (2) an energy-
specific radiation weighting factor (wR) to convert absorbed dose to equivalent dose. The
ICRU published neutron kerma conversion coefficients in Report 63 for twelve
elements. 91 To determine the kerma coefficient for a compound containing any of these
elements, the individual coefficients are weighted by their respective mass-percent and
summed. Energy-specific neutron wR factors were taken from Publication 60 of the
International Commission on Radiological Protection (ICRP).s5 In addition, thermal
neutron scattering functions, i.e., S(a,3), was utilized when appropriate to provide
accurate modeling of neutron thermalization and incoherent scattering.
For primary photon transport, the *F4 tally estimator was used in conjunction
with a tally modifier (i.e., DE and DF) to determine the absorbed dose to ICRU four-
component tissue in a vacuum. Energy absorption coefficients published by Hubbell and
Seltzer71 transformed energy-flux per neutron [MeV cm-2] to absorbed dose [J kg-'].
Additional unit conversion was included to determine the absorbed dose [Gy], which is
equal to the equivalent dose as WR is unity for photons. Due to the small population of
high-energy photons, photonuclear physics (PHYS:P) was not incorporated.
A sufficient number of photon histories were used to ensure statistical
uncertainties remained less than 2%. For most cases, preliminary calculations using 106
histories were sufficient to meet this requirement. Final calculations performed at C-Pile
computed between 1x10 7 and 2x10 9 starting particles, and variance reduction techniques
were not utilized.
Three shielding materials, polyethylene, RICORADTM, and Pb, were evaluated
towards the construction of a HDR 252Cf storage safe. Elemental compositions of the
shielding materials used in this study are given in Table 4.1.1. The composition of ICRU
four-component tissue is included, which was used to determine the neutron kerma
coefficients and photon energy absorption coefficients.
Table 4.1.1: Percent mass composition of materials included in shielding
analyses.
Material
Element ICRU Tissue polyethylene lead RICORAD TM
H 0.101174 0.143716 - 0.1206
B - -- 0.0200
C 0.111000 0.856284 - 0.8493
N 0.026000 - - -
0 0.761826 - - 0.0046
Al - - - 0.0015
Si - - - 0.0020
Fe - - - 0.0020
Pb - - 1.000 -
p [g cm 3 ] 1.00 0.93 11.35 0.945
S(a,pj3) - POLY.60t - POLY.60t
For elements that did not have DLC-220 neutron cross-sections for their natural
isotopic abundances, relative isotopic abundances by atom were assigned considering the
available neutron libraries. Hydrogen was modeled using 99.985 % 1H and 0.015% 2H;
boron was modeled using 19.9% '0B and 20.1% "B; oxygen was modeled as 100% 160;
and, Pb was modeled as 24.4% 206Pb, 22.4% 207pb, and 53.2% 208Pb.
4.1.3.2.2 Simulation geometry
A spherical geometry was used that was similar in design and composition to that
employed by both Hootman and Stoddard and by da Silva and Crispim. An
unencapsulated point source was positioned at the center of a solid aluminum sphere with
radius 0.6204 cm and a volume of 1 cm3. While da Silva and Crispim employed a 0.02
cm-thick aluminum shell with inner radius 0.62 cm, a solid sphere more accurately
represented the geometry and density of a physical source without requiring a vacuum,
which would remove the effects of self-shielding. Shells of varying thickness were added
outside of the source for the three shielding materials evaluated, as shown in Figure
4.1.3. F4 and *F4 tallies for neutrons and photons were determined in a vacuum for a
shell of thickness 0.1 ýtm surrounding the outer boundary of the shield.
Aluminum sphere,
.6204 cm
1 5 t 5 125 cm
Figure 4.1.3: Schematic of the spherical shielding geometry employed in these
Monte Carlo calculations. A shield of varying thickness, t, was placed around an
isotropic source at the center of an aluminum sphere.
A two-component Pb:RICORADTM shield was evaluated by fixing the total shield
thickness and varying the relative amount of the two materials for a 1 mg 252Cf source.
To minimize total weight, Pb was employed as the internal layer and RICORADTM
surrounded it externally. Pb thickness of 2, 4, 6, 8, and 10 cm were calculated for a
shield of total thickness 50 cm. For a larger shield, 100 cm thick, Pb thickness of 5, 10,
15, and 20 cm were calculated.
4.1.4 RESULTS AND DISCUSSION
4.1.4.1 Single component shield analysis
Figures 4.1.4, 4.1.5, and 4.1.6 show the product of the equivalent dose rate and
the distance squared [mSv h' x d2] from 1 mg of 252Cf for neutrons, secondary photons,
~hiclA thirrt
and primary photons, respectively. The square of the distance was incorporated to
remove the influence of divergence. The total equivalent dose for each shielding material
is shown in Figure 4.1.7.
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Figure 4.1.4: Equivalent dose to ICRU four-component tissue from 252Cf
neutrons for the three shielding materials.
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Figure 4.1.5: Equivalent dose to ICRU four-component tissue from primary
gamma rays for the three shielding materials.
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Figure 4.1.6: Equivalent dose to ICRU four-component tissue from secondary
gamma rays (neutron capture photons) for the three shielding materials.
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Figure 4.1.7: Total
attenuation through Pb,
equivalent dose to ICRU four-component
polyethylene, and RICORADTM.
tissue after
Pb provides significant attenuation of the primary photons, but does not provide
neutron protection. RICORADTM and polyethylene provide similar primary photon and
neutron attenuation. Fewer secondary photons escape from the RICORADTM shield
101
because thermal neutrons are preferentially captured by boron, which minimizes capture
gamma ray emission after capture by hydrogen.
4.1.4.2 Multiple component shield analysis
Table 4.1.2 displays the neutron and photon equivalent doses at the exit of the 50
cm-thick Pb:RICORADTM shield.
Table 4.1.2: Comparison of neutron and photon equivalent dose rate (H) at the
exit of a 50 cm spherical Pb:RICORADTM safe for a 1 mg 252 Cf source.
Equivalent dose rate [gSv h']
Pb thickness [cm] Hn  Hn, HA Htotal
2 173.0 121.6 270.2 564.8
4 181.8 121.1 112.9 415.7
6 185.8 119.6 48.5 353.9
8 190.4 118.7 21.0 330.1
10 199.6 119.4 9.2 328.1
ICRP 60 recommends limiting the annual effective dose to a radiation worker
below 50 mSv. Therefore, a Pb:RICORADTM shield designed to maintain a radius of 50
cm would allow only 89 to 149 hours of work per year adjacent to the safe for the 2 and
10 cm of Pb designs, respectively.
For a Pb:RICORADTM shield designed to maintain a radius of 100 cm, the annual
workload would increase to over 7,800 hours. Equivalent dose values for a multi-
component safe with a total shield thickness of 100 cm diameter are shown in Table
4.1.3. Assuming 2,000 work-hours per year, a radiation worker positioned at the exterior
of the safe would receive 12.8 mSv per annum, one-quarter of the ICRP 60 allowance.
Thus, a safe employing one of the designs in Table 4.1.3 would provide adequate
protection for a source containing almost 4 mg of 252Cf
102
Table 4.1.3: Comparison of neutron and photon equivalent dose rate (H) at the
exit of a 100 cm spherical Pb:RICORADTM safe.
Equivalent dose rate [gSv h-1]
Pb thickness [cm] n H r  r total
5 0.25 2.86 3.35 6.46
10 0.20 2.53 0.43 3.16
15 0.23 2.42 0.06 2.71
20 0.20 2.53 0.01 2.74
Although storage safes are typically placed in restricted areas and require minimal
maintenance, a robust shield would be desirable to assure minimal radiation exposure to
personnel and the public. One disadvantage with the 100 cm safe design is that it would
occupy a volume of 4.2 m3. The total shield weight would be 4,040, 4,085, 4,199, or
4,415 kg for safe models with 5, 10, 15, or 20 cm of Pb, respectively. Potential
installation sites would require thorough engineering analyses prior to construction.
4.1.4.3 Comparison to other studies
Hootman and Stoddard modeled the shielding properties of 32 different materials
in their 1971 report, but only one of those materials is in common with those studied here
- polyethylene. Using a spherical shield and a point source, Hootman and Stoddard
calculated the equivalent dose to tissue. Figure 4.1.8 displays the ratio of the results
presented here to those of Hootman and Stoddard.
103
1.4
1.2
S0.8
0.4
N NEUTRONS
0.2 A SECONDARY PHOTONS
* PRIMARY PHOTONS
0.0
0 20 40 60 80 100 120
Shield Thickness (cm)
Figure 4.1.8: Ratio of Monte Carlo shielding calculations for polyethylene from
this study to Hootman and Stoddard (1971).
Our neutron equivalent dose data in polyethylene was within 20% agreement of
those presented by Hootman and Stoddard. The secondary photons and primary photons
exhibit a near constant ratio, although they differ from the current Monte Carlo results by
approximately 71% and 55%, respectively.
The models employed by da Silva and Crispim were designed for the construction
of a neutron irradiator and included a 30 cm sphere of high-density polyethylene around
the source. Three shielding materials were studied, but none were similar to those
investigated here. In addition, da Silva and Crispim included a thin (0.1 cm) shell of
cadmium at the shield outer surface to absorb thermal neutrons. Because of these
differences, it is difficult to directly compare the results obtained herein to those obtained
by da Silva and Crispim. However, direct comparisons can be made at the exterior of a
30 cm radius sphere of polyethylene that is included to moderate the neutron spectrum.
Table 4.1.4 shows this comparison.
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Table 4.1.4: Comparison of equivalent doses (H) at the exterior of a sphere of
polyethylene containing 1 mg of 252Cf
Equivalent dose rate [gSv hl]
Investigator Hn n,r Hr
da Silva and Crispim 2790 3230 5950
This Study 3510 3550 4940
Ratio 1.26 1.10 0.83
As shown in Figure 4.1.8 and Table 4.1.4, neutron equivalent dose values in this
study were typically higher than those reported by Hootman and Stoddard or by da Silva
and Crispim. While this difference is partially due to employing different neutron
spectra, differences in dosimetric conversion factors likely caused the discrepancies, e.g.,
differences between the radiation weighting factors and neutron kerma coefficients. For
photons, the energy spectra of Hootman and Stoddard included a larger component of
low-energy photons that resulted in increased equivalent dose at the shield outer surface.
In addition, the results of this study included the most up-to-date photon cross-section
libraries. The results of Hootman and Stoddard and of da Silva and Crispim are subject
to photon cross-sections that have been shown to result in differences in comparison to
the DLC-220 library for low-energy photons (E7 < 100 keV).'0 '2 10' Additional research is
required to determine the magnitude of the effect of the different neutron and photon
spectra, as well as, the impact of using older (e.g., MCLIB02) photon cross-sections.
4.1.5 CONCLUSIONS
Monte Carlo methods have been used to determine the shielding characteristics of
three materials: polyethylene, RICORADTM, and Pb. Each has desirable shielding
characteristics for either neutrons or photons. A storage safe with spherical geometry
which combines Pb and RICORADTM has been evaluated. Using a total shield thickness
of 50 cm, a 1 mg 252Cf source can be safely stored according to ICRP 60 standards,
allowing over 100 hours of work directly adjacent to the shield. Fabrication of this or a
similar design is needed for confirmation with experimental measurements to compare
with calculated exposure rates preceding installation of the storage safe and
implementation of HDR 252Cfbrachytherapy treatments.
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4.1.6 ADDENDUM
4.1.6.1 Materials and methods
Additional single-component shielding materials were modeled following the
methodology described in section 4.1.3. Liquid water, concrete, and barite concrete were
simulated using the weight percents," material densities,7 and MCNP5 cross-section
libraries in Table 4.1.5. Liquid water is frequently used to moderate neutrons. Concrete
and barite concrete are similar to low-density and high-density concrete, which are used
to construct shielding for radiation therapy centers.
Table 4.1.5: Percent composition by mass and density of liquid water, concrete,
and barite concrete. The MCNP5 neutron and photon cross-section libraries used
in calculations are also shown.
cross-section Mass percent of material [%]libraries
nuclide n /p Water Concrete barite concrete
1H 62c / 04p 11.19 2.21 0.3585
12C 66c / 04p 0.2484
160 62c / 04p 88.81 57.493 31.1622
23Na 62c / 04p 1.5208
Mg 62c / 04p 0.1266 0.1195
27A1 62c / 04p 1.9953 0.4183
S 62c / 04p 10.7858
Si 60c / 04p 30.4627
K 62c / 04p 1.0045
Ca 62c / 04p 4.2951 5.0194
Fe 55c / 04p 0.6435 4.7505
138Ba 66c / 04p 46.34
P [g cm 3]: 0.998 2.3 3.35
For these three materials, 2 x 107 starting particles were sufficient to obtain statistical
uncertainties below 2%.
4.1.6.2 Results and discussion
The distance-corrected equivalent dose rates [mSv h-1 x d2] from a 1 mg 252 Cf
source are shown for neutrons, secondary photons, primary photons, and total radiation
emissions in Figures 4.1.9, 4.1.10, 4.1.11, and 4.1.12, respectively.
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Figure 4.1.9: Distance-corrected equivalent dose rate to ICRU four-component
tissue from 252Cf neutrons for water, concrete, and barite concrete.
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Figure 4.1.10: Distance-corrected equivalent dose rate to ICRU four-component
tissue from primary 252Cf gamma rays for water, concrete, and barite concrete.
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Figure 4.1.11: Distance-corrected equivalent dose rate to ICRU four-component
tissue from secondary gamma rays (neutron capture photons) for water, concrete,
and barite concrete.
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Figure 4.1.12: Total distance-corrected equivalent dose rate to ICRU four-
component tissue after attenuation through water, concrete, and barite concrete.
For comparison lead polyethylene, and RICORADTM are included.
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4.2 Shielding evaluation of a medical linear accelerator vault in preparation
for installing a high-dose rate 252Cf remote afterloadert
4.2.1 ABSTRACT
In support of the effort to begin high-dose rate californium-252 (252Cf) brachytherapy
treatments at Tufts-New England Medical Center, the shielding capabilities of a clinical
accelerator vault against the neutron and photon emissions from a 1.124 mg 252Cf source
were examined. Outside of the clinical accelerator vault, the fast neutron dose equivalent
rate was below the lower limit of detection of a CR-39 track-etch detector and below 0.14
± 0.02 tiSv h-1 with a proportional counter, which is consistent, within the uncertainties,
with natural background. The photon dose equivalent rate was also measured to be
below background levels (0.1 pSv h-1) using an ionization chamber and an optically
stimulated luminescence dosimeter. A Monte Carlo simulation of neutron transport
through the accelerator vault was performed to validate measured values and determine
the thermal- to low-energy neutron component. Monte Carlo results showed that the dose
equivalent rate from fast neutrons was reduced by a factor of 105 after attenuation
through the vault wall, and the thermal-energy neutron dose equivalent rate would be an
additional factor of 103 below that of the fast neutrons. Based on these findings, the
shielding installed in this facility is sufficient for use of at least 5 mg of 252Cf.
4.2.2 INTRODUCTION
252Cf is a man-made transuranic, which disintegrates via either alpha emission
(96.908%) or spontaneous fission (3.092%), with an associated neutron emission rate of
2.314 x 109 s-1 mg-'. 45 In addition, the long half-life of 25 2Cf (2.645 y) compared to 192Ir
(73.8 d),33 which is currently used in commercial high-dose rate (HDR) brachytherapy
systems, is desirable because it allows for relatively infrequent source exchanges and
related cost savings. Rivard et al. have shown that costs for HDR 252Cf brachytherapy do
not exceed 30% more than costs for standard-of-care HDR 192Ir brachytherapy.104 252Cf
t Reproduced from: C. S. Melhus, M. J. Rivard, J. KurKomelis, C. B. Liddle, and F. X. Mass6, "Shielding
evaluation of a medical linear accelerator vault in preparation for installing a high dose rate 252Cf remote
afterloader," Rad. Prot. Dos. 113, 428-437 (2005).
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neutrons are similar in energy to a reactor fission spectrum (mean 2.1 MeV) and exhibit
desirable radiobiological qualities, e.g., reduced oxygen effect, decreased cell-cycle
dependence, and increased relative biological effectiveness (RBE). As a result, 252Cf
treatment has demonstrated efficacy for tumors that have not responded to traditional,
photon-based therapies. 36
Several thousand patients have been treated with 252Cf brachytherapy at various
centers worldwide for a diverse assortment of lesions from head-to-toe. Clinical
observations from this patient population included an RBE of 6 for low- and-medium
dose rate brachytherapy, an RBE of 3 for HDR brachytherapy, acute tissue effects
comparable to photon brachytherapy, dose rate independence, local tumor control, and
rapid tumor regression. Cervical cancers, in particular, exhibited positive results for
advanced, late-stage (III-IV) bulky tumors, including a 54% 5-year survival for early
(i.e., before photon therapy) 2 52Cf implants compared to 12% 5-year survival with
conventional therapy for stage IIIB tumors. 105 Similarly, Ta'ev et al. noted an 18.9%
increase in 5-year survival for stage IIB and IIIB cervical cancers compared to
conventional photon therapy due to a significant decrease in local relapse.10 6 Similar
results were obtained after 12-year followup.37 Positive local control was observed for
several diseases and sites, including traditionally radioresistant melanomas that achieved
complete local control with external 252Cf plaque irradiation. 10 7 252Cf brachytherapy in
China began in 1999 using a remote afterloading device called the Linden Neutron Knife,
and thirty similar 2 52Cf treatment centers are expected to be in operation by 2008 to
provide one center per 40 million people. 10 8 Similar acceptance in the United States may
be expected after the development of a suitable HDR 252 Cf source, remote afterloader,
and associated infrastructure to complement HDR 192Ir brachytherapy practice.
Currently, no institution in the Western Hemisphere utilizes 252Cf clinically.
However, Tufts-New England Medical Center (Tufts-NEMC) is actively pursuing
implementation of 252Cf brachytherapy. 93,1o01 10 9' 110  Simultaneously, the Radiochemical
Engineering Development Center (REDC) at Oak Ridge National Laboratory (ORNL),
currently the sole producer of californium isotopes on Earth, is striving to produce a HDR
252Cf brachytherapy source (> 1.0 mg) that would be compatible with the HDR 192Ir
brachytherapy remote afterloading environment. In conjunction with the development of
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a clinical HDR 252Cf brachytherapy system, it is necessary to provide adequate treatment
room shielding to minimize incidental radiation exposure to the public and occupational
radiation exposure to physicians, physicists, and allied health personnel involved with
irradiating cancer patients. The National Council on Radiation Protection and
Measurements (NCRP) has published shielding recommendations in Report No. 49,111
described neutron production from medical electron accelerators in Report No. 79,112 and
recently published Report No. 144 to update these and other reports that thoroughly
evaluates the radiation protection characteristics of neutrons generated in particle
accelerator facilities. 113 Nevertheless, there is no radiological protection guidance for the
medical use of neutron-emitting radionuclides.
As with any new radiation-emitting medical device, shielding requirements
should be published preceding implementation of regulatory standards. This has been
demonstrated by Robinson et al. for tomotherapy,114 Mutic et al. for intensity-modulated
radiation therapy, l" 5 and Meth6 for positron emission tomography. 116 Consequently, the
shielding characteristics of a clinical linear accelerator vault for the mixed-field radiation
emitted by 252Cf were investigated at Tufts-NEMC.
4.2.3 MATERIALS AND METHODS
4.2.3.1 Vault and source description
Originally constructed in 1968, the linear accelerator vault, hereafter the "vault,"
houses a medical accelerator that can generate upto 25 MV electron and photon beams.
A schematic of the facility is shown in Figure 4.2.1. The walls of the vault are composed
of high-density concrete at 4.00 g cm -3 (250 lbs ft-3) between 50.8 and 133.5 cm thick,
although, one wall that is only 38.1 cm thick abuts the original building foundation-
providing an additional 41.3 cm of standard concrete at 2.35 g cm -3 (147 lbs ft-3). The
ceiling thickness is 27.5 cm of high-density concrete and is 4.5 m from the floor.
Shielding has been added on the walls and ceiling about the isocenter of the clinical
accelerator to attenuate primary radiation, including at least 2.5 cm of 5% borated
polyethelene and a minimum of 15.2 cm of lead. Along the ceiling, a 1.3 cm thick steel
plate supports this shield. Situated outside the vault are a technologist workstation,
patient waiting room, employee workroom, storage closets, corridors, and entrance maze
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that precludes primary radiation from streaming into uncontrolled areas. Below the vault
is a mechanical crawlspace, and above the vault are hallways, office space, and a
restricted-access mechanical space.
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Figure 4.2.1: Floorplan of the clinical linear accelerator vault. Boxed letters
correspond to positions where the dose was measured using portable radiation
monitors, and circled numbers delineate where solid state dual-detector (Luxel®
and Neutrak®) badge-type dosimeters were placed. The ® symbol near position 7
indicates the cask and source position during 252Cf source removal. Position A
was located on the floor of the room directly above the source.
An industrial HDR 252Cf source, serial No. SR-CF-3026, was manufactured at
Savannah River Laboratory on 1 December 1983. This source was selected for
evaluating the utility of the vault as its source strength was similar to that planned for a
medical HDR 252Cf brachytherapy source. On 28 April 2004, the HDR 252Cf source
contained 1.124 mg of 252Cf (22.3 GBq) in the form of Cf2 03.117 Nearly all of the
neutrons were emitted by 252Cf, with 3.3% from spontaneous fission by the other
radionuclides. Measuring 53.4 mm in length and 9.4 mm in diameter, the special form
material was doubly-encapsulated using TIG welds within a Pt-Rh (90-10 wt %) alloy
inner capsule and 304L stainless steel outer capsule. An Atkinson shipping cask (serial
No. 241; the company is now defunct) of approximately 1,670 kg was used to transport
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and store the HDR 252Cf source when not in use. Including the lifting tabs and I-beam
base, the cylindrical cask was 128 cm in height, 127 cm in diameter, and largely
composed of water extended polyester. At ORNL using robotic manipulator arms, a
length of string was attached to the HDR 252Cf source and taped to the bottom of the cask
shield plug (53.3 cm long; 10.2 cm diameter), allowing removal of the source from a safe
distance.
The cask was positioned in the vault to place the source at a distance of 1.3 m
from the linear accelerator isocenter and 1.1 m from the nearest wall. Then, a tripod
suspending a pulley was secured atop the cask. Surgical suture silk was tied to the string
attached to the HDR 252Cf source and threaded through the pulley. In this way, the
source could be lifted from the cask from outside of the vault and monitored with closed-
circuit video cameras.
Once the cask and tripod assembly were secured in place, the source was lifted to
a height of 176 cm from the floor (57 cm from the cask top surface), as shown in Figure
4.2.2. The source was lifted outside the cask in the vault for a total of 3.4 hours.
Radiation survey measurements were obtained with the maze doors open and closed to
the vault at the measurement positions within the entrance maze. The cask and source
was on-site at Tufts-NEMC for about 24 hours.
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Figure 4.2.2: The industrial HDR 252Cf source is suspended in-air above the
shipping cask during the shielding assessment. Note the surgical suture silk that
extended outside of the vault to permit manipulation of the source from within the
vault maze.
4.2.3.2 Radiation detection instruments
As recommended in NCRP Report No. 79, multiple detectors were used to
measure the fast neutron and photon dose rates. For each radiation type, both gas-filled
portable instruments and solid-state dosimeters were employed. The solid-state badge-
type personnel dosimeters were in place for the duration of the 3.4 hour exposure,
whereas the portable instruments either took an instantaneous reading or integrated for
between 0.1 and 1 hour.
Neutron dose rates were measured with four calibrated Health Physics
Instruments (HPI; Goleta, CA) model REM 500 survey meters. The REM 500 contains a
spherical proportional counter with A150 tissue-equivalent plastic chamber walls (5.7 cm
inner diameter) and propane filling gas. i"8 A 256-channel multi-channel analyzer allows
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for neutron energy-specific quality factors to determine the channel-integrated dose
equivalent in Sv. Operating in time-integrate mode, the REM 500 can measure between
0.01 mSv and 9.99 Sv and has an approximately dose equivalent response to neutrons
between 70 keV and 20 MeV. The contributions of thermal- to low-energy neutrons, for
which the REM 500 does not have an ambient dose equivalent response, were estimated
using Monte Carlo methods. The photon radiation response is reported to be less than
one percent in a 0.01 Gy h-' field.
Photon dose equivalent was measured with calibrated Keithley (Keithley
Instruments, Inc., Cleveland OH) 36150 and 36100 survey meters to integrate or measure
the dose equivalent rate, respectively. Both models are air-equivalent ionization
chambers, with a volume of 250 cm 3, vented to the atmosphere. 19 The resolution is 1
tSv h-1 for exposure measurements for low-levels of radiation. Using the front window
and build-up cap, the energy response is ± 10% for photons between 32 keV and 2 MeV.
Duel element, i.e., neutron- and photon-sensitive, dosimeters supplied by
Landauer Inc. (Glenwood, IL) were situated in and around the perimeter of the vault at a
height of 1.52 m for each numbered position labeled on Figure 4.2.1. Luxel® optically
stimulated luminescence (OSL) detectors were utilized to monitor the photon dose, and
the incorporated Neutrak® 144 CR-39 track-etch detector was employed to quantify the
fast-neutron component. The Luxel® dosimeter detects photon energies from 5 keV to
over 45 MeV, with a range of 10 gSv to 10 Sv; the Neutrak® dosimeter is sensitive to
neutron energies from 40 keV to over 35 MeV and responds between 200 gISv and 0.25
Sv.120
While a phantom may be used in conjunction with a passive dosimeter to measure
personal dose equivalent, i.e., Hp(10), there were not enough phantoms available for the
full complement of twenty Neutrak® dosimeters. Thus, each dosimeter badge was affixed
to the wall and an approximate determination of Hp(10), which excludes the effect of
backscatter, is presented here.
4.2.3.3 Monte Carlo calculations
Because the REM 500 and Neutrak® 144 dosimeters were insensitive to thermal-
to low-energy neutrons, Monte Carlo calculations were performed to estimate the
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contribution of neutrons below 1 keV to the dose equivalent rate outside of the vault. A
cylindrical model of the vault wall was constructed to simulate neutron transport between
positions 7 and 9 on Figure 4.2.1, as shown in Figure 4.2.3. This wall segment was
selected for it's minimal thickness and proximity to the source. Neutrons emitted from a
point source or along the long-axis of a 12.5 cm radius cylinder were transported through
air, high-density concrete, and low-density concrete using material compositions
published by NIST for dry air, barite concrete (with density 4.00 g cm-3), and normal
concrete (with density 2.35 g cm-3), respectively. 71
D Dry air
High density concrete[] Low density concrete
r = 12.5 cm
110 cm 38 cm 41 cm
Figure 4.2.3: Schematic of the Monte Carlo geometry performed to simulate
neutron transport through the vault wall between positions 7 and 9 on Figure
4.2.1. Neutrons were emitted along the central axis and scored in the volume air
following the low-density concrete. Neutrons that scattered outside of the 12.5
cm radius cylinder were not scored.
The track length estimator of heating tally (F6) was employed in MODE N of the
radiation transport code MCNP5 to determine the average energy deposited [MeV g-1]
per neutron at the entrance and exit of the vault wall.67 A 10 cm radius cylindrical cell
with 1 [tm thickness of ICRU four component tissue70 was placed at the entrance and exit
of the vault wall, and tally results were tabulated over the innermost 5 cm of radial
distance. Radiation weighting factors (wR) from ICRP 60 were incorporated to estimate
the dose equivalent [giSv] to ICRU four-component tissue per starting particle.5 0
Tally energy cards (En) divided the output into 26 neutron energy bins and were
subsequently grouped into three regimes: below 10-6 MeV, between 10-6 and 10-3 MeV,
and between 10-3 and 20 MeV. A total of 2x10 8 and 1x10 9 histories were computed for
the collimated beam and point source geometries, respectively.
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4.2.4 RESULTS
4.2.4.1 In preparation of the vault assessment
Unless otherwise noted, the uncertainty in the fast neutron dose equivalent
measured with a REM 500 is a combination of statistical and systematic uncertainties,
with systematic uncertainties including a 14% calibration uncertainty (upper bound) and
timing error (< 0.1%).
Two calibrated REM 500 meters were placed at 1.00 m from 0.9 gig of 252 Cf for
35 minutes, and measured 27 ± 2 (± 1 s.d.) giSv h' 1. For comparison, an ORNL-provided
rule-of-thumb yields a neutron dose rate of approximately 22.1 giSv h-1 g-1 of 252Cf at 1
m, showing agreement within 36% of the measured value. Differences between the
measured and expected values may be attributed to neutron room scatter during the
measurement. To evaluate the relative calibration and response of four REM 500 survey
meters, the survey meters were placed alongside each other 2.00 m from a shielded 252Cf
source and allowed to integrate for 14.8 h. The average reading was 0.57 ± 0.04 (± 1
s.d.) gSv h'1, showing good agreement between the four meters. Additionally, the photon
response of the REM 500 neutron meter was examined using a 137Cs calibration source.
As expected, the meters responded by less than one percent in both 0.40 and 1.60 mSv h-1
fields.
Multiple background measurements with durations between six and fifteen hours
were made using REM 500 meters. An average background rate of 0.14 ± 0.02 gSv h-1
was established with a correlated count rate of 3.2 ± 0.3 counts h-1, implying that a wide
range of neutron energies were present in the background measurements. At the 95%
confidence limit, the lower limit of detection (LLD) was 5.2 counts per hour such that
measurements below the LLD were presumed to be from background sources.121
4.2.4.2 Vault assessment using a HDR 252 Cf source
Results of neutron measurements from surveying the linear accelerator vault are
shown in Table 4.2.1 with photon measurements presented in Table 4.2.2. At position H
with the vault doors opened, a significant number of neutrons were detected as a result of
scattering and transport through the maze. Closing the shielded doors returned the area to
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background levels. Neither neutron nor photon radiation fields were measured outside of
the sealed vault.
Corresponding badge-type dosimeter readings for the Luxel® and Neutrak®
dosimeters are shown in Table 4.2.3. These dosimeters were posted with double-sided
tape before the cask was transported into the vault and remained in place for the duration
of the 3.4-hour exposure. Only those badges posted within the vault produced
measurable readings. The remaining badges yielded results below the minimum
reporting limit, 0.2 mSv for neutrons and 0.1 mSv for photons. The minimum
measurable quantity for an OSL dosimeter is 10 giSv (1 mrem); however, a facility-
selected minimal reporting limit of 100 giSv (10 mrem) is employed. Landauer results
included a calibration factor of 0.65. t For determining personnel dose equivalent,
Landauer would use a quality factor (Q) of 10 for neutrons of unknown energy as
stipulated by the U. S. Nuclear Regulatory Commission in the U. S. Code of Federal
Regulations (Title 10, Part 20); however, the ICRP recommends a neutron energy
dependent radiation-weighting (wR) factor.' 22'50 Rivard determined an energy-averaged
radiation weighting factor based on a spontaneous fission neutron spectrum of 15.4.123
Because the ratio of the Q and WR is equivalent to the Landauer calibration factor,
uncorrected values were employed in this study.
t Neutrak® 144 CR39 track etch detectors are calibrated with an Am:Be neutron source.
The factor corrects for differences in the incident energy spectra for the two sources.124
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Table 4.2.1: Result of neutron dose equivalent rate (gtSv h-') measurements
around the vault during suspension of the source in air with the associated count
rate. All measurements made with Health Physics Instruments model REM 500
detectors. For each measurement position, as designated on Figure 4.2.1, the
dose equivalent rate (+ 1 s.d.), count rate (± 1 s.d.), and total integration length or
range of lengths are shown. Position A was measured on the floor of the room
directly above the vault.
Hp(10)n Count Rate Integrati
Position [pSv h-1] [cts h-1] on
Time [h]
A-G, K-O 0.0 + 0.3 < LLD 0.25 - 2.0
Door Open 8 ± 1 300 ± 30 0.33
H
Door Closed 0.0 + 0.2 < LLD 0.50
Door Open 60 ± 8 2,250 ± 80 0.33
I
Door Closed 6.1 ± 0.9 280 ± 20 0.67
Door Open 2,200 + 300 84,800 ± 400 0.43
J
Door Closed 70 ± 10 3,080 ± 80 0.43
Table 4.2.2: Result of photon dose equivalent rate [pSv h'1] measurements
around the vault during suspension of the source in air. All measurements made
with Keithley model 36100 or 36150. The position corresponds to the boxed
letters on Figure 4.2.1 with the exception of position A, which was measured on
the floor of the room directly above the vault.
Position Hp(l0)y
[pSv h-1]
A-G, K-O < 1
Door Open 1H
Door Closed < 1
Door Open 8I
Door Closed < 1
Door Open 175
J
Door Closed 1
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Table 4.2.3: The neutron (n) and photon (y) dose equivalent rates measured using
Neutrak® and Luxel® Landauer dosimeters, respectively. The position
corresponds to the circled numbers on Figure 1 with the exception of position 20,
which was placed on the floor of the room directly above the vault. Based on the
time the industrial HDR 252Cf source was outside the cask, the total exposure for
these 20 positions lasted 3.4 hours.
Position Hp (lO) Hp (10) Hp (10) TOTAL Distance
[mSv h- 1] [mSv h- 1] [mSv h- 1] [m]
1 0.06 1.03 1.08 5.0
2 0.15 2.53 2.68 4.0
3 0.18 4.21 4.38 3.7
4 0.18 3.91 4.09 3.5
5 0.09 1.29 1.38 4.1
6 0.15 3.56 3.71 3.8
7 1.21 21.32 22.53 1.1
8 0.88 12.74 13.62 1.3
9 - 19 < 0.03 < 0.06 < 0.09 2.1 to 6.5
20 < 0.03 < 0.06 < 0.09 3.7
4.2.4.3 Monte Carlo calculations
Statistical uncertainties for the point source geometry at the interior of the vault
wall were below 3%, 4%, and 0.2% for thermal-, low-, and high-energy neutrons,
respectively. For the collimated beam of neutrons, uncertainties were below 0.3%, 0.2%,
and 0.1% at the interior of the wall and below 6%, 14%, and 3% at the exterior for
thermal-, low-, and high-energy neutrons, respectively. Uncertainties for the point source
geometry were significantly higher because less than 1% of the starting particles
interacted with the vault wall in the simulation. As such, the relative uncertainties in the
tally results at position 9 in the point source geometry were prohibitively large.
The F6 tally for the point source geometry yielded 4.28 ± 0.01 x 10-12 mSv (± 1
s.d.) per neutron at the entrance of the vault wall. The corresponding dose equivalent
rates for the HDR 252Cf source studied were 40.1 + 0.1 mSv h-' (± 1 s.d.) at position 7.
Compared to the Neutrak® dosimeter reading at position 7, the MCNP result is 88%
higher. As the MCNP result was based on an ideal detector with a dose equivalent
reading for all neutron energies and included a spectrally weighted WR, these values show
reasonable agreement.
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Table 4.2.4 shows the F6 tally results from the collimated beam of neutrons
before and after the vault wall. Neutrons between 1 keV and 20 MeV were reduced by
almost 10-5 after transport through the wall, and indicate that the dose equivalent rate
would have been approximately 0.2 gtSv h-1 at position 9, which is significantly below the
sensitivity of the Neutrak® dosimeter. Furthermore, dose equivalent rate for thermal
neutron at position 9 would be approximately 103 times smaller than that for fast
neutrons.
Table 4.2.4: MCNP5 calculated cell heating tally results [MeV g-1] per source
particle for 252Cf neutrons in the source geometry shown in Figure 4.2.3. For
comparison, results are presented at the entrance and exit of the vault wall model
with a ratio illustrating the population change in each energy regime. Neutrons
energies are characterized in three regimes: below 1 eV, between 1 eV and 1 keV,
and between 1 keV and 20 MeV.
Maximum Vault Wall Vault Wall
Neutron Energy Entrance Exit Ratio
[MeV] [MeV g-l] [MeV g-l]
1 x 10-6 2.58 x 10-8 ± 0.003 4.80 x 10-11 + 0.06 1.9 x 10-3
1 x 10-3  3.01 x 10- 8 ± 0.002 1.63 x 10- 12 + 0.14 5.4 x 10-s
2 x 101 2.93 x 10 -3 + 0.0001 2.55 x 10-8 + 0.03 8.7 x 10-6
4.2.5 DIscussIoN
4.2.5.1 Radiation Protection
The radiation dose limit to a member of the public is 1 mSv per annum and 0.02
mSv in any given hour in an unrestricted area.125 To determine the corresponding annual
allowable HDR 252Cf brachytherapy workload, an estimate of the neutron and photon
dose rates are needed. Based on the lower limit of detection in Table 4.2.1 and 4.2.2, a
conservative estimate of the neutron and photon dose rates outside of the vault would be
0.2 iSv h'1 and 0.1 iSv h-1 from a 1.124 mg HDR 252Cf source. These dose equivalent
rates would permit 10,000 twenty-minute patient treatments per annum. While the use
factor is unity for an isotropic source, an occupancy factor of one-fourth would be
applied to the surrounding corridors and a factor of one-sixteenth to the patient waiting
area, such that 40,000 treatments could be provided per year with the current HDR 252Cf
source. Assuming that the dose rate outside of the shield varies linearly with 252Cf source
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strength, which is a reasonable based upon the work of Hootman and Stoddard,4 9
increasing the source strength to 5.0 mg of 252Cf would decrease the allowed number of
twenty-minute treatments to - 9,000. The maximum expected patient volume, 100
patients per year, could be easily accommodated by this limit.
Similarly, the hourly dose limit to a member of the public was not met with a
1.124 mg HDR 252Cf source. A 5.0 mg HDR 252Cf source would register an estimated
maximum of 1.3 tSv over one hour outside the vault. While the maximum 252 Cf source
strength that could be employed would be 75 mg before incorporating the occupancy
factor, it may not be prudent to extrapolate these results by a factor of - 70 before
performing additional measurements and Monte Carlo simulations.
In the development of a 252Cf brachytherapy afterloading device at Masaryk
Memorial Cancer Institute (MMCI; Czech Republic), Ta'ev et al. converted a vault
designed for cobalt teletherapy into a facility suitable for low-dose rate treatments using
between 0.05 and 0.20 mg 252Cf sources.4 7 The original barrier was composed of barite
concrete (- 3.35 g cm-3) with thickness between 60 and 120 cm, and an additional 24 cm
of neutronstop polyethylene bricks was installed on the walls and ceiling. Although
Ta'ev et al. did not analyze the radiation shielding characteristics of this design,
comparisons can be made to the Tufts-NEMC vault. The concrete thickness at the
MMCI is similar to that at Tufts-NEMC; the Tufts-NEMC shield does not include any
neutron-absorbing material, except along the axis of gantry rotation (see section 4.2.3.1);
and the Tufts-NEMC source strength used in the present analysis was five times greater
than that employed at MMCI. Considering these points, the inclusion of the neutronstop
shielding material may have been an unnecessary expense, as the Tufts-NEMC vault
demonstrated acceptable protection without a neutron-specific absorber. However,
significant differences in the size of the room, the occupancy factors of the surrounding
areas, and other nearby ionizing radiation emitting devices could necessitate inclusion of
additional neutron shielding.
4.2.5.2 Neutron transport analysis
Neutron transport through a labyrinth of general shape was calculated using
universal transport data in NCRP Report No. 144. These data are based on the combined
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results of several neutron transport software codes. The fraction transmitted through the
maze is presented as a function of the centerline length and cross-sectional area of each
tunnel leg. Because the initial segment has direct exposure to the source, it is considered
separately from each successive segment.
The NCRP 144 calculated fraction was compared to relative intensities between
position J at the maze entrance and positions H and I in the maze with the vault doors
open (Table 4.2.1). The neutron field at position I was reduced by a factor of 36 ± 7
compared to that recorded at position J. NCRP 144 predicted reduction by a factor of 22
using the vault maze dimensions with maximum and minimum extremes of 48 and 11,
respectively, where the extrema represent individual calculations with the largest
variation from the average. Similarly, the neutron intensity at position H was decreased
by a factor of 275 ± 107 relative to position J, and NCRP 144 predicted 714-fold
reduction with maximum and minimum of 3,300 and 170, respectively. Thus, the
generalized curves for neutron scattering through a tunnel or labyrinth published in
NCRP Report No. 144 were found to well-characterize spontaneous fission neutrons from
a HDR 252Cf source transported through the Tufts-NEMC vault maze.
4.2.5.3 Shielding analysis
Hootman calculated the attenuation of 252Cf neutron and photon emissions
through a spherical shield having varying thickness of polyethylene, water, concrete, and
other materials, 48 and Hootman and Stoddard significantly improved the work by
thoroughly describing their methodology and including over thirty different shield
compositions. The neutron and photon dose rates per neutron-emission of 252Cf were
included, but the minimum shield thickness calculated was 10 cm and lead was excluded
as a shield material. Comparison to Hootman and Stoddard's results can be made using
measurements at positions 7 and 9 in Figure 4.2.1. The total neutron and photon dose
equivalent (Hp(10)) at position 7 was 21.32 mSv and 1.21 mSv, respectively. Data from
Hootman and Stoddard for a 1.124 mg HDR 252Cf source provide calculated in-air dose
equivalent rates of 21.64 and 1.52 mSv h-1 at 1.1 m for neutrons and photons,
respectively; and modem ORNL-based parameters predicted 20.5 mSv h-1 from neutrons
and 1.76 mSv h-1 from photons at 1.1 m. In-air neutron measurements with Neutrak®
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dosimeters agreed with predicted values within 5% and photon measurements using
Luxel® dosimeters agreed within 32%.
Between positions 7 and 9 there was 38.1 cm of high-density concrete and 41.3
cm of low-density concrete. As the data in Hootman and Stoddard could not be directly
tabulated for a multi-component shield, calculations were made for various thickness of
each shield type and presented in Table 4.2.5. Because of the 1.1 m air gap between the
source and the vault wall, a geometrical factor of (4nxr 2)-' was added to reduce the
calculated values by a factor of 15. Table 4.2.5 shows that the full thickness of low-
density concrete and the actual thickness of high-density concrete (38.1 cm) would not
provide adequate shielding to prevent a reading on the Landauer dosimeters. However,
the 38.1 cm thick high-density shield in combination with a low-density shield would
likely provide the expected attenuation, as shown by dual element Landauer dosimeters at
positions 7 and 9.
Table 4.2.5: Calculated neutron and photon dose equivalent rates at the surface
of a high- or low-density concrete shield containing 1.124 mg of 252Cf. A
geometrical factor of (4nr )-1 was included to account for the position of the HDR
52Cf source within the vault.
ConcreteDensity Thickness Hp(10) Hp (1O) LLDDensity < LLD+
[g cm-3] [cm] [pSv h-x] [pSv h-1]
2.33 41.3 726 ± 40 88 ± 5 N
2.33 79.4 87 ± 7 15 ± 1 N
4.63 38.1 42 ± 2 9 ± 0.7 N
4.63 79.4 0.2 + 0.01 0.09 ± 0.007 Y
3.14 79.4 < 0.6 < 0.3 Y
LLD < 0.06 iSv h- for neutrons and < 0.03 gSv h-1 for
photons.
Calculated using a thickness-weighted average of the two
types of concrete in the vault wall.
Few 252Cf shielding analyses have been published to date. In addition to the
reports of Hootman and of Hootman and Stoddard, da Silva and Crispim used Monte
Carlo methods (MCNP4B) to calculate the shielding capability of spherical shells of
borated polyethylene, stainless steel, and borated-lead polyethylene around a 252Cf source
within a 30 cm radius sphere of high-density polyethylene. 99 Because of the variable
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combination of multiple materials used in the analysis by da Silava and Crispim,
comparison to Hootman and Stoddard is not practical.
Based on improvements in radiation transport software over the past 30 years
since the first 252Cf shielding report by Hootman, and advances in the field of health
physics (e.g., ICRP 26 being replaced by ICRP 60) not addressed by da Silva and
Crispim, further 252Cf shielding analyses that provide a breadth of data similar to the
report for diagnostic x-ray facilities by Dixon and Simpkin are needed.'2 6
4.2.6 CONCLUSIONS
The shielding capability of a medical linear accelerator vault for containing 252Cf
radiations was demonstrated using multiple measuring techniques, including personnel
dosimeters, portable radiation detectors, and Monte Carlo simulation. CR-39 track-etch
detectors, optically stimulated luminescent dosimeters, ionization chambers, and neutron-
sensitive proportional counters yielded no measurable radiation fields outside of the vault
when a 1.124 mg 252Cf HDR source was positioned in-air at the proposed treatment
location for 3.4 hours. As the dosimeters employed were not sensitive to thermal- to low-
energy neutrons, the Monte Carlo simulations validated the fast neutron findings and
indicated that lower energy neutrons would similarly not be of concern.
With an assumption that radiation fields outside of the vault approached the lower
limit of detection, over 10,000 twenty-minute treatment fractions per year could occur
without reaching the annual radiation dose limit for a member of the public. The vault
provided adequate reduction in radiation dose equivalent rate to treat patients with a
medical HDR brachytherapy source with - 75 mg of 252Cf. While an assessment of this
type may be repeated at other facilities, the authors recommend that comprehensive 252Cf
shielding analyses for common building materials and treatment room geometries be
performed to facilitate widespread implementation of medical HDR 252Cf brachytherapy
in the future.
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5 Conclusions
5.1 Summary
Aspects of photon- and neutron-based brachytherapy were examined using MC
methods, the AAPM TG-43 brachytherapy dosimetry formalism, and measurements. MC
simulations employing monoenergetic photon and neutron radiation demonstrated
generalizable characteristics of TG-43 brachytherapy dosimetry parameters. These
findings can be employed to estimate the shape of brachytherapy dose distributions for
new radionuclide sources.
Limited phantom size and material inhomogeneity were shown to impact MC
calculations of photon dose distributions, and in some instances, significant variations
from TG-43-calculated dose distributions were obtained. The related impact on the
brachytherapy patient was explored in two clinical cases: eye plaque brachytherapy with
103Pd, 1251, and 131Cs sources and superficial 252Cf plaque brachytherapy. For eye plaque
brachytherapy, MC studies demonstrated that material inhomogeneities engendered dose
distributions that were -18%, -11%, and -10% at a prescription depth of 5 mm for 103Pd,
125I, and 131Cs, respectively. As such, patient doses were at least 10% less than
prescribed doses, and physicians may change prescriptive goals in concert with
improvements in dosimetry calculations. 127,1 28 For 252Cf plaque brachytherapy, partial
scatter conditions were shown to similarly decrease planned therapy doses by
approximately 10%. Since a 10% change in dose may be clinically relevant, future
brachytherapy treatment planning systems should incorporate corrections to account for
scatter conditions.' 29,13
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Finally, calculations and measurements were employed to evaluate shielding
requirements for 252Cfbrachytherapy. Water, concrete, barite concrete, Pb, polyethylene,
and borated polyethylene were examined using MC simulations for neutron, primary
photon, and secondary photon attenuation. These results can be employed towards
selecting appropriate shielding materials and estimating the shielding capability of a
proposed storage safe. In addition, measurements of a 252Cf radiography source in a
linear accelerator vault were performed to determine suitability for HDR 252 Cf
brachytherapy. The linear accelerator vault, which had walls constructed primarily of
high-density and low-density concrete, could adequately attenuate neutrons and photons
from a 5 mg 252Cf source.
5.2 Future work
5.2.1 PHOTON BRACHYTHERAPY
In sections 2.1 and 2.2, correction factors are presented to account for
brachytherapy dosimetry formalism limitations due to phantom size (Figure 2.1.1) for
point sources and to heterogeneity effects (Table 2.2.3) for eye plaques using the source
models 200, 6711, and CS-1 Rev2. Similar evaluations are in progress to evaluate and
compare scatter effects in limited phantom sizes. For example, recent MC-based
phantom studies demonstrated that the 192Ir point source radial dose function calculated in
a 24 cm diameter sphere of liquid water is comparable to one calculated in a cubic water
phantom with side length 20 cm.' 3' Factors were developed for comparing spherical,
cubical, and cylindrical phanta. Because many source calibration measurements with
TLDs are performed in a rectangular geometry and MC calculations are generally in a
spherical phantom, factors such as these may account for differences observed between
calculated and measured dosimetry parameters. Other authors have similarly studied the
impact of partial scatter environments and offered specific correction factors.132,13 3 For
example, Melchert et al. evaluated dose decrease for an 1921r point source in a rectangular
phantom using MC calculations, an algorithm based on electric field theory, and
ionization chambers.'33
While one-dimensional corrections such as those described above can correct
contemporary treatment planning algorithms following the AAPM TG-43 brachytherapy
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dosimetry formalism, it is preferred to directly calculate patient dose without requiring
numerous publications and references for case-specific correction factors. In 2005,
Chibani et al. described a MC-based treatment planning program for prostate implants
(MCPI) that incorporates tissue hetereogeneities, patient scatter conditions, and inter-seed
effects. 13 4', 35 MCPI can calculate dose distributions in a prostate for -100 radioactive
sources in minutes. Rapid calculations are possible because MCPI employs a stored
phase space data model for each brachytherapy source to eliminate simulations of intra-
source photons, which can account for up to 50% of computational time in MCNP5
brachytherapy source simulations.'13  In comparison to MCPI which uses phase space
data, BrachyDose is a MC radiation transport code using EGSnrc that can simulate
prostate implants in minutes of computational time.136  BrachyDose calculated
brachytherapy dosimetry parameters for different commercial seeds and radionuclides
that are within -1% of AAPM consensus data.136
MCPI and BrachyDose are likely the predecessors of the next generation of
brachytherapy treatment planning systems. These systems will employ MC calculations
to accurately correct for tissue heterogeneity, inter-seed attenuation, and phantom size
effects. Furthermore, short computation times will enable routine clinical use. However,
additional work is needed to integrate patient-specific data with MC simulations using
either a pre-calculated dose kerne 12 9,130 ,13 5 or direct MC calculation.136
5.2.2 NEUTRON BRACHYTHERAPY
Interest in HDR 2 52Cf brachytherapy by the medical community continues.
However, commercial treatment delivery systems have not been introduced. In 1999,
ORNL entered into a Cooperative Research and Development Agreement with Isotron,
Inc. (Alpharetta, GA) to develop HDR sources.' 37 In addition to the development of a
252Cf remote afterloading system, Isotron, Inc., is also exploring combinational
therapeutic techniques, such as combining neutron brachytherapy with boron neutron
capture therapy.44" 37
One limiting factor in the development of 252Cf-based brachytherapy is the
availability of 252Cf. In 1970, the Atomic Energy Comission sold 252Cf to the University
of Kentucky for $10 tg-1.34 Rivard reported the cost to be $56 tg-1 in 1999, 93 and Rivard
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et al. noted an increase to $72 ig-' by 2004.104 Thus, a commercial medical HDR 252Cf
source with source strength > 1 mg may be prohibitively expensive. In the past, ORNL
has made 252Cf sources available to hospitals and universities through the Californium
University Loan Program.' 38 With sufficient medical interest, the Department of Energy
may support a growing 252Cf brachytherapy industry by providing discounted 252Cf for
clinical use.
5.3 Summary statement
In this dissertation, contemporary challenges in brachytherapy were addressed
with an emphasis on calculation of brachytherapy dose distributions for photon- and
neutron-emitting sources. These efforts were directed towards improving the accuracy of
dose calculation in the absence of full-scatter and in heterogeneous media. In addition, a
radiological health evaluation was performed for the unique shielding challenges posed
by neutron brachytherapy.
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7.1 Appendix I: List of acronyms and abbreviations
AAPM American Association of Physicists in Medicine
ABS American Brachytherapy Society
COMS Collaborative Occular Melanoma Study
ENDF Evaluated Nuclear Data File
HDR High-dose rate
ICRP International Council for Radiation Protection and Measurements
ICRU International Commission on Radiation Units and Measurements
LDR Low-dose rate
LLD Lower limit of detection
MC Monte Carlo
MCNP Monte Carlo N-Particle
MMCI Masaryk Memorial Cancer Institute (Czech Republic)
NCRP National Council on Radiation Protection and Measurements
NEMC New-England Medical Center
NIST National Institute of Science and Technology
NNDC National Nuclear Data Center
ORNL Oak Ridge National Laboratory
RBE Relative biological effectiveness
REDC Radiochemical Engineering Development Center
TED Threshold erythema dose
TG-43 AAPM Task Group 43 Report (Ref. 10)
TG-43U1 Updated AAPM Task Group 43 Report (Ref. 20)
WAFAC Wide-Angle Free-Air Chamber (Ref. 18)
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7.2 Appendix II: Summary of the AAPM TG-43UI dosimetry formalism
The AAPM report TG-43U1 brachytherapy dosimetry two-dimensional (2D)
formalism is given in Eq. 7.2.1.20
D (r,)= SK A GL(r gL (r) F (r, 0) (7.2.1)
Where: b(r,9)
SK
A
GL (r,0)
gL (r)
F (r, 9)
ro
o0
dose rate at position (r,0) in spherical coordinates [cGy h1]
Air kerma strength [cGy cm 2 h-1]
Dose rate constant [cm 2 ]
Geometry function for the line-source approximation
Radial dose function
2D anisotropy function
Reference radial distance (ro = 1 cm)
Reference angle from the seed long axis (00 = 900)
Eq. 7.2.1 employs a spherical coordinate system to calculate dose rate distributions in the
plane coincident with the source long axis. Cylindrical symmetry about the source is
assumed. The first two terms, SK and A, normalize the individual source strength to the
reference dose rate, D (r, 00). The remaining terms account for the geometrical effects
of inverse square law and attenuation through source components. The subscript L
denotes the line source approximation of the geometry function.
Eq. 7.2.2 defines A and describes the reference dose rate characteristics for a
given seed design. The brachytherapist need only multiple A by SK for a given
seed/source to obtain the dose rate [cGy h-1] at the reference point.
A (7.2.2)
S,
The geometry function corrects for inverse square law effects. For a point source,
the geometry function follows the inverse square law and is called G, (r, ) where the
subscript P denotes the point source approximation. As source length increases;
however, the geometry function must account for the distributed nature of the source.
Two defining regimes are given in Eq. 7.2.3.
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if 0 6 0#
GL (r) Lr -sin (0) (7.2.3)
r
2 
- L2/4) -  if 0=0'
In Eq. 7.2.3, P3 is the angle in radians between the line source and calculation point, and L
is the active length of the source. For linear sources including hollow right cylinders, L is
defined as the length of the active region. An effective active length, Leff, should be
calculated by multiplying the number of distinct internal elements and their center-to-
center spacing for sources with multiple internal components. If the calculated Leff
exceeds the source capsule length, brachytherapists are advised to use the maximum
extent of the radioactivity distribution. Additional discussion of Leff can be found in Ref
63.
The radial dose function, gL (r), calculates the rate of dose fall-off in the plane
bisecting the source, known as the "transverse plane." Inverse square effects are
accounted for in GL (r,0) ; thus, the radial dose function determines the relative amount
of scattering and attenuation along 0=900. Eq. 7.2.4 defines the radial dose function.
) (r, 00) GL (ro ,0)
Dg(rO 00 GL (rO) (7.2.4)
As shown in Eq. 7.2.4, gL (r) is normalized to unity by the value at r0.
In comparison to the relative dose decrease on the transverse plane, the 2D
anisotropy function, F(r, ), is the relative dose as a function of polar angle. As for
gL (r), the 2D anisotropy function accounts for the scattering and attenuation in water
and in source components. The definition of F(r, 0) is given in Eq. 7.2.5.
F (r, O) GL (rO) (7.2.5)b (r, 00 ) GL(r,0)
Some treatment planning systems do not allow for the characterization of source
orientation. As such, the TG-43U1 dosimetry formalism includes a one-dimensional
(lD) formalism. In this formalism, G,(r,0) is used, and F(r,0) is replaced with the
ID anisotropy function, 0,,, (r). The ID anisotropy function is the solid-angle weighted
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dose rate at a distance r relative to the dose rate at the same distance on the transverse
plane. Eq. 7.2.6 shows the equation for determining ,an (r).
bd(r, 0) -sin (0) dO
Oan (r)=  21)(r, 00) (7.2.6)
Substituting Gp (r,9) and a, (r) into Eq. 7.2.1 provides the recommended 1D
dosimetry formalism shown in Eq. 7.2.7.
b(r,0)=SK -.A- .gP(r)-.,(r) (7.2.7)
It is important to note that the TG-43U1 brachytherapy dosimetry formalism allows
additional formulae for the 1D formalism, and the interested reader is referred to Ref. 20
for further reading.
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